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1.1 Proteomics in the Post-Genomic Era
The availability of the human genome map [1–3] has greatly enhanced our under-
standing of the underlying biology of disease progression and response and galvanized
research in the rapidly advancing field of proteomics and biomarker discovery. Iden-
tifying, quantitating and characterizing all expressed proteins in the proteome is the
ultimate goal for a deeper understanding of disease response at a molecular level. All
genetic mutations which gives rise to disease are ultimately manifested at the protein
level. These are characterized by derangements in protein function and information
flow within diseased cells and the interconnected tissue micro-environment. Thus,
the study of proteins altered in the course of a disease holds great importance toward
realizing this goal. These changes in protein expression can not only reveal biomark-
ers for the diagnosis of diseases but also provide novel therapeutic targets for more
effective personalized cure. Moreover, such studies can reveal valuable information
about the underlying biological processes, such as perturbations in protein signaling
pathways.
Genomics or transcriptomics is a common way to study diseases such as cancer, but
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recent studies point out that the correlation between mRNA and protein levels in
cells of most organisms is remarkably and unexpectedly low [4–7]. It implies there-
fore, that mRNA studies are less predictive of complex traits than protein studies.
Though it is too early to completely discount mRNA studies and favor protein ex-
pression profiling [8] nonetheless, proteomics offers an alternative diagnostic platform
for analysis of excreted proteins and body fluids like blood serum which is essential
for pathological applications. As such, studies in determining the protein content
of the cell are important in attempting to understand cellular processes in cancer.
Though current multidimensional separations and mass spectrometry platforms can
rapidly generate a high resolution map of the proteome, we are still far from decipher-
ing cellular functions that are maintained by proteins. The study of the proteome
poses great challenges due to its complexity and dynamic range. Though estimated
to originate from around 40,000 genes [9], there are close to an estimated 1 million
proteins in the human proteome and the dynamic range in their expression levels
exceeds 10 orders of magnitude [10,11].
The low correlation in mRNA and protein concentration in cells is generally hypoth-
esized to result from post-translational modifications in proteins [12] which seems to
be more prevalent than previously assumed. Additionally, numerous isoforms [13]
add up to the complexity of the proteome. Proteins undergo post-translational mod-
ifications, cleavage and degradation in response to various cell signals both for main-
taining normal cellular functions as well as in response toward diseases [14, 15]. In
this respect, phosphorylations are most important and are directly responsible for
regulating cellular signaling pathways in cells, where any alterations in which can
lead to cancer [16]. Glycosylations also are common and are a heterogeneous class
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of PTMs playing a key role in cellular recognition which is responsible for normal
functioning in cells. Defects in glycosylation mediated signaling can also result in
disease [17]. Alternative splicing of mRNA which is the proposed mechanism by
which higher order diversity is created among proteins [18] for instance, can produce
many different proteins from a single gene. As many as 30% of the genes in humans
and other eukaryotes are thought to be alternatively spliced. Splice variant proteins
are known to display the same, opposite or completely different and unrelated phys-
iological activity. This in turn affects key non biological factors such as stability,
clearance rate, cellular localization, temporal pattern of expression, up-regulation
or down-regulation mechanisms and response to agonists or antagonists which are
critical aspects in the studies of disease progression.
1.2 Applications of Proteomics in Cancer Research
Cancer has been one of the most widely studied diseases using proteomics. Cancer
is not a single disease but an accumulation of several events, genetic and epigenetic,
arising in a single cell over a long time interval. A high priority has been attached
to the identification of these events. This can be achieved by characterizing cancer-
associated genes and their protein products. Identifying the molecular alterations
that distinguish a cancer cell from a normal cell will ultimately help in defining the
nature [19] and predict the pathologic behavior [20] of a cancer cell. It will also
indicate the responsiveness to treatment of that particular tumor. Understanding
the profile of molecular changes in cancer is extremely useful to be able to correlate
the phenotype of cancer with molecular events. Achieving these goals will provide
an opportunity for discovering new biomarkers for early detection of cancer and de-
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veloping approaches for prevention. Early detection is a difficult challenge for proper
diagnosis and prevention, since in many cases, cancer is not diagnosed and treated
until cancer cells have become invasive or metastatic [21]. Early detection could
then enable effective interventions and therapies contributing to reduction in mor-
tality and morbidity. Through the course of progression of cancer, biomarkers serve
as molecular signposts of the physiologic state of the cell [22] and are therefore truly
dynamic unlike the genome. Biomarkers could prove to be vital for the identification
of early cancer and subjects at risk of developing cancer, though presently, biomark-
ers that allow precise monitoring or classification of disease are very limited. The
discovery of new highly sensitive and specific biomarkers for early detection of dis-
ease and development of personalized therapies holds the key to effective treatment
of diseases. Apart from cells and tissues, the circulatory proteome contains a rich
source of information that is helpful both in the early detection of disease state and
risk assessment [23–27]. Being easily obtainable through non invasive techniques,
biofluids are well suited for pathological applications. It is important then, that any
analytical method for the analysis of biofluids must be robust enough to deal with
the associated complexities for effective pathological applications.
1.3 The Mass Spectrometry Advantage
Current multidimensional separation and mass spectrometry based platforms for pro-
teomics can rapidly generate a high resolution map of the proteome. Though devel-
opments in separation technologies had been crucial toward attaining that capability,
the ability to progressively detect lower concentrations of proteins in biological sam-
ples has largely been brought about by the recent advances made in the field of mass
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spectrometry. The applicability of mass spectrometry for the analysis of peptides as
well as large biomolecules was greatly improved through the introduction of two soft
ionization techniques, MALDI [28,29] and ESI [30,31]. Though the exact mechanism
of generation of charged analytes in MALDI is not clear, nevertheless, MALDI was
successfully introduced for the analysis of peptides and proteins commonly using a
TOF based analyzer which is suited for pulsed techniques. Peptide mass fingerprint-
ing (PMF) obtained using MALDI-TOF MS is the most common method for rapid
identification of proteins in which the pattern of peptide m/z values obtained through
MS analysis of a proteolytically digested protein is compared against a database of
theoretical fragmentations to identify the original protein. Though MALDI-MS is a
fast and efficient method capable of identifying proteins from very small amounts of
sample, it is not suitable for identifications of PTMs for which MS/MS techniques
are more suited.
Electrospray ionization (ESI) produces gas phase ions from analytes in the liquid
phase using an electric field. It also generates multiply-charged ions that not only
allow determination of accurate molecular weights but also provide the ability to
detect large molecules using an analyzer with limited mass range. Moreover it has
excellent capabilities of online interfacing with chromatographic and other various
liquid separation techniques. Online LC-ESI-MS can add another dimension to liq-
uid separations thereby increasing the peak capacities of this hyphenated technique.
Both MALDI and ESI had been effectively used for peptide sequencing where the
peptide chains are fragmented commonly using ion-neutral collisions and the m/z of
the fragments are measured and queried against a theoretically generated database
for protein identification. Recently, using nano-electrospray combined with ion traps
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(IT), it had been possible to detect proteins at sub-picomolar levels [32]. Moreover,
the ability to conduct mass spectrometric analysis at MS3 level make it valuable for
detection of PTMs. The use of hybrid MALDI-IT-TOF instruments on the other
hand have demonstrated the ability to obtain information on glycoprotein structures
and attain sensitivities of low femtomolar levels.
1.4 Multidimensional Separation Technologies
The advances in analytical techniques that were driven by the needs of the post-
genomic era have provided us with the ability to analyze biological samples for bio-
markers in ways never before possible. With a huge array of potential methodologies
with very unique capabilities, it is not often clear however, which of these analyti-
cal technologies or a combination thereof, will yield the most comprehensive results.
2D-PAGE has been one of the principal tools for proteomics since its inception [33].
It enabled high resolution separation of proteomes where the spot patterns between
two or more samples could be compared for differences and analyzed thereafter us-
ing mass spectrometry [34, 35]. However, despite its resolving power, 2D-PAGE has
significant limitations with respect to throughput, reproducibility, mass resolution
and dynamic range, making it far from an ideal tool for biomarker discovery. Also,
large amounts of manual labor involved in this method make it difficult to auto-
mate. Alternative liquid based multidimensional separation technology has been
used effectively as a means for fractionating and purifying protein fractions. This
technique is easily adaptable to mass spectrometry and several preparative as well
as analytical scale separation methodologies have been used to study various bi-
ological samples. Besides the applicability in top-down approaches, this technique
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makes possible bottom-up analysis where whole cell lysates are digested and the pep-
tide mixture is separated and analyzed using mass spectrometry. Commonly used
bottom-up approaches or MudPIT use strong cation exchange followed by reversed
phase separation to fractionate the peptide mixture [36]. Alternative 1-D separation
of complex peptide mixtures using a long reversed phase capillary HPLC column
can also be performed [37], but in general, protein identifications obtained through
bottom-up methods have high false positive rates since they are identified using too
few peptides [37]. The most important aspect though, is the loss of valuable in-
formation at the protein level unlike in top-down approaches where intact proteins
are digested separately so that in-depth mass spectrometry based analysis is possible.
1.4.1 Liquid Chromatography
The most widely used fractionation technique applied for top-down proteomics uses a
2-D separation method where chromatofocusing (CF) [38] is used in the first dimen-
sion and nonporous reversed phase (NPS-RP) HPLC is applied for separation in the
second dimension. CF is performed on a silica based weak anion exchange column
where proteins are loaded on the column at a higher pH and then eluted gradually
using a low pH buffer. The mixing of the two buffers during elution creates a pH
gradient inside the column eluting out proteins in the order of decreasing pI. This 2-
D LC separation scheme has been successfully applied for the study of human cancer
and bacterial cells where proteins were identified using ESI-TOF and MALDI-TOF
MS based techniques [39–41]. The intact MW of the proteins can also be used to
create virtual 2-D maps resembling gels which can then be used for interlysate com-
parisons. Unlike in gels, the experimental conditions for 2-D LC can be maintained
easily so as to produce highly reproducible maps. The use of non porous silica in the
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second dimension reversed phase column eliminates irreversible protein binding to
the stationary phase thereby providing higher recovery. A short column packed with
such nonporous silica C18 material enables fast separations and provides sufficient
peak capacity to reliably fractionate pH fractions obtained using chromatofocusing.
One disadvantage of CF with respect to gels is the pH limitation associated with the
usage of silica based stationary phase. CF performed using columns with polymeric
stationary phases on the other hand are free from such limitations. Since the 2D-LC
fractionated proteins are obtained in intact form, they can also be collected off-line
for characterization of PTMs. Typically collected protein fractions are digested and
subjected to MALDI-TOF MS. Due to a number of factors associated with sample
preparation that affect MALDI ionization and sensitivity, ESI-MS/MS is commonly
performed to verify protein identifications. Also proteins are commonly subjected to
ESI-MS/MS analysis to obtain information about sequence variations and modifica-
tions because the peptide sequence coverage obtainable from MALDI-MS analysis is
usually low. The sensitivity levels offered by ESI-MS/MS can be greatly enhanced
when interfaced with liquid chromatography at very low flow rates.
1.4.2 Capillary Electrophoresis
Capillary Electrophoresis (CE) separation is based on differential migration of an-
alytes that arises from the differences in electrophoretic mobility [42] determined
by charge, size and shape of the ions in the liquid phase [43]. CE demonstrates a
very high separation efficiency where electroosmotic flow (EOF) caused by an electri-
cal double layer formed at the stationary/solution interface inside a silica capillary,
generates a uniform flow profile across the cross-section and length of the capillary
minimizing band broadening. Capillary electrophoresis separations can have several
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hundred thousand theoretical plates. The efficiency of CE separation is only limited
by diffusion and is proportional to the strength of the electric field. Applying a high
voltage during CE separation also helps achieve high speeds in separation of complex
peptide mixtures so that a typical separation can be completed in a few minutes.
The problem though with fast separations is the introduction of Joule heating from
high voltage which can adversely affect peak resolution and separation efficiency. For
proteomic applications, CE is normally applied on samples that had been separated
in one or more dimensions using isoelectric focusing, capillary gel electrophoresis and
other methods [43]. The slow flow rate of CE had been successfully applied in inter-
facing it with mass spectrometry using electrospray ionization as well as MALDI [44].
CE-MS had been applied for both identification [45] and characterization of impor-
tant modifications [46–48] in biological samples.
Despite the excellent resolution and speed of CE, it has exhibited several problems
when interfaced with ESI-MS. When CE is used for MS analysis in positive ion mode,
applying a low pH condition to generate the ions, the inner capillary wall must be
modified to minimize interaction between negatively charged silanol groups and the
positively charged analytes [49]. A dynamic coating procedure based on adsorption
as described in Chapter V does not provide sufficiently long lifetime. The unstable
EOF at low pH gives poor reproducibility in analyte migration times and poses a
serious challenge when comparison of several runs becomes necessary. The interfac-
ing of CE to MS is also complicated. Sheathless flow has been utilized in the work
in Chapter V to obtain maximum sensitivity by preventing sample dilution and as-
sociated reduced sensitivity which occurs when make-up flow is used in sheath-flow
interfaces [50]. The sheathless interface created by attaching an emitter at the end
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of the separation column is prone to detachment on contact with liquid phase col-
umn effluent making it difficult to maintain a closed circuit in the CE-ESI setup.
Moreover, analyte samples must be highly purified to avoid interruption of voltage
gradients from column clogging.
1.4.3 Monolithic Capillary HPLC
HPLC separations using monolithic capillary columns prepared with either silica or
other polymers [51–54] provides with an alternative method for separation of peptides
in protein digests with a very high efficiency comparable to that of CE. Monolithic
LC is an emerging separation method which has been successfully applied to the
analysis of biomolecules including nucleic acids, RNA, proteins and peptides [55–57].
Monolithic capillary LC columns provide unique characteristics of high speed, high
resolution, high efficiency and high recovery rates because of fast mass transfer ow-
ing to lack of interstitial space [58]. These separation qualities are comparable to
that of CE. Monolithic capillary HPLC moreover, allows for higher loading capacity
and is a much simpler technique to interface with ESI-MS, thus providing a highly
robust, rugged and reproducible analysis tool. Polymer-based monolithic columns
have higher stability at extreme conditions [59] and have also been used for analysis
of phosphorylations using alkaline solvent systems for detection with MS in negative
ion mode [60]. Monolithic capillary LC has also been applied for separations utilizing
affinity chromatography techniques [61,62] and as support material for enzymatic di-
gestions [63] apart from more common applications in quantitative analysis of human
serum proteins [64] and in peptide mapping [65]. Monolithic capillary based separa-
tion is an ideal technique when analysis on a small amount of sample is desired. The
high recovery rate can provide better sensitivity for very low sample amounts.
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1.5 Microarray Technology
A concerted effort by scientists and engineers from many different fields helped de-
velop DNA microarrays, a key technology in the field of genomics that made possible
the monitoring of expression levels of all genes in an organism simultaneously [66–70].
The key element in this new technology was the development of surface based assays
in which numerous probes are immobilized in a spatially addressable manner [71].
Such array formats were suitable for miniaturization and multiplexing. Though the
concept of microarrays was first introduced in 1989 [72], the term ‘microarray’ was
not used widely till much later [73,74].
The principle of miniaturized ligand binding assay was first described by Ekins et
al. almost two decades ago [72] who argued that a miniaturized assay with ‘mi-
crospots’ of immobilized capture molecules on solid phase would be more sensitive
than conventional macroscale methods. Although the amount of capture molecules
present in a ‘microspot’ is low, a high density of molecules can be obtained. Due
to a limited number of capture molecules, only a small number of analyte molecules
can be captured during an assay procedure so the concentration of free analyte in
the solution is not changed much by the binding reaction. This phenomenon termed
‘ambient analyte condition’ ensures high sensitivity [72]. Since the analyte molecules
are confined to a very small area, microspot assays result in a much higher sensitiv-
ity compared to other 96-well plate based macro assays. As a result, femto-molar
concentrations of antigens could be easily detected [75]. Miniaturization also allowed
for parallelization which in combination with higher sensitivity provided microarrays
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with an enormous potential in diagnostic applications.
Technologies established for DNA chips were adapted for microarray based research.
Although DNA microarray provided the leads in the development of protein microar-
rays, the methodology for the latter were significantly different. The main reason
for this is the tendency of proteins to undergo denaturation and exhibit nonspecific
binding. Miniaturization made these issues more complex, since the surface to vol-
ume ratio increases dramatically when the volume of a sample spot is scaled down.
Despite these difficulties, important advances in methods and technology enabled
the use of protein microarrays for various applications.
Initial reports demonstrated the feasibility of antibody microarrays using a vari-
ety of methods that had included spotting on membranes [76–79], derivatized glass
slides [78, 80–82] and hydrogels [83, 84] and detection of bound antibodies using ra-
dioactive isotopes [76], fluorescence [80–84] and chemiluminiscense [78, 79, 84, 85].
These kinds of experiments utilizing the protein microarray format could be broadly
categorized into two classes - direct labeling experiments, and dual antibody sand-
wich assays. In the direct labeling method, all proteins in a complex mixture are
covalently labeled with a fluorescent tag. After incubation on an antibody microar-
ray, the tag provides a means of detecting the bound proteins. The signal from
the bound proteins can also be amplified using suitable tag chemistry. In the sand-
wich assay, proteins captured on an antibody microarray are detected by a cock-
tail of detection antibodies. The detection antibodies are in turn detected through
fluorophore-labeled secondary antibodies. The disadvantage of direct labeling ex-
periments is the potential for high background since all proteins are labeled so the
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sensitivity achievable is not very high.
1.5.1 Applications in Diagnostics
Protein microarray immunoassays offer an attractive alternative when several para-
meters of a single sample have to be analyzed in parallel, such as in allergy [86,87] or
autoimmune diagnostics in which patient sera needs to be screened for a number of
different auto antibodies [78,88]. Auto antibodies toward immobilized auto antigens
used as diagnostic markers for autoimmune conditions can be accurately determined
from less than 1 µL of patient serum. This reflects the enormous potential of pro-
tein microarrays employed to study the humoral response against a large number
of antigens. Microarrays have also been successfully used to detect the presence of
specific IgG and IgM antibodies directed against parasitic and viral antigens [89–91].
The analytical sensitivity of these assays were similar to those obtained using stan-
dard ELISA technology [89]. Sandwich immunoassays were therefore adapted to the
microarray format [85, 92, 93] creating highly specific and sensitive protein microar-
rays which were capable of quantifying many different cytokines from patient sera.
However the parallelization of sandwich immunoassays has limitations from cross re-
activity of certain detection antibodies making the routine use of highly multiplexed
sandwich immunoassays difficult.
Despite the problem with antibody cross reactivity which limits the scope of cer-
tain experiments when compatible antibodies are unavailable, the potential of array
based proteomic approaches is enormous [94,95]. Protein microarray technology had
been used to simultaneously determine levels of large numbers of target proteins us-
ing comparative methods [96] where the array bound proteins are usually detected
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using biotin-based signal amplification [97]. Protein microarrays were also applied
to discovery of diseases and tumor markers [98]. These approaches reflect the power
of antibody microarrays in determining changes in protein expression in a single ex-
periment.
Protein microarrays also offer the opportunity to study protein-protein interactions
by immobilizing purified recombinant proteins. Purified proteins, enriched protein
fractions or complete cell lysates had been used for interaction assays [99]. These
experiments demonstrated the stability of microarrays to screen for protein-protein
interactions at a proteome wide level [100–103] and similar approaches could be
applied to study protein-drug and protein-lipid interactions which were difficult to
study using other approaches.
1.5.2 Reversed Phase Microarrays
In contrast to the techniques described above, cellular lysates prepared from cultured
cells or tissues can also be immobilized on a microspot and screened with specific
antibodies for the presence of defined target proteins. Characteristic features of re-
versed phase microarrays include high linearity and excellent sensitivity. The biggest
advantage is that the samples need not be labeled [104]. Reversed phase arrays can
use denatured lysates so that the retrieval of antigens do not pose problems. Non
denatured lysates can also be used to identify the target protein of interest as well
to elucidate protein-protein, protein-DNA and/or protein-RNA interactions. The
samples arrayed in dilution series can provide an internal standard and direct quan-
titative assessments can also be made by including several positive and negative
controls and internal calibration standards. Because measurements lie within the
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linear dynamic range of the antibody-analyte interaction at any given point in the
dilution curve [105], direct quantitative measurements can be made using reverse
phase microarrays. Rather than arraying cell lysates, where the identity of the bind-
ing protein to an antibody probe is difficult to ascertain, fractionated lysates offer a
remarkable methodology where multidimensional LC fractionated cellular or tissue
lysates provide purified proteins for spotting on to the array [106]. Though numerous
methods had been used for obtaining proteins for the purpose of spotting [92,99,107],
2-D LC fractionation provides the most robust technique thus far. This method has
the advantage associated with obtaining proteins with biologically relevant PTMs
that is difficult to obtain using other means.
The use of protein microarrays allows the measurement of several parameters in one
reaction. For systems like autoimmune or humoral response assay, the degree of
multiplex achievable is limited to the number of antigens available. The sensitivity
of such systems is high and so the amount of serum required can be <1 µL. Autoim-
mune assays work with serum dilutions of 1:200 to 1:1000. Nevertheless, we should
keep in mind that the results obtained with antibody microarrays must be verified
and confirmed since some antibodies exhibit strong cross reactivity. In addition,
proteins are often assembled in multi-protein complexes. Thus a strong signal on a
microspot can result not only from the presence of a large number of target mole-
cules but also from the nonspecific capture of a labeled dye molecule or antibody.
Standard methods such as immuno-histochemical staining and immunobloting are
commonly used for validation.
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1.5.3 Analysis of Post-translational Modifications
As described earlier is Section 1.1 protein post translational modifications specifi-
cally phosphorylation is critical in maintaining cellular functions, and methodologies
for sensitive and accurate phosphoprotein analysis are very essential. Though the
undeniable strengths of large scale mass spectrometry based approaches cannot be
ignored, protein microarrays offer a complementary but faster and more sensitive
method for detection of protein modifications. Sandwich assays have been applied
successfully for large scale phosphoprotein analysis. Techniques like probing an-
tibody spotted arrays with cellular lysates followed by detection using fluorophore
conjugated anti-phosphotyrosine antibodies [108] had not been very popular owing to
the difficulties in generating specific antibodies but holds great promise for in-depth
analysis. Using such methods and using only nanogram quantities of total protein
extracts, a ratio metric study could be conducted to obtain differential phosphory-
lation patterns. Alternative reversed phase protein microarray methods have relied
on anti-phosphoprotein antibodies, but the drawback is the ‘ligand problem’ which
revolves around the unavailability or inability at synthesizing high quality antibodies
so as to eliminate non-specific interactions [109]. Recent developments in alternative
dye based modification detection arrays [110] have received much attention and work
presented in this thesis describes methodologies using the dye-based approach for dif-
ferential detection of phosphorylations across cellular proteomes. Other PTM detec-
tion methodologies eg. glycoprotein microarray strategies employing lectins [111,112]
had also been applied for biomarker discovery using 2-D LC fractionated cell lysates.
These applications serve to present protein microarrays as an efficient platform for
proteome wide PTM discovery and quantitative detection.
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Since traditional PTM detection relies on immunoassay based techniques the limits
of detection are dictated by antibody recognition chemistry and nonspecific complex-
ation with fluorophores may give rise to false positives. As a result, alternative mass
spectrometry based detection strategies [109] using isotope-labeling techniques had
been proposed [113], however, it cannot be applied to protein-detecting arrays. In-
vivo protein labeling followed by direct MS can be a better alternative which needs
to be explored further.
1.6 Molecular Concept Modeling
The power of microarray based approaches lie in the ability to provide genome or
proteome wide expression patterns otherwise impossible to obtain. Experiments us-
ing this ability had largely focused on the differential expression of disease related
biomarkers but recently, construction of disease response pathways had been demon-
strated [114]. This methodology uses an analytical framework for exploring the
network of relationships among a growing collection of ‘molecular concepts’, or bio-
logically related gene sets [115]. As a result, visualization of disease specific signaling
networks has become possible. This not only opens up a new dimension in disease
classification and diagnosis but also demonstrates the versatility of microarray based
parallel techniques. Work described in this thesis demonstrates the use of the MCM
technique for generating protein signaling networks and associated applications in
cancer diagnosis. The inclusion of protein modification information in this analyti-
cal model would provide us with a truly versatile technique.
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1.7 Statement of Research
This thesis discusses research in multiplexed high-throughput proteomic approaches
to identify molecular signatures of cancer and post translational modifications in
cell-line and tissue proteomes. 2-D LC fractionated human breast cancer SUM-52PE
cell-line, pancreatic cancer Panc-1 cell-line and prostate cancer tissue have been used
in the work described in Chapters II, III and IV respectively to generate protein
microarrays which were then used for phosphorylation detection or autoantibody re-
sponse mapping. Chapter II demonstrates the use of a small molecule phosphoprotein
dye for global phosphoprotein detection. Around 100 differential phosphorylations
were detected and differentially phosphorylated proteins were identified using ESI-
TOF MS and MALDI-TOF MS, the later employing a modified MALDI matrix.
Chapters III and IV discuss autoantibody response based methods for biomarker dis-
covery and disease response pathway discovery respectively. Panc-1 cell-lines were
used in the biomarker discovery experiment since pancreatic cancer poses a challenge
for early detection and diagnosis. nESI-LC-MS/MS was used for protein identifi-
cation and glycosylation patterns were obtained using lectin microarrays to study
possible correlations with autoantibody response. Chapter IV presents the use of
bioinformatics using a molecular concept modeling based method for obtaining dis-
ease progression pathways in prostate cancer.
Chapters V and VI presents monolithic capillary HPLC based techniques for ana-
lyzing peptides and proteins providing high sequence coverage and sensitivity. High
sequence coverage is essential for detecting reliable identification of proteins and iden-
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tifying PTMs. Applying the monolithic LC based method, several modifications in
MFC10A derived human breast cancer cell lysates were detected and characterized
using ESI-TOF MS and MALDI-TOF MS.
Lastly, Chapter VI describes a hyphenated technology where monolithic LC sepa-
ration of intact proteins from human esophageal tissue samples was combined with
on-plate digestion and MALDI-MS based protein identification. This work describes
a method which retains the advantages of top-down proteomics and at the same time
uses automation to increase throughput.
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CHAPTER II
Differential Phosphoprotein Mapping in Cancer Cells Using
Protein Microarrays Produced from 2-D Liquid
Fractionation
2.1 Introduction
Phosphorylation is one of the most common posttranslational modifications found
for proteins. Phosphorylation and dephosphorylation of proteins is intimately con-
nected to the signaling pathways in the cell. Initial changes in phosphorylation
of a receptor usually result in large numbers of changes in protein signaling path-
ways downstream typically associated with major changes in cellular function [1–5].
As such, alterations in phosphorylation are highly correlated to new pathways that
lead to oncogenesis [6]. It becomes essential then to be able to monitor changes in
phosphorylation patterns on a global scale in order to identify the critical proteins
involved in cell-cycle regulation related to cancer onset and progression.
A number of techniques have been used to detect phosphoprotein expression in cells
on a global scale [7–9]. In one approach, cells were incubated with radioactive 32P
and then detected following 2-D gel electrophoresis [9]. This method however, re-
quires the handling of radiolabels and the identification of phosphoproteins with slow
turnover rates, which only incorporate small amounts of radioactive phosphate lead-
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ing to poor detection. Monoclonal and polyclonal antibodies have also been used to
detect phosphorylated proteins blotted onto membranes. In particular, changes in
signal transduction pathways stimulated using platelet-derived growth factor were
studied using anti-phosphotyrosine antibodies [10–12]. Changes in tyrosine phos-
phorylation could be monitored as a function of time, and large numbers of proteins
involved in different signaling processes were observed. This method has been proved
to be very sensitive with only a few femtomoles of the target required for detection.
However, antibodies for detection of phosphorylated threonine and serine are still
unreliable, and phosphorylated antibodies may not detect certain phosphorylated
proteins due to steric hindrance [13]. Analytical mass spectrometry based methods,
more specifically shotgun proteomics [14, 15], have been developed for monitoring
phosphorylation as well. Protein digestion followed by MS/MS analysis of the result-
ing peptides can identify proteins in complex mixtures after comprehensive database
searching [16–20].
In more recent work, ultrasensitive detection of small amounts of phosphorylated pro-
teins has been achieved using a small molecule phosphosensor dye technology [21,22].
This phospho-sensitive dye was capable of quantitatively detecting phosphotyro-
sine, phosphoserine and phosphothreonine on a global scale. It has been used di-
rectly on 2-D gels and also in a microarray format on a variety of surfaces for
monitoring substrates of kinase reactions. This has been shown to be a universal
method for detection of phosphorylation, which could further discriminate against
thio-phosphorylation and sulfation.
It is clear, however, that any global screening of cellular protein expression must em-
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ploy methods that can readily separate large numbers of proteins and be amenable to
the various techniques possible for phosphoprotein detection. 2-D gel electrophoresis
has generally been the technique of choice, but the disadvantages of 2D gel technol-
ogy are well known [23]. New methodologies for comprehensive protein expression
will need to be explored. More recently, we have evaluated microarray formats as
a high throughput screening method for studying global protein expression [24, 25].
This format could potentially provide a convenient platform for monitoring not only
changes in protein expression but also the effects on protein modifications as a func-
tion of time and specific kinase activity.
In the present work, an all-liquid 2-D separation method has been explored to map
the protein expression of a cell lysate for differential protein expression to study
changes in phosphorylation patterns. This method uses chromatofocusing to frac-
tionate proteins in a first dimension based on their pI, followed by nonporous silica
RP-HPLC separation of the pI fractions to further fractionate proteins based on
their hydrophobicity [26]. The method provides a means of separating large num-
bers of proteins in the liquid phase, as expressed in the cells, for deposition on a
microarray surface [27]. The resulting protein microarray could be used to study
global protein expression using fluorescent phospho-sensor dyes or phospho-specific
antibodies. Specifically, the method has been used for differential protein expres-
sion to study changes in phosphorylation patterns in the human breast cancer cell
lines SUM-52PE before and after inhibition of the fibroblast growth factor receptor 2
(FGFR2) protein [28]. The method provides a new and convenient means for protein
identification and phosphorylation site searching by mass spectrometry where each
microarray spot can be matched to the original vial (fraction) containing the purified
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protein in the liquid phase.
2.2 Experimental
2.2.1 Chemicals
Methanol, ACN, urea, thiourea, iminodiacetic acid, DTT, OG, glycerol, bis-tris,
TFA, PMSF, and β-mercaptoethanol were obtained from Sigma (St. Louis, MO).
Water was purified using a Milli-Q water filtration system (Millipore, Inc., Bed-
ford, MA) and all solvents used were HPLC grade unless otherwise specified. The
reagents used were in the most pure form commercially available. Polybuffer 74 and
Polybuffer 96 were purchased from Amersham Pharmacia Biotech (Piscataway, NJ).
Pro-Q Diamond phosphoprotein gel stain and Pro-Q Diamond phosphoprotein gel
destaining solution were obtained from Molecular Probes (Eugene, OR). BlockIt 1X
blocking buffer and ArrayIt 2X printing buffer were obtained from Telechem Inter-
national, Inc. (Sunnyvale, CA). 1X PBS and ultrapure DNase/RNase free distilled
water were obtained from Invitrogen (Carlsbad, CA). Anti-phosphotyrosine antibody
4G10 clone was obtained from Upstate (Charlottesville, VA), Cy5-conjugated sec-




SUM-52PE is a human breast cancer cell line isolated from a patient’s pleural effu-
sion and developed in the Ethier laboratory [28]. The SUM-52 cells were cultured
in Ham’s F12 medium under serum-free conditions. The medium was supplemented
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with 0.1% BSA, 0.5 µg/mL fungizone, 5 µg/mL gentamicin, 5 mM ethanolamine,
10 mM HEPES, 5 µg/mL transferrin, 10 µM T3, 50 µM selenium, 1 µg/mL hydro-
cortisone and 5 µg/mL insulin. All cell culture reagents were obtained from Sigma
Chemical Co. The SUM-52PE cells were exposed to 1 µM PD173074 for 24 hr, and
untreated cells received DMSO as a vehicle control.
SUM-52PE Cell Lysis
Cell pellets were reconstituted in lysis buffer consisting of 7 M urea, 2 M thiourea,
100 mM DTT, 0.5% biolyte ampholyte 3-10, 2 % OG, and 1 mM PMSF. The cell pel-
lets were lysed at room temperature for 0.5 hr, followed by centrifugation at 35,000
rpm at 4◦C for 1 hr. The supernatant was stored at -80◦C for future use.
Sample Preparation for Chromatofocusing
A PD10 column (Amersham Biosciences) was equilibrated with a buffer solution
containing 25 mM bis-tris in 6 M urea and 0.2% OG and then used to exchange the
cell lysate from the lysis buffer to the above buffer according to the manufacturer’s
protocol.
Chromatofocusing of the SUM-52PE Cell Lysate
A schematic of the experimental apparatus used in this work is shown in Figure 2.1.
The liquid separations were performed on the ProteomeLab PF-2D liquid fractiona-
tion system (Beckman-Coulter). A 5 mg sample of cell lysate was loaded on to the
first-dimension column. The start buffer consisted of 6 M urea, 0.2% OG and 25
mM bis-tris, adjusted to pH 8.5 using IDA. The elution buffer consisted of 6 M urea,
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0.2% OG and a 10-fold dilution of Polybuffer 96 and Polybuffer 74 in a ratio of 3:7,
the pH adjusted to 4.0 using IDA. A PS-HPCF 1D column (Beckman-Coulter) was
equilibrated with the start buffer until the pH of the effluent was the same as that of
the start buffer. Sample was applied to the column with multiple injections. Once a
stable baseline was achieved, the elution buffer was switched on to elute the proteins
on the column in an isocratic mode. UV detection was performed at 280 nm, and
the pH of the effluent was monitored using a flow-through on-line pH probe. The pH
fractions were collected in 0.3 pH intervals and 15 fractions in all were taken over the
range of pH 8.5-4.0. The CF separation was completed when the pH of the effluent
reached 4.0. A 1 M NaCl solution followed by 100% IPA were then used to elute the
strongly binding proteins as salt wash and IPA wash fractions respectively.
2.2.3 Reversed-Phase HPLC on pI Fractions
RP-HPLC separation was performed using PS-HPRP 2D (4.6×33 mm) columns
(Beckman-Coulter). Solvent A was 0.1% TFA in water and solvent B was 0.1% TFA
in acetonitrile. The gradient was run from 5 to 15% B in 1 min, 15% to 25% B in 2
min, 25% to 31% B in 2 min, 31 to 41% B in 10 min, 41 to 47% B in 6 min, 47 to 67%
B in 4 min, finally up to 100% B in 3 min, held for another 1 min, and then back to
5% B in 1 min at a flow rate of 1 mL/min. The column temperature was 40◦C higher
than the ambient temperature. The UV absorption profile was monitored at 214 nm.
RP fractions were taken using a FC204 fraction collector in 96-well plates. Using a
SpeedVac at 75◦C, the fractionated proteins were dried down to 20 µL volume and
transferred to a 384-well plate after which they were dried down completely. More
than 2000 fractions were obtained after the 2-D separation and around half of these
fractions from each cell line were used for spotting on the array. The dried protein
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fractions (plates) were stored at -80◦C until further use.
2.2.4 Protein Microarrays
A 3 µL sample of a 1:1 mixture of PBS and printing buffer was added to each well us-
ing a multipipet. Printing was done on super-epoxy slides (TeleChem International)
using a Magna Spotter microarray printer (Bioautomation) and SMP4 microarray
spotting pins (TeleChem Int). Using these pins, the uptake volume was 0.25 µL and
the delivery volume was 1.1 nL, resulting in spot diameters of 135 µm. A minimum
spot spacing of 160 µm can be achieved and 2300 spots per 1×3 in. slide can be
printed. After spotting, the slides were stained with Pro-Q Diamond phosphoprotein
gel dye (Molecular Probes) for 45 min. Destaining was performed three times for
10 min each using destaining solution from Molecular Probes. After destaining, the
slides were washed with DNase- and RNase-free water for 10 min and then left to
dry. For the antibody detection, the slides were washed 5 times for 5 min each in 1X
PBS and incubated with 1:750 anti-phosphotyrosine antibody for 3 hr. The slides
were then washed three times with 1X PBS-T and twice with 1X PBS for 5 min each.
After washing, the slides were incubated with 1:1000 Cy5-conjugated secondary an-
tibody for 1 hr following which they were washed three times in 1X PBS-T and 1X
PBS for 5 min each. The slides were then rinsed with 1X PBS and dried by cen-
trifuging for 1 min on a microarray high-speed centrifuge (Telechem Int.). All steps
following the staining with Pro-Q Diamond dye were performed in the dark under
aluminum foil wraps. Both antibody solutions above were prepared in 1:1 BlockIt
buffer and 1XPBS. Hybridization chambers were used for antibody incubation, and
a minirotator (Geneq Inc., Montreal, Canada) was used for all the washing and in-
cubation steps. Scanning was done using an Axon 4000A scanner, and GenePix Pro
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3.0 software was used for data acquisition and analysis.
2.2.5 Protein Digestion
The targeted UV peak in the second dimensional RP-HPLC chromatogram, which
showed a positive response to the phospho dye, was collected and dried down to
eliminate ACN and TFA. 1 M NH4HCO3 and 10 mM DTT were then added to a
final concentration of 100 mM and 1 mM respectively, and incubated at 60◦C for 15
min. Trypsin was then mixed with the denatured proteins at the ratio of 1:50. The
mixture was incubated at 37◦C for 24 hr.
2.2.6 Enzymatic Dephosphorylation
After completion of the proteolytic cleavage, the samples were divided into two equal
parts. The enzymatic dephosphorylation step [29] was performed by treating one part
with 5 units calf alkaline phosphatase reconstituted in 25 mM NH4HCO3 buffer (pH
8.0). The mixture was incubated at 37◦C for 2 hr, and 2.5% TFA was added to stop
the enzymatic reaction. The other part was treated as a control.
2.2.7 Matrix Preparation and Spotting
In preparation for MALDI-MS, the samples were first aspirated using Zip Tips, and
then 1 µL of the eluent was mixed with an equal volume of CHCA matrix solution
prepared in 60% ACN/0.1% TFA and spotted on a MALDI plate. Once the spot
dried, 1 µL of 9:1 THAP/DAC matrix solution [30] prepared in 60% ACN/0.1% TFA
was applied on top. The spot was allowed to dry slowly afterward.
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2.2.8 Protein Identification by MALDI-MS
MALDI-TOF MS (Micromass Inc. TOFSpec2E) was used to generate peptide mass
fingerprints and then searched for registered peptide masses of proteins in the exist-
ing SwissProt database. The peptide map database search was also used to initially
confirm the possible presence of a phosphorylation site. To verify and locate the
phosphorylation sites on the proteins, MALDI-MS spectra of the phosphorylated
(control) and the dephosphorylated samples were compared.
2.2.9 MW Determination by ESI TOF-MS
An ESI TOF-MS (Micromass Inc. LCT) was used for determination of intact protein
molecular weights. The intact molecular weights from the LCT and the PMF ob-
tained from the MALDI-TOF MS analysis provided the complete identification of the
proteins in the fractions of interest. Fractions from the second-dimension RP-HPLC
analysis for LCT were first dried down using a SpeedVap and then reconstituted
in 60% ACN with 2% FA. The samples were directly infused at 10 µL/min using a
syringe pump. A desolvation temperature of 150◦C and source temperature of 100◦C
was used. Nitrogen gas flow was maintained at 400 L/hr. The capillary voltage was
set at 3200 V, the sample cone voltage at 35 V, the extraction cone voltage at 3
V, and the reflection lens voltage at 750 V. One mass spectrum was acquired every
second. The intact molecular weight was obtained by deconvolution of the spectra
using the MaxEnt1 software (Micromass Inc.).
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2.2.10 LC-MS/MS
The tryspin-digested samples were analyzed by reversed-phase chromatography us-
ing a 0.075×150 mm C18 column attached to a Paradigm HPLC pump (Michrome
Bio Resources). Peptides were eluted using a 23 min gradient from 5 to 95% B
(0.1% FA/95% ACN), where solvent A was 0.1% FA/2% ACN. A Finnigan LTQ
mass spectrometer (Thermo Electron Corp.) was used to acquire the spectra, the
instrument operating in data-dependent mode with dynamic exclusion enabled. The
MS/MS spectra on three most abundant peptide ions in full MS scan were obtained.
All MS/MS spectra were analyzed using the MASCOT search tool against the com-
posite, nonidentical protein sequence database MSDB.
2.3 Results and Discussion
SUM-52PE cells highly overexpress FGFR2 at both the message and protein lev-
els. There are nine alternatively spliced isoforms of FGFR2 expressed by the SUM-
52PE cells [28]. The isoforms differ in the number of immunoglobulin-like domains,
the presence or absence of the acid box, and the carboxyl terminal region. The
SUM-52PE cells display the transformed phenotypes of growth factor-independent
growth and the ability to grow under anchorage independent conditions and inva-
sion. PD173074 is a small molecule kinase inhibitor against the FGFR family [31].
PD173074 blocks the phosphorylation of FGFR2, as well as the downstream signaling
components of the MAP kinase and PI3 kinase pathways [32]. The PD compound
also inhibits SUM-52PE cell growth in monolayer and in soft agar [28].
The cell lysates of SUM-52PE and SUM-52PE inhibited by PD173074 were separated
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using the 2-D liquid separation method, and protein maps were obtained using the
Beckman Coulter ProteoVue Software suite for each of the cell lines. A comparison
of the two cell lines before and after inhibition is shown in Figure 2.2 in differential
display format (using DeltaVue from Beckman Coulter) for two different pH regions.
In Figure 2.2, the protein profile for SUM-52PE is displayed in green and that for
the inhibited cell line is shown in red. The differential display in the center lane
shows that there are proteins that are up- and down-regulated following inhibition
of the SUM-52PE cell line. This might be expected since inhibition of the FGFR2
growth factor results in changes in protein pathways that would change the protein
expression in the cell. Nevertheless, most of the proteins observed are similar in the
SUM-52PE before and after inhibition.
Each of the protein bands were collected in the liquid phase following 2-D liquid
fractionation and spotted on the protein microarray as described above. Each array
spots can be associated with a protein band collected during the 2-D liquid separa-
tion. The array is then stained with the Pro-Q Diamond phospho-dye to screen for
the presence of phosphorylation on the different protein spots. The result is shown
in Figure 2.3 for an array cluster with three pH fractions where several spots are
clearly lit up by the dye when scanned by the 532 nm excitation source indicating
the presence of phosphorylation. The microarray image of Figure 2.3 reveals the
limited quality of the spot printing using the contact printer on glass slides. The
method, however, does allow one to identify phosphorylated proteins on a global
scale using only a limited amount of material.
The result of a differential phosphoprotein array for proteins printed from a single
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pH range is shown in Figure 2.4. Each pair of arrays compares the SUM-52PE cell
line before and after inhibition of FGFR2. The arrows that point to pairs of protein
spots clearly identify proteins that are phosphorylated in the SUM-52PE cells under
control conditions but not so following treatment with the inhibitor in response to
changes in phosphorylation pathways due to inhibition of the FGFR2. Of the nearly
1000 protein bands printed on the array for each cell line, there were at least 50
proteins showing changes in the state of phosphorylation due to inhibition. In many
cases, the protein spot is lit up on one array but not the other, indicating that the
protein is phosphorylated in one cell line but not the inhibited counterpart. In other
cases, the protein spot is lit up, but the quantitative degree of excitation may change,
indicating a different degree of phosphorylation between the two cell lines. There
are also some spots that remain unchanged, indicating that these proteins are not
involved in the FGFR2 signaling pathway.
It should be noted in Figure 2.4 that the corresponding spots in the arrays for the
two cell lines may not contain the same protein. The spotting process is performed
according to the 2-D liquid fractionation of protein bands. There are several bands
that appear in one cell line but not the other so that the number of protein peaks in
each pH fraction is different. The corresponding peaks in the arrays for the two cell
lines can be matched using the %B on the chromatographic gradient and then by us-
ing MALDI-TOF MS of the protein digests to verify that they are the same proteins.
The use of MALDI-TOF MS for definitively matching the protein spots is essential
since phosphorylated proteins often show pH shifts, which can significantly shift the
position of the spot on the array. These shifts would likewise be observed on 2-D gels.
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The use of protein arrays with the Pro-Q dye, which is selective toward phosphoryla-
tion, allows one to rapidly detect the presence of phosphorylation in specific proteins.
This eliminates the need to perform detailed analysis on a large number of proteins,
thus simplifying the problem of studying differential phosphorylation in biological
systems. It is essential, though, to perform detailed mass spectrometric analysis
of the proteins selected as candidates to establish the identity of the protein and
to confirm changes in phosphorylation as outlined in Figure 2.5-2.8. An important
aspect of this work is that each spot on the array can be correlated to the original
protein well from which it was spotted for further analysis. MALDI-TOF MS on the
tryptic digest of proteins was initially performed for identification and confirmed by
LC-MS/MS.
When using the matrix CHCA, the negative charge on the phospho groups make
the phosphopeptides difficult to detect in positive ion mode. THAP, a less acidic
matrix, has been demonstrated to enhance the ionization of phosphopeptides by 10-
fold [30]. We experimented with a technique described above using both THAP and
CHCA where improved sensitivity for phosphopeptides in the positive ion mode was
achieved without affecting the ionization of the non-phosphorylated peptides. This
matrix mixture though, required a higher laser power than when using only CHCA
to give comparable signal intensities for non-phosphorylated peptides.
A key issue in this work involves using mass spectrometric methods to confirm the
presence of phosphorylations in the array spots that light up when stained with Pro-Q
Diamond dye. This was performed using CAP to dephosphorylate the proteins that
were identified as being phosphorylated on the arrays and performing MALDI-TOF
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MS on the digests before and after dephosphorylation. The mass spectra of the pep-
tides should show an 80 Da shift to lower mass after dephosphorylation if they were
originally phosphorylated. The MALDI-TOF MS spectra for several phosphorylated
proteins and their dephosphorylated counterpart are shown in Figure 2.5-2.8. Figure
2.5 shows the phosphorylated and dephosphorylated counterpart of a peptide from
Zinc Finger Protein 492, clearly indicating a shift of the peak at m/z 2333 correspond-
ing to (K)LYKPESCNNACDNIAKISK(Y) to m/z 2253 following dephosphorylation
by CAP. Rab13 (Figure 2.6) shows a shift from m/z 1934.96 to 1855, which cor-
responds to the peptide (K)-GSKPVRPPAPGHGFPLIK(R). Figure 2.7 shows the
peptide (-)-MMLGTEGGEGFVVK(V) at m/z 1534.67 from heterogeneous nuclear
ribonucleoprotein H shifted to m/z 1454, and Figure 2.8 shows the peptide at m/z
2342.04 with sequence (R)FHTGKTSFACTECGKFSLR(K) from zinc finger protein
615 shifted to m/z 2262.24 following dephosphorylation. In all these cases, the peaks
corresponding to the phosphorylated peptide are absent from the dephosphorylated
sample spectra, indicating that the enzymatic reaction is complete. This method
clearly shows that these proteins which were illuminated by the Pro-Q dye on the
microarray are indeed phosphorylated, although the position and type of phospho-
rylation need to be confirmed by further experimentation.
The MW of the intact protein was also obtained using ESI-TOF MS when there
was a sufficient amount of protein available in order to constrain the peptide map
and LC-MS/MS search and unambiguously identify the protein. A partial list of
differentially expressed proteins that lit up on the array is shown in Table 2.1 as
identified by MALDI-TOF MS and LC-MS/MS. The last column in Table 2.1 indi-
cates whether the phosphoprotein is upregulated or downregulated in the SUM-52PE
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cell line compared to the inhibited sample. In each case in Table 2.1 performed by
LC-MS/MS, the initial database search showed the probable presence of one or more
phosphorylation sites, although the specific phosphorylation generally could not be
identified. In addition, the experimental MW often did not precisely match the
database value, indicating the presence of a modified protein. Though there may be
several different modifications on any protein in addition to phosphorylation, there
are significant shifts in the measured pI toward lower pH compared to the database
values in all the proteins in Table 2.1, which is often indicative of the presence of
phosphorylations [33]. Zinc finger protein 492 was isolated in the salt wash fraction,
pH <4.0, although the theoretical pI of the unphosphorylated form is 9.3. This shift
in pI may be due to the presence of up to 14 phosphorylations based on the MS data.
To further confirm the type of phosphorylation site modified, anti-phosphotyrosine
antibodies were used. Figure 2.9 shows two arrays that had been processed with
Pro-Q Diamond Dye. In Figure 2.9a, the green spots obtained in this process dis-
play all the proteins that have phosphorylated Ser, Thr, or Tyr residues as detected
by the Pro-Q dye. In Figure 2.9b, the array was also processed with 4G10 anti-
phosphotyrosine antibody after the Pro-Q analysis, and the red spots correspond
to Tyr phosphorylations detected by the antibody. The green spots in this image
identify proteins that are not phosphorylated at Tyr, and the yellow spots identify
those that have only a small number of phosphorylated Tyr. The data clearly show
that the spots corresponding to Eps15 and SHPS-1 are phosphorylated on Tyr, al-
though there may also be a small number of Thr or Ser phosphorylations present.
In principle, an anti-phosphoserine or anti-phosphothreonine antibody may also be
used after the Pro-Q analysis.
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It should be noted that in most cases shown in Figure 2.9 the spots lit up by the Pro-
Q dye are in concordance with those lit up by the Cy-5-labeled anti-phosphotyrosine
antibody. However, the spot marked by ‘X’ on the array is not detected by the Pro-Q
dye but is detected by the anti-phosphotyrosine antibody as shown by the bright red
color. The response to the antibody could be due to a possible nonspecific binding
of the antibody. Alternatively, the lack of response to the Pro-Q dye may be due
to the protein concentration in this spot, which is too low for detection by the dye.
This spot has presently not been positively identified by MALDI-MS, and evidence
of a phosphorylation site by mass spectrometric analysis has not yet been found.
A quantitative analysis was also conducted with the Pro-Q Diamond dye. The
sensitivity of the dye for epoxy-coated surfaces turned out to be ∼100 pg of total
protein/well, which is equivalent to ∼100 fg of protein/spot where β-casein was used
as a quantitation standard (Figure 2.10). β-Casein was dephosphorylated and used
as a quantitation control. The dye appears to have an improved sensitivity when
used with hydrogel slides as shown previously by Patton et al. [21], where they ob-
tained a sensitivity of ∼50 fg using the same standard. Epoxy-coated slides were
selected for analysis since they resulted in lower background absorbance compared
to the amine substrate when working with the Pro-Q dye. This quantitative data
should not be treated as absolute since contact printing with its inherent drawbacks
is less reliable for quantitative analyses than noncontact printers. Nevertheless, the
method can be used as a reference for comparisons within the slide. Figure 2.11
shows the linear dynamic range of the Pro-Q dye, which turned out to agree quite
well with the values obtained by Patton et al [21]. Since with contact printing the
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spot size is not consistent, a more convenient measure of ‘total protein per well’ was
used to obtain the quantitative data representing a more practical approach.
2.4 Conclusion
The use of 2-D liquid separations can generate protein microarrays that reflect the
natural posttranslational modifications as produced in cells. Of critical importance
is the detection of changes in phosphorylations, since these PTMs are often respon-
sible for signaling pathways related to essential processes in cells related to cancer.
In this work, we have shown that these microarrays can be used to detect changes
in phosphorylation in a malignant breast cancer cell line due to inhibition of the
FGFR2 receptor. Pro-Q Diamond dye was used as a global means to detect phos-
phorylations while an anti-phosphotyrosine antibody was used to detect proteins with
tyrosine phosphorylations. These arrays can be clearly used to detect the presence of
phosphorylated proteins, although the specific phosphorylation sites require further
work using LC-MS/MS. When using CAP - which was applied to proteins detected
as phosphorylated on the arrays - a shift of -80 Da detected in the mass spectrum
resulted in easier identification of proteins by MALDI-TOF MS. Although changes in
phosphorylation patterns could be detected due to inhibition of the FGFR2 receptor
by a small-molecule inhibitor, this detection was only performed 24 hr after initial
stimulation. To obtain meaningful biological data on this system, future work will
require a time course study to monitor changes in phosphorylation at various times
immediately after inhibition.
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Table 2.1: List of differentially phosphorylated proteins identified by MALDI-MS and LC-MS/MS








Zinc finger protein 492 Q9P255 65952/9.3 66010 salt wash -
RalBP1-interacting protein 1 Q96D71 80770/5.6 80758 4.3-4.6 -
Eps15 P42566 98675/4.4 4.3-4.6 -
MAPK interacting protein Q15750 54645/5.3 54436 4.3-4.6 +
Signal transducer and activator of
transcription 3 (STAT3)
P40763 88069/5.9 4.3-4.6 +
Heterogeneous nuclear ribonucleo-
protein H3
P31942 36927/6.4 36915 6.1-6.4 -
SHPS-1 P78324 54813/6.3 55163 6.1-6.4 -
Zinc finger protein 324 (zinc finger
protein ZF5128)
O75467 61104/9.7 61074 6.1-6.4 -
60S ribosomal protein L13 P26373 24116/11.65 24285 6.1-6.4 -
Cofilin-1 P23528 18371/8.26 18425 6.1-6.4 -
Lamin A/C (70 kDa lamin) P02545 74139/6.57 74304 5.2-4.9 +
Protein kinase C binding protein 1 Q9ULU4 131692/6.83 5.2-4.9 -
Peroxisome proliferator-activated
receptor binding protein (PBP)
Q15648 168334/8.88 5.2-4.9 -
Splicing factor 1 Q15637 68287/9.07 68415 5.2-4.9 +
Proto oncogene C-crk P46108 33850/5.49 33715 5.2-4.9 -
Octamer-binding transcription fac-
tor 1
P14859 76426/6.34 76785 5.2-4.9 -
Cytoplasmic protein NCK1 P16333 42838/6.06 5.2-4.9 -
Histamine H1 receptor P35367 55748/9.33 55637 5.2-4.9 +
Neurofilament triplet M protein P07197 102256/4.9 salt wash -
Antigen KI-67 P46013 358526/9.46 salt wash -
Neuroblast differentiation associ-
ated protein AHNAK
Q09666 312295/6.29 salt wash +
Ribosomal protein S6 kinase alpha
5
O75582 89810/6.63 salt wash +
Signal transduction protein CBL-C Q9ULV8 52450/7.83 52522 salt wash -
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Figure 2.1: Overview of the approach used in this experiment.
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Figure 2.2: 2D-UV difference maps of FGFR2-inhibited SUM-52PE (left) and normal SUM-52PE
(right) cell line for two different pH fractions: lane 12 - pH 7.6-7.9 (top); and lane 7 -
pH 6.1-6.4 (bottom)
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Figure 2.3: Microarray image showing fractions with pH 5.2-4.3 for SUM-52PE where phosphory-
lation is detected using Pro-Q Diamond dye
Figure 2.4: Microarray image showing pH fraction 4.6-4.3 for SUM-52PE before (left) and after
(right) stimulation by PD173074
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Figure 2.5: MALDI spectrum of zinc finger protein 492 obtained before (bottom) and after (top)
dephosphorylation by CAP
Figure 2.6: MALDI spectrum of Rab13 interacting protein (MIRab13) (MICAL-like protein 1) ob-
tained before (bottom) and after (top) dephosphorylation by CAP
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Figure 2.7: MALDI spectrum of heterogeneous nuclear ribonucleoprotein H (hnRNP H) obtained
before and after dephosphorylation
Figure 2.8: MALDI spectrum of zinc finger protein 615 obtained before and after dephosphorylation
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Figure 2.9: Slide image for pH fraction 4.6-4.3 processed with antiphosphotyrosine antibody (b)
after having been visualized with Pro-Q Diamond dye (a). Eps15 and RalBP1 show
Tyr phosphorylation and STAT3 shows phosphorylation on amino acids other than
tyrosine. The spot marked X displays the case where the antibody binds to the protein
either through nonspecific interactions or the concentration of the protein in that spot is
below the sensitivity limit of Pro-Q Diamond dye. Spots reacting positively to the Pro-
Q dye are shown in green while those that bind with the anti-phosphotyrosine antibody
are shown in red.
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Figure 2.10: Detection sensitivity of β-casein visualized using Pro-Q Diamond dye. Figure shows
10 and 100-fold serial dilutions of β-casein from 100 µg to 100 fg per well spotted
on superepoxy slides; The first and the third rows from top show the phosphorylated
form and the other two rows show controls (dephosphorylated β-casein treated with
calf alkaline phosphatase). A sensitivity limit of ∼100 pg of total protein/well was
obtained.
Figure 2.11: Linear dynamic range for β-casein visualized using Pro-Q Diamond phosphoprotein
dye. A dynamic range of ∼100 was obtained when epoxy-coated glass slides were used
for analysis.
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CHAPTER III
Natural Protein Microarrays using Liquid Phase
Fractionation of Panc-1 cell-lines for the study of Humoral
Response in Pancreatic Cancer
3.1 Introduction
Major advances in cancer control will be greatly aided by early detection so as to
diagnose and treat cancer in its pre-invasive stage prior to metastasis. Unfortu-
nately, for Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of
cancer-related death in the United States [1], effective early detection and screening
are currently not available and tumors are typically diagnosed at a late stage, fre-
quently after metastasis. PDAC is generally considered to be incurable by available
treatment modalities, with a 5-year survival rate of less than 4 percent. Existing
biomarkers for PDAC are inadequate [2]. CA19-9 has been tested for its utility as
an early detection marker in pancreatic cancer [2–5]. However, the sensitivity and
specificity of this biomarker are not high, and serum levels are significantly increased
in inflammatory diseases of the pancreas and biliary tract. Therefore, CA19-9 is not
useful for early diagnosis, mass screening or for distinguishing between PDAC and
chronic pancreatitis. Thus, there is a great need for new biomarkers for PDAC. In
the absence of good biomarkers, 80% to 90% of PDAC cases are diagnosed too late
in the disease process for surgical resection to be an effective option. Among the 10%
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to 20% of PDAC cases where surgical resection is an option, most patients ultimately
die of recurrent or metastatic disease [6].
The development and progression of PDAC is generally believed to be caused by the
activation of oncogenes, inactivation of tumor suppressor genes and the dysregula-
tion of cellular signal transduction pathways, e.g. EGFR, Akt and NFκB [7]. The
analysis of gene mutations, growth factors and their receptors and other downstream
signaling proteins may have utility in the early detection of PDAC. For instance, acti-
vating point mutations in codon 12 of the K-ras gene are present in the large majority
of PDAC [8–10]. Mutations in p53 have also been observed in approximately 50% of
PDAC tumors [11].
Mutations in a few key signaling proteins may deregulate the expression of a large
number of downstream proteins that interact with each other, possibly through post-
translational modifications such as phosphorylation and glycosylation. While both
N-linked glycosylation and sialylation regulate receptor expression and signaling
by modifying ligand binding sites [12], protein phosphorylation acts as a molecu-
lar switch to activate or deactivate diverse cellular signaling networks. Importantly,
identification of deregulated proteins has utility in elucidation of the protein signaling
networks. Such identifications may be facilitated by protein microarray technologies
for proteome-wide screening.
Protein microarrays have utility as a high-throughput screening method for whole-
cell lysates, fractionated proteomes, tissues, and antigen-antibody reactions [13–21].
Such microarrays, arrayed with naturally produced proteins that have been sepa-
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rated using multi-dimensional liquid-based separation of a proteome, followed by
the arraying of all proteins found in the individual fractions, can subsequently be
probed with a variety of detection agents, including lectins for glycoprotein detec-
tion [22, 23]. In the present work, we have utilized protein microarrays to analyze
post-translational modifications as potential epitopes that elicit a humoral response
in PDAC. We have used 2-D HPLC based fractionation of Panc-1 derived proteins,
followed by non-contact piezoelectric spotting for generation of protein microarrays.
These microarrays were utilized for evaluation of the humoral response in patients
with PDAC, and for assessing post-translational modifications on Panc-1 derived
tumor antigens. Statistical analysis of the humoral response data facilitated a quan-
titative estimate of the humoral response against specific tumor antigens between
the diagnosis groups. Specific tyrosine phosphorylation patterns were elucidated for
each protein fraction using anti-phosphotyrosine antibodies. In addition, analysis
of the glycoproteins involved in generation of a humoral response was obtained us-
ing five different biotinylated lectins to analyze the glycan structure of glycoproteins.
3.2 Experimental
3.2.1 Chemicals
Methanol, acetonitrile, urea, thiourea, iminodiacetic acid, DTT, OG, glycerol, bis-
tris, TFA, and PMSF were obtained from Sigma (St. Louis, MO). Water was purified
using a Milli-Q water filtration system (Millipore Inc., Bedford, MA) and all sol-
vents were HPLC grade unless otherwise specified. Reagents used were in the purest
form commercially available. Polybuffer 74 and polybuffer 96 were purchased from
Amersham Pharmacia Biotech (Piscataway, NJ). Pro-Q Diamond phosphoprotein gel
stain and Pro-Q Diamond phosphoprotein gel destaining solution were obtained from
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Molecular Probes (Eugene, OR). 1X PBS and ultra-pure DNase/RNase free distilled
water were obtained from Invitrogen (Carlsbad, CA). Mouse anti-phosphotyrosine
antibody, clone 4G10 was obtained from Upstate (Charlottesville, VA), Mouse anti-
phosphotyrosine antibody, clone PY20, was obtained from Perkin-Elmer and the
Cy5-conjugated secondary antibodies were obtained from Jackson ImmunoResearch
Lab Inc. (West Grove, PA.). Five biotinylated lectins (Aleuria aurentia (AAL),
Maackia amurensis lectin II (MAL), peanut agglutinin (PNA), Sambucus nigra bark
lectin (SNA) and Concanavalin A (ConA)) were all purchased from Vector Labo-
ratories (Burlingame, CA). The streptavidin-AlexaFluor555 conjugate was obtained
from Invitrogen (Carlsbad, CA.).
3.2.2 Serum Samples
Serum was obtained at the time of diagnosis following informed consent using IRB-
approved guidelines. Sera were obtained from 15 patients with a confirmed diagnosis
of pancreatic adenocarcinoma in the Multidisciplinary Pancreatic Tumor Clinic at
the University of Michigan Hospital. These sera were randomly selected from a clinic
population that sees, on average, at the time of initial diagnosis, 15% of pancreatic
adenocarcinoma patients presenting with early stage (i.e., stage 1/2) disease and
85% presenting with advanced stage (i.e., stage 3/4). Inclusion criteria for the study
included patients with a confirmed diagnosis of pancreatic cancer, the ability to pro-
vide written, informed consent, and the ability to provide 40 mL of blood. Exclusion
criteria included inability to provide informed consent, patient’s actively undergoing
chemotherapy or radiation therapy for pancreatic cancer, and patients with other
malignancies diagnosed or treated within the last 5 years. Sera were also obtained
from 8 patients with chronic pancreatitis who were seen in the Gastroenterology
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Clinic at University of Michigan Medical Center, and from 15 control healthy indi-
viduals collected at University of Michigan under the auspices of the Early Detection
Research Network (EDRN). The mean age of the tumor group was 65.4 years (range
54-74 years) and from the chronic pancreatitis group was 54 years (range 45-65). The
sera from the normal subject group was age and sex-matched to the tumor group.
All of the chronic pancreatitis sera were collected in an elective setting in the clinic
in the absence of an acute flare. All sera were processed using identical procedures.
The samples were permitted to sit at room temperature for a minimum of 30 minutes
(and a maximum of 60 minutes) to allow the clot to form in the red top tubes, and
then centrifuged at 1,300×g at 4◦C for 20 minutes. The serum was then removed,
transferred to a polypropylene, capped tube in 1 mL aliquots, and frozen. The frozen
samples were stored at -70◦C until assayed. All serum samples were labeled with a
unique identifier to protect the confidentiality of the patient. The handling of all




The Panc-1 PDAC cell line was cultured in Dulbecco’s modified Eagle medium sup-
plemented with 10% fetal bovine serum, 100 units/mL penicillin and 100 units/mL
streptomycin (Invitrogen, Carlsbad, CA). Upon reaching 80% confluence, the cells
were washed twice in 10 mL 1XPBS containing 4 mM Na3VO4, 10 mM NaF and one
half of a protease inhibitor cocktail tablet. The sample was then solubilized in 300
µL lysis buffer consisting of 7 M urea, 2 M thiourea, 100 mM DTT, 0.5% biolyte
ampholyte 3-10, 2% OG, 4 mM Na3VO4, 10 mM NaF and 1 mM PMSF at room
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temp for 30 min, followed by centrifugation at 35,000 rpm at 4◦C for 1 hr. The
supernatant was stored at -80◦C until use.
Sample Preparation for Chromatofocussing (CF)
A PD10 column (Amersham Biosciences) was equilibrated with a pH 7.9 buffer solu-
tion containing 25 mM bis-tris in 6 M urea and 0.2% OG and then used to exchange
the cell lysate from the lysis buffer to the CF buffer according to the manufacturer’s
protocol.
3.2.4 Chromatofocusing of Panc-1 Cell Lysate
The liquid separations were performed on the Gold Model 128 HPLC Pump along
with a Model 166 UV Detector (Beckman-Coulter, Inc.). An AX300 4.6×250 mm
(Eprogen Inc.) weak anion exchanger column was utilized for the first dimension
separations. The start buffer consisted of 6 M urea, 0.2% OG, 25 mM bis-tris (pH
adjusted to 7.9 using saturated IDA). The elution buffer consisted of 6 M urea, 0.2%
OG and a 10-fold dilution of polybuffer 96 and polybuffer 74 in a ratio of 3:7 (the
pH was adjusted to 4.0 using saturated IDA). The chromatofocusing column was
pre-equilibrated with the start buffer until the pH of the effluent was the same as
that of the start buffer. 13 mg of the cell lysate was applied to the chromatofocusing
column with multiple injections. Once a stable baseline was achieved, the elution
buffer was switched on to elute the proteins on the column in an isocratic mode. UV
detection was performed at 280 nm and the pH of the effluent was monitored using
the PF2D’s flow-through on-line pH probe. The pH fractions were collected in 0.3
pH intervals and 15 fractions in total were collected over the range of pH 7.9-4.0. The
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CF separation was completed when the pH of the effluent reached 4.0. The column
was then washed with a 1 M NaCl solution followed by 100% IPA to elute out the
strongly binding proteins as salt-wash and isopropanol-wash fractions respectively.
3.2.5 Reverse Phase HPLC Separations
RP-HPLC was performed using an ODS-I (8×33 mm) column (Eprogen Inc.). Sol-
vent A was 0.1% TFA in water and Solvent B 0.1% TFA in acetonitrile. The gradient
was run from 5% to 15% in 1 min, 15% B to 25% in 2 min, 25% to 31% in 2 min,
31% to 41% in 10 min, 41% to 47% in 6 min, 47% to 67% in 4 min, then up to
100% B in 3 min where it was held for 1 min, and then reduced to 5% in 1 min
at a flow rate of 1 mL/min. The column temperature was 40◦C higher than the
ambient temperature. The UV absorption profile was monitored at 214 nm. The RP
fractions were collected automatically in 96 well plates, then lyophilized to dryness
using vacuum centrifugation at 75◦C, and stored at -80◦C until use.
3.2.6 Protein Microarrays
Printing
The fractionated Panc-1 proteins (1152 fractions) were resuspended in 60% ACN
with 0.1% TFA and transferred into 96-well microtiter plates. The samples were then
lyophilized to dryness, and then reconstituted in 15 µL printing buffer comprising
of 125 mM Tris-HCL (pH 6.8), 1% w/v SDS, 5 w/v DTT, 1% glycerol and protease
inhibitors in 1X PBS. All of the fractions were printed on nitrocellulose (Whatman)
and/or SuperEpoxy (Telechem International) slides using a GeSiM Nanoplotter2
non-contact piezoelectric printer. Each spot measured approximately 300 µm in di-
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ameter with a spot spacing of 600 µm. The slides were dried overnight at room temp
and were either used immediately or stored in a desiccated chamber at -20◦C.
Hybridization of Slides for Humoral Response Analysis
Nitrocellulose slides spotted with Panc-1 protein fractions were blocked in 1X PBS
containing 1% BSA (Sigma, St Louis) and 0.1% Tween-20 overnight at 4◦C. The
slides were then incubated individually with serum from pancreatic adenocarcinoma
patients, from normal subjects or from patients with chronic pancreatitis. The sera
used were diluted to 1:400 in probe buffer (1X PBS, pH 7.4 containing 1% BSA, 5
mM MgCl2, 0.5 mM DTT, 0.05% Triton X-100 and 5% glycerol) and hybridized to
the microarray slides. The slides were incubated for 2 hr at 4◦C, washed 5 times with
probe buffer for 5 min each, and then incubated with Alexa Fluor 647-conjugated
anti-human IgG (1:2000, Invitrogen, Carlsbad, CA) for 1 hr at 4◦C. The microar-
rays were then washed 5 times for 5 min each with probe buffer, dried and scanned
on an Axon 4000A scanner (Axon Instruments Inc., Foster City, CA). GenePix Pro
6.0 software (Molecular Devices, Sunnyvale, CA) was used for data acquisition and
preliminary data filtering.
Hybridization with Lectins to Delineate the Glycan Structure of Panc-1 Glycoproteins
The microarrays were blocked in 1% BSA in 1X PBS-T (with 0.1% Tween-20)
overnight at 4◦C. The slides were then incubated with biotinylated lectins diluted in
1X PBS-T. The lectins used were biotin conjugated Aleuria aurentia (AAL), Maackia
amurensis lectin II (MAL), peanut agglutinin (PNA), Sambucus nigra bark lectin
(SNA) and Concanavalin A (ConA). The working concentration of all lectins used
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was 5 µg/mL except for SNA, which was used at 10 µg/mL. After primary incu-
bation, all slides were washed 5 times with 1X PBS-T for 5 min each. Secondary
hybridization was performed with a streptavidin-Alexa Fluor 555-conjugate (Invitro-
gen, Carlsbad, CA) in a working concentration of 1µg/mL in 1X PBS-T containing
0.5% BSA. After secondary hybridization, the microarrays were washed 5 times for
5 min each in 1X PBS-T and then completely dried by centrifugation. The dried
microarray slides were subsequently scanned on an Axon 4000A scanner. GenePix
Pro 6.0 software was used for data acquisition and preliminary data filtering.
Hybridization to Delineate Panc-1 Phosphoproteins
The microarray slides were blocked overnight in 1% BSA in 1X PBS-T The mi-
croarrays were then incubated in goat monoclonal anti-phosphotyrosine (Upstate,
Charlottesville, VA) antibody diluted to 2 µg/mL in probe buffer After primary hy-
bridization, the slides were washed 5 times for 5 min each in probe buffer. Secondary
hybridization was performed for 1 hr using Cy3 conjugated anti-mouse antibody at
a concentration of 1 µg/mL in probe buffer. The microarray slides were washed 5
times for 5 min each in probe buffer, dried by centrifugation and scanned on an
Axon 4000A scanner. GenePix Pro 6.0 software was used for data acquisition and
preliminary data filtering.
Microarray Data Acquisition and Filtering
All processed slides were scanned using an Axon 4000A scanner. GenePix Pro 6.0
software was used for data acquisition and preliminary data filtering. Single channel
intensity values for the green channel were obtained for each microarray processed
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with lectins and the intensity values for the red channel were obtained for each
microarray processed with human sera. Initial spot analysis was performed with
GenePix software, where all irregularly formed spots manually flagged. The back-
ground corrected median intensities were calculated. Spots that had negative inten-
sity for greater than 50% of the serum samples were removed. Each array was then
centered on its median intensity value and scaled by the median absolute deviation
(MAD). Quantile matching was used to standardize the data across arrays.
3.2.7 Statistical Analysis of Humoral Response Data
A supervised analysis was conducted with the humoral response array data (all 1152
fractions) to select the protein fractions that were predictive of cancer. Array data,
normalized as described above, was applied to a test statistic-based feature selection
procedure. Protein signatures of varying length (10 to 100 proteins) were used to
build a Support Vector Machine (SVM) prediction model. The SVM over multiple
kernel test permutations was embedded in a finite grid-search of paired values of
exponentially growing sequences of cost (C) and gamma (γ). Leave-one-out cross-
validation (LOOCV) was used to evaluate the performance of the signatures. A
signature that yielded the best accuracy was selected. Principal component analysis
(PCA) was also used to verify the accuracy of the differentiation among the diag-
nostic groups. All statistical analyses were performed using R 2.3.0 and SPSS.
3.2.8 Protein Digestion
The UV fractions collected from the 2nd dimension RP-HPLC chromatogram that
showed a positive response to PTM detection experiments or that demonstrated pos-
62
itive reactivity from the humoral response experiment were collected and dried down
to 20 µL in order to eliminate ACN and TFA. 1 M NH4HCO3 and 10 mM DTT
were then added to a final concentration of 100 mM and 1 mM, respectively and
incubated at 60◦C for 15 min. Trypsin was then mixed with the denatured proteins
at the ratio of 1:50. The mixture was incubated at 37◦C for 24 hr.
3.2.9 Peptide Sequencing by LC-MS/MS
Trypsin digested samples were separated by a capillary reversed phase chromatogra-
phy column (MagicAQ C18, 0.1×150 mm) (Michrom Biosciences, Auburn, CA) on a
Paradigm MG4 micro-pump (Michrom Biosciences) with a flow rate of 300 nL/min.
Peptides were eluted using a 45 min gradient which was started at 3% B, increased
to 35% B in 25 min, 60% B in 15 min, 90% in B min, maintained at 90% B for
1 min and finally changed back to 3% B in 3 min. Both solvents A (water) and
B (acetonitrile) contained 0.1% formic acid and 0.05% HFBA. The resolved pep-
tides were analyzed on an LTQ mass spectrometer (Thermo, San Jose, CA) with a
nano-ESI platform (Michrom Biosciences) operating in data dependent mode with
dynamic exclusion enabled. The capillary temperature was set at 200◦C, the spray
voltage was 2.4 kV, and the capillary voltage was 20 V. The normalized collision
energy was set at 35% for MS/MS. The MS/MS spectra for the top three peaks from
full MS scan were obtained. The spectra were searched using SEQUEST algorithm
against the non-redundant Swiss-Prot human protein database. One missed cleav-
age was allowed during the database search. Protein identification was considered
positive for a peptide with Xcorr of greater than or equal to 3.0 for +3, 2.5 for +2,
and 1.8 for +1 charged ions. Peptide identification accuracy for protein identifica-
tion was further increased using PeptideProphet (maintained by Trans Proteomic
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Pipeline Project). PeptideProphet [24] validates peptide assignments from MS/MS
spectra which in turn is used to validate protein identities using ProteinProphet [25].
3.3 Results and Discussion
Clinical detection of early stage pancreatic cancer has been hampered, in part due to
the lack of suitable biomarkers. In this study, we used the Panc-1 human pancreatic
ductal adenocarcinoma cell line to analyze the humoral response in pancreatic cancer,
as Panc-1 cell lines have been shown to maintain some of the differentiated charac-
teristics of normal mammalian pancreatic ductal epithelial cells [26]. The analytical
work flow is depicted diagrammatically in Figure 3.1. The Panc-1 cell line was lysed
as described in Methods. 13 mg solubilized protein was subjected to 2-D HPLC in
order to resolve sufficient protein for the microarray analysis. The first dimension
separation, between pH 7.9-4.0, was achieved using a weak anion exchange column.
A 4.6×250 mm column was used to resolve sufficient protein for all the experiments.
Each of the collected pI fractions from the first dimension separation were then re-
solved in the second dimension using nonporous silica reverse phase HPLC on an
8×33 mm NPS C18 column. 1152 protein fractions were obtained following RP-
HPLC. All fractions were subsequently printed on nitrocellulose-coated glass slides
as described in Methods.
For the humoral response experiment, 38 serum samples were hybridized individu-
ally to the protein microarrays. The serum included 15 sera from pancreatic cancer
patients, 15 from normal subjects and 8 serum samples from patients with chronic
pancreatitis. Following hybridization of all the slides with patient serum, in parallel
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so as to mitigate any day-to-day variation, the obtained microarray data was used
for rigorous statistical analysis.
Statistical Analysis for Protein Selection: To eliminate the humoral response
signature of all protein fractions that are related to pancreatic inflammation, but
which are not cancer-specific, protein fractions which distinguished chronic pancre-
atitis sera from normal sera were first identified. SVM algorithm was used on the
data from both chronic pancreatitis and normal samples, and LOOCV was used to
train and test possible protein signatures. A signature comprising 68 protein frac-
tions had the highest accuracy at 69.6%. 72 proteins were found to be in common
among the 23 protein signatures generated by LOOCV. After exclusion of these 72
proteins from the data set (group A; Figure 3.4), a comparison between the control
and cancer serum samples yielded a 28 protein fraction signature with 60% accuracy,
with 33 common protein fractions among the signatures (group B, Figure 3.4). Fur-
ther, a broader comparison between normal and cancer samples conducted without
excluding the protein fractions in the chronic pancreatitis signature yielded a 23 pro-
tein signature with 60% accuracy, comprising 23 common protein fractions (group
C, Figure 3.4). The heat-map of protein fractions obtained from the above analysis
is shown in Figure 3.2. To obtain an overview of how well the hybridization intensi-
ties of the protein fractions obtained in this experiment would differentiate the three
diagnostic groups, principal component analysis (PCA) was performed. Figure 3.3
shows the first two components from PCA. Although exclusive separation was not
observed, very different clustering patterns were seen between the three diagnostic
groups.
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Humoral Response: Following the low accuracy of the results from the statistical
analysis, a complementary filtering method was used to increase the reliability of the
biomarker selections in which manual analysis of the fluorescence intensities indicat-
ing differential humoral response was conducted. The differences in overall response
to the three diagnostic serum groups for some spots was found to be very small. Be-
cause of the likelihood of experimental variations arising from sample handling, such
small differences were ignored even when the centroid of signal intensity for the dif-
ferential response were different. Thereafter, the data was reprocessed to retain those
spots that showed higher response for cancer sera for at least 30% of the samples
compared to both normal and pancreatitis. In this respect, it is important to note
that spots showing higher humoral response in normal compared to cancer were also
registered in small numbers and may indicate a loss in humoral response. It is argued
that around 30-40% of cancer patients will respond to any given cancer antigen. This
arises from the fact that serum samples obtained from different patients are biolog-
ically unique as each person in the study has an unique genetic makeup. Various
environmental factors like food habits also critically affect immune response. This
feature relating to the diversity of response to cancer antigens is difficult to process
using statistical algorithms. As such, the use of complementary manual inspection of
the data proved to be useful. The candidates short-listed after filtering of data using
this method were then plotted as scatter-plots as shown in Figure 3.7. Using the
above technique the discriminating nature of 16 fractions were verified and 39 more
protein fractions were selected. These 39 fractions showed differential response but
were not detected by the statistical analysis. All the short-listed protein fractions
were then digested and MS/MS analysis was conducted for their identification as de-
scribed in Section 3.2.9. The use of complementary techniques provided a larger set
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of proteins that showed differential response and reduced the chance of false positives.
Table 3.1 shows the proteins that had been identified in the first set (16 fractions)
showing differential response between the three diagnostic groups (A-C; Figure 3.4),
among which two proteins had previously been associated with pancreatic cancer
and four of the others were observed to be up-regulated in breast cancer. The pro-
teins identified in the second group (39 fractions) are shown in Table 3.3 and Table
3.2 shows the peptides identified for each protein. 37 proteins were identified in
this group including previously identified pancreatic cancer biomarkers like Cu-Zn
superoxide dismutase. Some overlap in proteins identified between the two sets was
observed where often neighboring fractions were selected as part of the two groups.
Figure 3.4 depicts the humoral response pattern against all the tested serum samples.
The top 10 proteins in the figure are from group B which lists the proteins that are
differentially responsive to cancer and normal sera (with proteins reactive to chronic
pancreatitis sera eliminated from the analysis). PDZ and LIM domain 1 protein,
Histidine Triad Nucleotide and RAD50 Homolog isoform 1 protein showed a differ-
ential humoral response between chronic pancreatitis and normal sera. PDZ domain
proteins are common protein interaction modules that play key roles in cellular sig-
naling [27]. The majority of PDZ-containing proteins are associated with the plasma
membrane [28], where they take part in signaling, mediating the adhesive properties
of particular cells, ion transport and formation of tight junctions. Over-expression
of PDZ domain-containing proteins in chronic pancreatitis, which change the nature
of interaction in the plasma membrane or epithelial region [29], may be a differen-
tiating feature between normal pancreata and chronic pancreatitis. Histidine Triad
Nucleotide protein (spectra shown in Figure 3.5a), also known as PKC-interacting
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protein (PKCI), has been identified in MFC-7 human breast carcinoma cells and it
probably plays the role of a tumor suppressor [30] protein, though its role in the
development of chronic pancreatitis is unknown. RAD50 Homolog forms a complex
with MRE11 and NSB1 and subsequently binds to DNA and plays important role in
DNA double-strand break repair. It exhibits decreased humoral response in PDAC
and chronic pancreatitis serum, as compared to normal sera. Mutations in RAD50
have been observed in breast cancer [31]. Though a phosphorylated peptide was not
detected by MS/MS analysis, the microarray data indicates possible tyrosine phos-
phorylation, as evident by reactivity to the PY20 anti-phosphotyrosine antibody. 10
proteins were identified from among the group B proteins, including Vimentin and
α-Enolase (spectra shown in Figure 3.5b). Both of these proteins had previously been
observed to be up-regulated in pancreatic cancer tissue when compared with normal
(and chronic pancreatitis) tissues using 2-D gel electrophoresis and mass spectrom-
etry [32]. The cytoskeleton-associated protein Vimentin has been found to play an
important role in the (TGF-β)-induced cell migration and invasion [33]. In a recent
study, a single isoform of vimentin has been shown to elicit a humoral response in
pancreatic cancer, as compared to both chronic pancreatitis and normal sera [34].
Interestingly, in the present study vimentin was shown to elicit a humoral response
in both PDAC and chronic pancreatitis sera. Similar reactivity was also seen with
α-Enolase, which was previously shown to have utility in differentiating PDAC tissue
from normal pancreata.
Thrombospondin-2 and elongation factor alpha-1 (eEF1A) were both observed to
have greater reactivity against PDAC sera as compared to control. The microarray
image in Figure 3.6 indicates the spot associated with Thrombospondin-2 that shows
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higher binding to auto-antibodies in PDAC serum. Figure 3.7 shows the spot fluores-
cence intensity pattern of Thrombospondin-2 and eEF1A in which greater reactivity
is observed for PDAC sera when compared to the others. eEF1A is responsible for
the enzymatic delivery of aminoacyl tRNAs to the ribosome and is expressed in other
tissues besides pancreas. eEF1A has been identified as an auto-antigen in 66% of
patients with Felty’s syndrome [35]. Amplification and over-expression of Elongin
C was detected in both the breast cancer cell line SKBR-3 and in prostate cancer
by cDNA microarrays [36]. In our study, however, the immunoreactivity of Elongin
C between the diagnostic groups was not significantly different. Among the pro-
teins in group C, Heat shock cognate (71 kDa) protein, a chaperone protein that is
involved in the cellular transport, was observed to exhibit lower immunoreactivity
with PDAC sera as compared to normal, while the regulatory protein hnRNPA2/B1
showed greater immunoreactivity with cancer sera.
Analysis of Post-Translational Modifications: The nature and extent of post-
translational modifications in critical cell-signaling proteins depends, to some extent,
upon the progression of cancer. For example, changes in phosphorylation patterns
have been observed in breast cancer progression in response to therapeutic drugs.
Our work utilizes a novel method in which the modification pattern of the proteins
on the microarray can be utilized to obtain information on the deregulated pathway,
and to aid in protein identification using mass spectrometry. The type of modifica-
tion detected through a blind database search of the MS/MS data can be verified
with data from the microarray experiments, which provides practical approach for
identification of modifications in those situations where very high sequence coverage
is difficult to obtain. To this end, we utilized protein microarrays that were printed
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at the same time as those utilized in the humoral response experiments above. Mouse
Anti-phosphotyrosine antibodies were used for the detection of protein phosphoryla-
tion and five biotinylated lectins were used to map the glycosylation pattern of the
Panc-1 proteome. Figure 3.8 demonstrates the glycosylation and phosphorylation
patterns in the Panc-1 proteome along with humoral response. It is interesting to
note that after the spot intensities from the microarray data were normalized for
UV peak intensities, and the spots having intensities below the cut-off value dictated
by negative standards spotted on the array were eliminated, almost all the proteins
showing intense humoral response (top portion of the Figure 3.8) were observed not
to be glycosylated, or only marginally so, with very low spot intensities. With the
exception of a few proteins that showed sialylation (as dictated by their response to
SNA lectin), glycosylations were largely detected in proteins from the injection peak
fraction comprising of proteins having a pI greater than 7.9 (lower half of Figure
3.8). Since glycosylation adds increasing amounts of negatively charged sugars and
eliminates a positive charge on asparagine, the modified protein will have a lower pI
and bulky glycan side chains can make the proteins difficult to elute from the first
dimension CF column.
As such, the glycosylation pattern on the microarray may be incomplete and hence,
the data presented here only demonstrates a methodology that can be applied for
effectively increasing the amount of data that can be obtained from a microarray
experiment. Though an analysis of the flow-through during loading of both the
chromatofocusing column and the reverse phase column was not conducted, there
is a possibility that some of the heavily glycosylated proteins were lost due to poor
chromatographic separation. Figure 3.9 demonstrates the above method where ni-
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trocellulose slides printed for the purpose of the humoral response experiment was
processed using SNA lectin. The spot labeled ‘c’ (Thrombospondin-2) is thus prob-
ably sialylated. Further MS/MS experiments for the verification of the abovemen-
tioned type of glycosylation or for the identification of the glycosylated peptide/s
were not pursued and the glycosylation state of the protein was only used as a factor
in improving protein identification and selection from the MS/MS database search
results. However, since blind database search for phosphorylated peptides was easier
to perform, the phosphorylation data from the microarray was used to verify the
database search results. Figure 3.10 shows the phosphorylated peptide DMRQpT-
VAVGVIK from Elongation Factor 1A. Through the blind search of MS/MS data, the
phosphorylated peptides TVETRDGQVINEpTpSQHHDDLE and SGAQASSTPLp-
SPTR were also identified, helping in validating Vimentin and Lamin A/C, respec-
tively, as the correct protein IDs. Such a method which incorporates experimental
modification data to verify protein IDs obtained through mass spectrometry is more
reliable than mass spectrometry data alone.
3.4 Conclusion
The use of complementary data analysis techniques for biomarker discovery using
protein microarrays is essential to reduce the chance of false positives. Because of
highly diverse nature of humoral response in general, a clear differentiation is dif-
ficult to observe. Moreover, for a complex disease like pancreatic cancer which is
characterized by a lack of strong humoral response and difficulty in detection till late
stages, the possibility of observing a clear differentiation is very low. In this respect,
the use of complementary techniques to analyze the microarray data is essential.
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The top-down mass spectrometric method that has been used in this experiment for
protein identification is able to more easily identify modified peptides, as compared
to a bottom-up method where enrichment is usually necessary. Without peptide
enrichment in the positive ion mode, ionization efficiency of the phosphopeptides is
suppressed by the presence of other non-phosphorylated peptides to some extent.
Thus, the purity of the sample fractionated using multidimensional liquid-based sep-
aration methodology allows us to use the modification information from the microar-
ray in eliminating false positives. Unlike bottom-up methods, where the cell lysate
proteins are digested and the protein-to-peptide correlation is lost, in this method,
all identified peptides can be assigned to a single protein. Owing to the complex and
competitive process associated with generation of sample ions in mass spectrometry,
peptide coverage is usually low for a moderately high molecular weight protein. In
this respect, the availability of information regarding the phosphorylation or glyco-
sylation state of a protein is immensely helpful in correctly identifying the protein.
Though humoral response experiments using protein microarrays and mass spec-
trometry method were previously developed, the use of protein modification on the
microarray and its subsequent application for improving the reliability of the mass
spectrometry based protein identifications was not previously described. This work
undertakes a proof-of-concept study to demonstrate the effectiveness and simplicity
of such methodology. The power of this method also lies in its ability to identify
a large group of proteins in a single experiment that are co-regulated in their post
translational modifications and which also elicit a humoral response. Detection and
analysis of such co-regulated proteins will enable delineation of functional pathways
that play an important role during cancer initiation and progression.
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Table 3.1: List of proteins showing humoral response and identified by nESI-LC-MS/MS. Positive
















Thrombospondin-2 P35442 129955/4.6 7.6-7.3 + ∼
Eukaryotic Elongation Factor
1 Alpha 1 (eEF1A)
NP001393 DMRQpTVAVG
VIK
50161/9.1 6.4-6.1 + ∼
Elongin C Q15369 12473/4.77 7.3-7.0 ∼ ∼
Acyl-CoA dehydrogenase P28330 47669/7.61 7.0-6.7 ∼ ∼
Transcription elongation fac-
tor A protein 1
P23193 33969/8.38 6.4-6.1 - ∼
Lamin A/C P02545 SGAQASSTPL
pSPTR




53652/5.06 4.9-4.6 + +
Rab-17 Q9H0T7 23490/7.84 6.1-5.8 - ∼
Heterogeneous Nuclear Ri-
bonuclear Protein A2/B1
P22626 37429/8.95 7.9-7.6 + ∼
α-Enolase P06733 47168/7.38 5.8-5.5 + +
PDZ and LIM Domain 1 NP066272 36071/7.02 7.3-7.0 - +
Histidine Traid nucleotide
binding protein
P49773 13801/6.95 7.3-7.0 - +
RAD50 Homolog Isoform 1 NP005723 153891/6.89 7.9-7.6 - -
ATP Synthase NP001676 12587/9.53 7.6-7.3 ∼ ∼
Glyceraldehyde 3-Phosphate
Dehydrogenase
AAP36549 36166/8.45 7.3-7.0 - ∼
WD Repeat Domain 35 Q9P2L0 133546/6.37 7.0-6.7 ∼ ∼
Heat Shock Protein 7C P11142 70897/5.52 5.8-5.5 - ∼
73
Table 3.2: Database search results for proteins analyzed using ESI LC-MS/MS. Proteins were iden-






Table 3.3: List of proteins showing higher humoral response in cancer sera. Proteins were identified
using LS ESI-MS/MS.
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Figure 3.1: Analytical work-flow of the experiment.
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Figure 3.2: Heat maps depicting the list of proteins for distinguishing cancer and normal tissue.
Analysis conducted after signature proteins distinguishing chronic pancreatitis and nor-
mal were removed (a) and included (b).
Figure 3.3: Plot of the first two components from PCA ( ◦ = cancer, 4 = normal and  = chronic
pancreatitis.
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Figure 3.4: Response map showing humoral response and modifications on the identified Panc-1
proteins.
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Figure 3.5: nESI-LC-MS/MS spectrum of (a) peptide AQVARPGGDTIFGK from Histidine Triad
Nucleotide protein and (b) peptide AVEHINKTIAPALVSK from α-Enolase.
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Figure 3.6: Slide image processed with normal serum (N) and with cancer serum (C) showing
humoral response to the protein Thrombospondin.
Figure 3.7: Spot fluorescence intensity for humoral response against (a) Thrombospondin-2 and (b)
Elongation Factor 1A from all tested serum samples in the three groups.
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Figure 3.8: Comparison Map between Humoral Response and Modification among Panc-1 Proteins.
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Figure 3.9: Slides processed with cancer sera (A) and SNA lectin (B) clearly distinguishes proteins
which are not glycosylated (a) and glycosylated (c, d). The picture on the right is
obtained by superimposing the picture on the left on top.
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Figure 3.10: nESI-LC-MS/MS spectrum of phosphorylated peptide DMRQpTVAVGVIK from
Elongation Factor 1A (eEF1A).
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CHAPTER IV
Humoral Response Profiling Reveals Pathways to Prostate
Cancer Progression
4.1 Introduction
Prostate carcinoma is the leading cancer diagnosis in American men where its early
detection facilitates effective treatment modalities and improved mortality [1]. Al-
though the advent of prostate specific antigen (PSA) screening has led to the de-
tection of prostate cancer [2] much earlier, its lack of specificity for neoplasm has
resulted in an increase in the number of subsequent prostate needle biopsies [3]. As
the population of men 65 years and older is expected to increase from 14 million in
the year 2000 to 31 million by 2030 [4] in the US, it will be increasingly important to
distinguish men with benign prostatic hyperplasia from those having neoplastic dis-
ease requiring clinical intervention. There is a compelling need to define additional
clinical markers for accurate detection of prostate cancers.
The scarcity of clinical markers has spawned a wide array of serum-based early de-
tection methodologies leveraging protein microarrays among other platforms [5]. But
this approach is complicated by the fact that potentially viable tumor biomarkers are
embedded among a huge array of proteomic noise. This noise includes housekeep-
ing and highly abundant proteins so the comparative low abundance of biomarker
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candidates confounds their detection. Thus, effective detection methodologies must
span as many as 10 orders of magnitude in dynamic range to reliably detect markers
in complex biofluids like plasma or serum [6]. No existing technology or platform
offers such a broad dynamic range without implementing pre-fractionation strate-
gies. This however may result in the loss or suppression of important biomarkers as
many high-abundant proteins removed by depletion act as carriers for low-abundant
proteins.
In this work we utilize the immune system-driven amplification of the autoanti-
body response to intracellular antigens which promises higher sensitivity, specificity,
predictive value and reproducibility in detecting low-abundant tumor markers [7].
Early efforts have identified many gene products eliciting the humoral response. So-
matic alterations in p53 are observed in 30-40% of affected patients, which has been
shown to be able to predate cancer diagnosis [8]. In other work, 60% of patients
with lung adenocarcinomas exhibited humoral response to glycosylated annexins I
and/or II, whereas none of the sera from non-cancer patients demonstrated such a
response [9]. Similarly, autoantibodies to the prostasome and to such antigens as
PSA, prostatic acid phosphatase (PAP), HER-2/neu, p53, alpha methylacyl-CoA
racemase (AMACR) and GRP78 have been observed in the sera of prostate cancer
patients [10–13]. Autoantibody signatures have also been identified using phage mi-
croarrays that can delineate prostate cancer patients from control individuals with
>90% accuracy [14]. However, one of the major disadvantages of this platform lies
in the fact that most of the humoral response targets identified may be mimitopes
that resemble the target protein in either the amino acid sequence or structure [14].
Further, it is important to note that most of the proteins that elicit humoral response
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are often differentiation antigens or antigens that are over-expressed or modified in
cancer [12, 13]. Additionally, the humoral response elicited by cancers is heteroge-
neous. This is supported by studies from humoral response trials where among the
large numbers of patients tested, only a subset of patients with a specific tumor type
develop a response to a specific antigen. This heterogeneity in humoral response
necessitates the use of a multiplex panel of protein targets as autoantibody biomark-
ers to be able to detect tumors with broad coverage for a large number of people.
This motivates our strategy of coupling comprehensive two-dimensional liquid-phase
fractionation of the prostate cancer tissue proteome to protein microarray analysis
of patient sera. Mass spectrometry is used for the identification of proteins elicit-
ing humoral response to prostate cancer antigens (Figure 4.1). In addition to using
the humoral response signature for prostate cancer detection, we have attempted to
highlight the power of autoantibody screening in delineating proteomic alterations
and proposing altered pathways during prostate cancer development.
4.2 Experimental
4.2.1 Patient Population and Sample Selection
The study was approved by the Institutional Review Board (IRB) of the University
of Michigan Medical School. Serum samples from patients who visited the Urology
Clinic for prostate cancer screening were collected before biopsy. The sera were then
stored at the University of Michigan Specialized Research Program in Prostate Can-
cer (SPORE) tissue/serum bank. A total of 34 serum samples from patients who
visited the clinic on two successive days were sequentially used for the experiments.
18 patients were biopsy-positive for prostate cancer (PCa) and 16 were negative for
neoplasm. The average age of all prostate cancer patients was 63.2 ± 12.8 years. For
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patients who tested negative for neoplasm and were diagnosed with benign prostatic
hyperplasia (BPH), the average age was 64.8 ± 10.7 years. PSA values for the PCa
and BPH groups were 7.81 ± 5.34 and 6.79 ± 3.76 ng/mL respectively. Detailed
clinical and pathology data for this study is available in Table 4.1.
4.2.2 Preparation of Reference Pools
Tissue samples obtained after surgery from clinically localized prostate cancer pa-
tients (n=5) and advanced prostate cancer patients (n=5) were used for 2D liquid
phase fractionation as described below. All chemicals were purchased from Sigma
(St Louis, MO) unless otherwise stated. For protein extraction, the tissue samples
were re-suspended in lysis buffer consisting of 7 M urea, 2 M thiourea, 100 mM
DTT, 0.5% biolyte ampholyte 3-10 (Pharmacia, Pitscataway, NJ), 2% OG and 1
mM PMSF. Samples were lysed at room temperature for 30 min, followed by cen-
trifugation at 35,000 rpm at 4◦C for 1 hr. The supernatant was then stored at -80◦C
for future use. Sample preparation for chromatofocusing (CF) included use of a
PD10 column, equilibrated with 25 mM bis-tris in 6 M urea and 0.2% OG, which
was used to exchange the tissue lysate from the lysis buffer to the above buffer.
4.2.3 Two-dimensional Protein Fractionation
Chromatofocusing (CF) on tissue lysate
Two buffers, a start buffer and elution buffer, were employed in the CF experiment.
The start buffer was 25 mM bis-tris with pH 7.1, and the elution buffer consisted of
a 10-fold dilution of polybuffer 96 and polybuffer 74 in a ratio of 3:7, the pH adjusted
to 4.0. Both buffers were prepared in 6 M urea and 0.2% OG. Iminodiacetic acid
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was used to adjust the pH of both buffers. A Beckman Coulter PF2D HPLC system
was used for all the separations stages. A PS-HPCF 1D (250×2.1 mm) column was
equilibrated with the start buffer until the pH of the effluent was 7.1. Sample was
applied to the column with multiple injections. Once a stable baseline was achieved,
the elution buffer was switched on to elute the proteins on the column in an isocratic
mode. UV detection was performed at 280 nm and the pH of the effluent was mon-
itored using a flow-through online pH probe. pH fractions were collected for every
0.2 pH intervals and 15 fractions in all were collected in the range of pH 7.0-4.0. The
CF separation was stopped when the pH of the effluent reached 4.0.
Reverse phase HPLC on pI fractions
RP-HPLC was performed using PS-HPCF 2D (33×4.6 mm) columns. Solvent A was
0.1% TFA (JT Baker, Phillipsburg, NJ) in water and solvent B was 0.1% TFA in
acetonitrile (Burdick and Jackson, Muskegon, MI). The Solvent B gradient was run
from 5% to 15% in 1 min, 15% to 25% in 2 min, 25% to 31% in 2 min, 31% to 41%
in 10 min, 41% to 47% in 6 min, 47% to 67% in 4 min, to 100% in 3 min, held at
100% for another 1 min, then back to 5% in 1 min. The flow rate was 1 mL/min, and
the column temperature was 65◦C. UV absorptions were monitored at 214 nm. RP
fractions were collected using a FC204 fraction collector (Beckman Coulter). The




Printing the Fractionated Proteins
The fractionated proteins were re-suspended in 15 µL buffer containing 1XPBS (at
pH 7.4) and protease inhibitors (Roche Biochemicals, Indianapolis, IN). The sam-
ples were transferred to a 96-well microtitre plate (MJ Research, Waltham, MA) and
printed on nitrocellulose slides (Schleicher & Schuell, Keene, NH) using a GeSim
Nanoplotter2, a non-contact ink jet printer. Each spot measured approximately 300
µm in diameter and was placed 1200 µm apart. The slides were dried for 1 hr at room
temperature and were either used immediately or stored in a dessication chamber at
-20◦C.
Hybridization of slides
Nitrocellulose slides containing spotted proteins were hydrated in 1XPBS for 10
minutes and blocked in 1XPBS containing 1% BSA (Sigma, St Louis, USA) and
0.1% Tween-20 (Sigma, St Louis, USA) overnight at 4◦C. The slides were then incu-
bated with either serum from prostate cancer patients or benign individuals (1:400
dilution) in probe buffer (PBS, pH 7.4 containing 1% BSA, 5 mM MgCl2, 0.5 mM
DTT, 0.05% Triton X-100 and 5% glycerol) for 2 hr at 4◦C. Slides were then washed
six times with probe buffer, each for 5 minutes. They were then incubated with
Alexa Fluor 647 conjugated anti-human IgG (1:2000 dilution, Invitrogen, Carlsbad,
CA) for 1 hr at 4◦C, and then washed with probe buffer as above, dried through cen-
trifugation at 8000 rpm, and analyzed using a GenePix 4000B microarray scanner
(Axon Instruments Inc., Foster City, CA).
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4.2.5 Data Analysis
Primary analysis, including scanning and quantification of slides, was executed with
GenePix 6.0 (Axon Instruments Inc.); gridding was completed per manufacturer
instructions. The single-channel Alexa Fluor 647 values were calculated for each in-
dividual fraction spot. An initial round of spot check was performed using GenePix
default parameters. This was followed by a second round of curation where spots
having any of the following characteristics were manually flagged: a diameter of less
than 300 µm, irregular outline, spots localized in region of high local background or
spot localized in areas of the array with obvious defects. Flagged spots were seeded
to -1 in raw intensity units in the subsequent analysis. The background corrected
median spot intensity values of the ‘Cy5 channel’ was extracted from each array
and normalized. The data set was filtered for dominantly negative clones, retain-
ing only those with non-negative raw intensity in ≥50% of samples in the cohort.
Intra-array standardization entailed median centering and scaling by their respective
median absolute deviations. Quantile normalization was then executed to obtain the
same empirical distribution across all arrays. Two-way average-linkage hierarchical
clustering of an un-centered Pearson correlation similarity matrix was executed and
figures were generated using Cluster and TreeView [15].
4.2.6 Development of a Predictor
A supervised analysis was conducted to coalesce around a subset of fractions from the
2,016-element humoral response arrays which were most predictive for class distinc-
tion across the serum samples. Array data, normalized as previously described, were
applied to a test statistic-based feature selection procedure calculating the F-statistic
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between cancer and BPH samples across all 2016 clones (fractions). Different counts
of the best ranking fractions by F-statistic (every count of best clones from 5 to 100)
were used to build a Support Vector Machine (SVM) prediction model. The SVM
over multiple kernel test permutations was embedded in a finite grid-search of paired
values of exponentially growing sequences of cost (C) and gamma (γ). A linear kernel
produced the best prediction, whose accuracy and error were calculated using leave-
one out cross validation (LOOCV) to evaluate the performance of the models. The
top-ranked 20 fractions were ultimately selected from the fraction predictor based
on their best performance in specificity and sensitivity and with highest stability of
recurrence at the top ranks over all the left-out iterations. These 20 fractions were
additionally tolerant to repeated testing and small changes to model parameters. All
statistical analyses were performed in R 2.3.0 and SPSS.
4.2.7 Mass Spectrometry
Targeted UV peaks in the second dimension RP-HPLC chromatogram were col-
lected and aliquoted into two fractions. The protein content of fractions identified
by best classification performance as well as 27 fractions demonstrating no differen-
tial response between classes were digested using Porcine Trypsin (1:50, Promega,
Madison, WI) in 1 M ammonium bicarbonate, pH 9.0. The digestion was performed
for 16 hr at 37◦C. At the end of 24 hr, the trypsin activity was stopped using 3%
formic acid. The peptide mixtures were separated by reverse-phase chromatography
using a 0.075×150 mm C18 column attached to a Paradigm HPLC pump (Michrome
BioResources Inc, Auburn, CA). Peptides were eluted using a 45-min gradient from 5
to 95% B (0.1% FA/95% ACN), where solvent A was 0.1% FA/2% ACN. A Finnigan
LTQ mass spectrometer (Thermo Fisher Corporation, Waltham, MA) was used to ac-
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quire mass spectra, the instrument operating in data-dependent mode with dynamic
exclusion enabled. The MS/MS spectra for the three most abundant peptide ions in
full MS scan were obtained. The spectra were searched using the Mascot algorithm
(MatrixSciences, Boston, MA) against the composite, NCBI human RefSeq database
(downloaded on 2005-06-28). The search was done using a mass tolerance of 2 Da for
the precursor and 0.5 Da for the daughter fragments. All searches were performed
using monoisotopic peptide mass with methionine oxidation (M+16) as the variable
modification. Confidence in peptide assignment accuracy and protein identifications
were assigned via the open source Trans-Proteomic Pipeline (Institute for Systems
Biology) implementing PeptideProphet and ProteinProphet, which validates pep-
tides assigned to MS/MS spectra and protein identifications respectively [16–18].
The resulting protein lists were filtered using a ProteinProphet probability of ≥0.90,
corresponding to an error rate of less than 1% as estimated by ProteinProphet. All
proteins identified by a single peptide having a charge state of +1 were also removed
due to reduced confidence in these identifications (where the raw data is obtained
using an ion trap mass spectrometer). Keratins were manually removed from the
filtered list of proteins. All validated identifications, peptide sequences and annota-
tions were stored in a relational database for downstream analysis.
4.2.8 MCM Analysis
The statistical model used for testing and storing the results of associations be-
tween independent molecular concepts has been previously described [19]. Protein
identifications from the humoral response signature were converted to Entrez Gene
identifiers and batch loaded to MCM (www.molecularconcepts.org) for analysis.
Concept-to-concept enrichment extensions as described in the text were performed
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with the same. To generate an immune program under STAT control for meta-
analysis with public gene expression studies, we downloaded the IRIS repository of
1622 genes expressed in, and classified by multiple immune cell lineages [20]. There
is a 179-gene overlap between the IRIS compendium and those genes under STAT
control (the union of either STATx, STAT1, STAT3 or STAT5B homodimer). This
seeds the metamap analysis described in the text above.
Additionally, 27 fractions lacking reactivity were selected from the array platform
for sequencing. Identical thresholds and standards were used to cull the subsequent
negative control protein list from 14 of those fractions for the MCM analysis. The
unique count of high-probability identifications from the negative control protein
content was 415, a similar number as the humoral response signature, eliminating
potential two-group offset issues between the putative signature and its negative con-
trol. The gene identifiers representing these 415 encoded proteins were uploaded to
MCM as a negative control enrichment analysis. Any concept enriching both the real
signature of increased humoral response in prostate cancer and the negative control,
were removed for further analysis.
4.3 Results
4.3.1 Development of arrays via proteome fractionation
An overview of the approach we took in identifying humoral response targets in
prostate cancer is depicted in Figure 4.1. To generate protein microarrays for prostate
cancer, we independently fractionated proteins from clinically localized and hormone-
refractory metastatic cancer tissues (n=5 each) in two dimensions using chromato-
focusing and reverse-phase chromatography. The fractionated proteins were spotted
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on nitrocellulose coated glass slides and served as bait for capturing potential au-
toantibodies found in serum. Proteins that reacted with prostate cancer sera but
not with the control were identified using mass spectrometry, database search and
downstream protein informatics (see Methods). The list of proteins obtained was
used to both characterize the predictor, but also in a ‘molecular concept’ analysis
for their involvement in disease processes (Figure 4.8, Table 4.5-4.8).
Approximately 2,300 fractions were used to generate the protein microarrays. Us-
ing this 2,300-feature protein microarray, we evaluated sera from prostate cancer
patients and controls. A one-color system with a red fluorescent Alexa Fluor 647
dye was used to measure the levels of bound IgG. Therefore, increased intensity
represented varying levels of immune reactivity. In this discovery approach we eval-
uated 34 serum samples consisting of 18 sera from prostate cancer patients (biopsy-
positive, high PSA) and 16 from individuals with BPH (biopsy-negative for cancer,
high PSA). Critically, these samples constitute the clinically challenging distinction
between cancer-negative (benign hyperplastic condition) and cancer-positive needle
biopsy findings in the setting of elevated levels of circulating prostate-specific antigen.
4.3.2 Identification and Validation of the 20-fraction Predictor
The primary aim of the microarray experiment was to obtain the pattern of differen-
tial autoantibody response that could discriminate between the benign and prostate
cancer groups. Cross-validated supervised analysis implementing the non-parametric
Support Vector Machine (SVM) was performed using the 34 samples as a training
set, looking for humoral response correlates of the two-class distinction between BPH
and PCa (see Methods). Of the 1522 features remaining after filtering for dominantly
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negative fractions as the result of hybridization, a subset of proteins demonstrated
differential reactivity patterns. Embedded feature re-selection during LOOCV pro-
duced a 20-fraction predictor having 75% specificity (4 of 16 BPH samples were
misclassified) and 78% sensitivity (4 of 18 prostate-cancer samples were misclas-
sified) in discriminating between the group with BPH and that with PCa (Table
4.3). This was an especially encouraging result, as this is a particularly challenging
classification; all members of the cohort have a baseline inflammatory physiological
condition that is eliciting a humoral response accompanying their biopsy-proven clin-
ical condition. The 20-fraction predictor was chosen as the minimum fraction count
producing maximum accuracy in classification without over-fitting the predictor and
with highest recurrence over left-out iterations during cross validation, otherwise
interpreted as highest tolerance in statistical significance to the leaving out of any
given sample in the cohort (Figure 4.2a, Methods and Table 4.3, 4.4). A heatmap of
the reactivity profile generated by the 20-fraction predictor reveals a distinct bipar-
tite pattern as would be expected by real reactivity to class-dependent antigens, in
lieu of silence in reactivity (Figure 4.2b, 4.3a). The heterogeneity of the reactivity
profile is likely attributable to many causes including loss of humoral response. The
latter has previously been reported in patients diagnosed with breast cancer where
loss of autoantibodies to mucin have been shown to be indicators of poor progno-
sis [21]. Additionally, in this study BPH is hyperplastic and already inflammatory,
representing a heterogeneous population consisting of a mixture of biopsy-negative
and potentially PCa-positive individuals. We are interested in identifying and quan-
tifying the increase using BPH as the baseline condition. Finally, some instability in
reactivity is observed certainly due to the above mentioned issues of the consistency
of response across patients to specific intracellular antigens.
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We next calculated receiver-operating characteristic curves for the 20-fraction predic-
tor and measured PSA levels in the sample cohort (Figure 4.3b). A variety of cutoff
values of the SVM decision scores were used as thresholds to plot the true- against
false-positive rates for the prediction model. The ability of the 20 fraction predictor
to discriminate PCa serum samples from BPH samples was significant (p=0.013)
with an area under the curve of 0.75 (95% confidence interval, 0.58 to 0.92, Figure
4.3b). On the other hand, the area under the curve for measured PSA level was
0.49 (p=0.94; 95% confidence interval, 0.29 to 0.70). This result is significant as
all benign patients in this cohort have elevated PSA levels associated with an early
inflammatory condition, again a more challenging clinical distinction than with a
healthy normal control. Further, a permutated rank-based test of significance of the
difference in AUC between the SVM-derived predictor and that of measured PSA
was also significant (p=0.05, Table 4.2 for association to additional pathological pa-
rameters).
4.3.3 Characterization of the 20-fraction Predictor
Though demonstrating promising results and certainly superior to the current PSA-
based clinical standard, this result falls short of the accuracy of a desired diagnostic
platform. Nevertheless, as these tumor-associated antigens are derived from the can-
cer proteome, and we expect them to be perturbed in cancer development given their
loss of immunological tolerance, we hypothesized that their identification could form
part of a larger alteration underlying a systematic biological process. To arrive at
such a systems perspective, it was critical to identify these humoral response targets.
Consequently, each of the 20 informative high-stability fractions from classification
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was taken for mass spectrometry (see Methods and Table 4.5). In addition, 27 non-
informative fractions were sequenced as a negative control for downstream analysis.
A total of 359 unique proteins were identified from sequencing the 20-fraction predic-
tor at probabilities of correct assignment greater than 0.90 [16]. A given fraction’s
immuno-reactivity profile is a complex combination of potential interactions. It may
be the case that a fraction is composed of as few as 5 to 8 proteins, all of which
elicit an autoantibody response to patient serum. Alternatively, fractions of equal
or higher protein content with similar reactivity may be a combination of isolated
proteins eliciting response, a cooperative humoral response between complexes of
proteins, ‘bleed-over’ of proteins common to adjacent fractions, and those proteins
that may appear in several fractions and represent no more than cellular machinery
having nothing to do with eliciting the class-dependent immuno-reactivity of the
fraction. We subsequently created a compendium of proteins from this sequencing
that met criteria making them the most likely subset of proteins eliciting the humoral
response signature. This included several rounds of subtraction for proteins consid-
ered either non-specific or noise to the reactivity profile (see Methods, Table 4.6, 4.7,
Figure 4.9). The final compendium of likely humoral response targets numbered 248
(Table 4.8).
Regulated proteins such as prostatic acid phosphatase (ACPP, Figure 4.10a) and
hypoxia up-regulated 1 (HYOU1), proteins involved in FGFR signaling pathway like
synaptotagmin binding and cytoplasmic RNA interacting protein (SYNCRIP), reg-
ulators of actin cytoskeletal reorganization including calponin 1 (CNN1), Was/wasl
interacting protein family member 2 (WICH2), and valosin containing protein (VCP),
and finally tumor suppressors including a novel ring finger B box, coiled-coil family
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member (HLS5), synaptopodin (SYNPO2), and trypsinogen IV (PRSS3) were iden-
tified.
To determine the ability of our PCa-specific humoral signature to identify pathways
that are deregulated during prostate cancer development and progression, we per-
formed a ‘molecular concept’ analysis (MCM) on the group of proteins that were
identified to have cancer-specific autoantibody repertoire (see Methods, Figure 4.4
and Table 4.8). Recent work in the enrichment analysis of gene sets biologically re-
lated in a meaningful way allows for the discovery of patterns of shared behavior over
a vast database of high-throughput experimental data and biological annotation [19].
Of the 27 fractions selected as a non-differential negative control and sequenced as de-
scribed, the subsequent protein content of 14, culled with the same criteria operated
as a control during concept enrichment. Any concept enriching both the differential
predictor and the negative control were subtracted from the analysis. The MCM
analysis of the ‘increased humoral response in prostate cancer’ signature identified
an enrichment network containing metabolism concepts, including the KEGG path-
way for nitrogen metabolism (p=4.6×10−5) as well as the mitochondrion cellular
localization (p=3.4×10−4), and multiple drug compounds, including a gene set up-
regulated upon cyclosporin treatment (p=0.006), which is an immuno-suppressive,
and a gene set down-regulated upon treatment of rosiglitazone (p=0.006), having a
potent anti-inflammatory effect (Figure 4.4). Additional concepts enriched by the
PCa-specific humoral targets included four promoter binding sites implicating the
enrichment of a STAT-regulating transcriptome, and HPRD interaction networks for
three proteins, which in concert, play a role in mRNA processing. Among these,
several concepts were taken for further analysis (Figure 4.4 and 4.6).
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Among the various aforementioned concepts, the nitrogen metabolism concept was
intriguing in the context of earlier results that revealed a shift in the metabolism
paradigm during prostate cancer development driven by increased protein biosyn-
thesis [19]. This in turn was thought to be regulated by a combination of androgen
and over-expression of the fusion isoform of the transcription factor ERG [19]. Criti-
cally, the observed humoral response to components of the nitrogen pathway correlate
well with increased utilization of protein or its derivatives (amino acids) by prostate
tumors as a prime source of energy generation. Furthermore, it is conceivable that
increased protein biosynthesis would lead to a linear increase in the generation of
nitrogen which would first be directed into the nitrogen metabolism pathway in
advance of downstream entrance into the urea cycle. Closer inspection of the ni-
trogen metabolism concept revealed three pathway components eliciting differential
humoral response. These include two functionally similar glutamate dehydrogenase
enzymes GLUD1 and 2 (Figure 4.10b), and carbonic anhydrase II. The former me-
diate the coupled conversion of alpha-ketoglutarate and ammonia to glutamate and
the transamination of glutamate to alpha-ketoglutarate and ammonia. Addition-
ally, glutamate participates in a second transamination reaction producing aspartate,
a nitrogen donor to urea synthesis, and a regenerated alpha-ketoglutarate (Figure
4.5). The up-regulation of glutamate as a metabolite coupled to the enhanced enzy-
matic mediation via humorally reactive GLUD1 shifts chemical equilibrium toward
increased ammonia output. The latter, coupled to the production of the nitrogen
donor aspartate, represents up-regulated nitrogen production directed to downstream
urea synthesis as well as activating a potential positive feedback mechanism in regen-
eration of alpha-ketoglutarate. Interestingly, an independent metabolomic dataset
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generated using 16 benign prostate tissues and 12 localized prostate cancer samples
shows significantly increased levels of glutamate and aspartate in prostate cancer
specimens (Figure 4.5).
Thus, using MCM we were able to directly extend our interrogation beyond single-
molecule targets to examine global changes in biological pathways. Nevertheless,
there existed a nested set of significant concepts including multiple STAT-family pro-
moter binding sites as well as c-Ets 1(68) sites, which in isolation, were not revealing.
This was especially noteworthy as both have been shown to play an important role
during prostate cancer development/progression [22–26]. This is not unexpected,
as measuring autoantibody response, which unlike protein expression, is an indirect
measure of protein abundance or modification state and is highly variable depending
on the immunogenicity of targets and their exposure to the immune system. Given
this situation, one could imagine a scenario where a change in a group of proteins
under the control of a common regulator can be attributed to a holistic change in
the programming controlled by the regulator. In other words, change in levels of the
master regulator could lead to a cascade of expression changes of its targets, only
some of which will subsequently elicit a humoral response. Thus, it was important for
us to understand the fate that results from deregulation of such regulatory compo-
nents (in this case, the five concepts enriched in our MCM analysis). In an attempt
to interrogate this aspect, we executed individual MCM enrichment extensions for
five concepts highlighted in Figure 4.4 and 4.6.
The analysis was effectively extended by one level. Instead of enriching for concepts
from the original humoral target list, each of the five concepts from the original analy-
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sis seeded a subset MCM enrichment. The five resulting enrichment networks were
sequentially merged into a single common network (Figure 4.6). Orphaned concepts
from a single-concept extension were removed during this merge stage. Interestingly,
extension of the four STAT concepts and c-Ets 1(68) binding site concept, revealed
a common and systematic theme of immune modulation. The extended concepts re-
veal a high count of immuno-modulatory events that included acute phase response,
complement and coagulation cascades, chemokine activity, and more. There was
a significant overlap of the STAT controlled-gene program with those regulated by
ETS-family transcription factors and AR, all of which have been critically impli-
cated in prostate cancer [22, 23]. The extension analysis also identified an overlap
with gene expression profiles that were down-regulated upon treatment with a va-
riety of anti-inflammatory drugs, further confirming the existence of an underlying
immune modulation theme in the humoral signature [25].
To confirm the existence of STAT-induced immune programming, we completed
a meta-analysis, seeded by a STAT-regulated immune signature (see Methods),
with six prostate gene expression signatures profiling different comparisons between
normal prostate, BPH or prostate carcinoma using Oncomine (Figure 4.7a, 4.7b,
www.oncomine.org) [27–29]. There is a dominant pattern of over-expression for
this STAT-regulated immune signature in clinically defined carcinoma relative to the
benign condition in each study (Figure 4.7b). Additionally, a subset of immune-
regulatory genes under STAT control was significantly enriched in BPH compared
to normal tissue, and the immune activity of PCa was found to be higher than BPH
(Figure 4.7b). It is important to note that our study design compares the immune
response profile between two immunologically active cohorts, and does not include
107
profiling of normal sample due the ambiguities of defining such a cohort of age-
matched individuals for prostate disease. In an attempt to address the scarcity of
humoral targets in the cancer-specific signature and appreciating the disadvantage
of low concordance between gene and protein expression, our aim was to identify any
difference in expression among a set of immuno-modulatory targets across a broad
set of study data.
4.3.4 Clinical associations of the humoral response signature
To evaluate whether the 20-faction predictor is useful as a supplement to measured
PSA, logistic regression analysis was performed on the sample cohort. Disease state
(cancer or non-cancer) was assigned to the response variable and univariate logistic
regression was executed for both the standardized SVM decision scores and mea-
sured PSA, independently at first, and then in combination. It was found that only
the SVM-derived decision score test was statistically significant (odds ratio, OR for
standardized decision scores=3.74, 95% CI=1.23-11.36, p=0.02; OR for PSA=1.019,
95% CI=0.87-1.18, p=0.80). In the multivariate logistic regression analysis with dis-
ease as the response and fitting both SVM decision scores and measured PSA as
covariates, we found that the effect of the decision scores was significant even af-
ter adjusting for the effect of PSA (OR=4.13, 95% CI=1.28-13.34, p=0.0177). We
then calculated the likelihood ratio test statistic to test whether the addition of the
added covariate improves the fit over the univariate logistic regression model of PSA.
The addition of decision scores to PSA was significant in fit improvement (p=0.0104).
This indicates that the 20-fraction predictor provides additional predictive value over
measured PSA alone.
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This was further validated with a rank-based permutation test of significance in dif-
ference between the SVM-derived and measured PSA AUCs. The real difference in
AUC between the SVM model and PSA was calculated. After converting both the
numeric measurements of PSA and the SVM decision scores to ranks, the sample
class labels were randomly permutated and the AUC difference between the two
metrics were recomputed over 10,000 iterations. The relative p-value of this test is
equivalent to a one-sided test of the alternative hypothesis that there is a larger dif-
ference in AUC between the two models and the null hypothesis of equal AUCs. The
calculated p-value, the count of AUC differences greater than the master difference
over the 10,000 iterations was significant (p=0.05).
4.4 Discussion
By coupling multidimensional protein fractionation with protein microarrays this
proof-of-principle study demonstrates the power of immune system-driven autoan-
tibody response for detection of prostate cancer. Through its ability to detect
proteomic alterations, the autoantibody response can reveal deregulated biological
processes during cancer development and progression. Further, this study utilizes a
clinically challenging population in which both the benign and localized cancer pa-
tients have high amounts of circulating PSA, the current clinical standard for prostate
cancer detection. Importantly, only biopsy results were used to cull the cancer sub-
group in this patient cohort. Needle biopsy by itself, in addition to being invasive, has
a well-documented false negative rate, missing 28% of existing prostate cancers [30].
This adds to the complexity of the study cohort as a subset of benigns (as defined
by negative biopsy) may very well harbor neoplasm that went undetected. Given
109
this fallacy, it was interesting that the 20 fraction tumor-specific humoral signature
could classify PCa with 75% specificity and 78% sensitivity, respectively. In addi-
tion to known autoantibody targets like ACPP and PSA, the PCa-specific humoral
signature contained proteins that could play a role during tumor development and
progression. For instance, the humoral signature included two proteins in the FGFR
signaling which has been implicated in prostate cancer development and progres-
sion [31–33]. Different predicted molecular phenotypes of increased FGF signaling
include increased motility, invasiveness, proliferation and androgen independence,
all of which are ultimately thought to promote tumor progression [33]. Notably,
elevated machinery regulating motility and invasion was evident in the PCa-specific
compendium of humoral targets that included known regulators of actin cytoskele-
tal reorganization, namely calponin 1 (CNN1), Was/wasl interacting protein family
member 2 (WICH2) and valosin containing protein (VCP). Also, FGF is known to
potentiate tumor progression by signaling through various pathways that include the
STAT pathway [33], components of which were present in the cancer-specific humoral
signature.
In addition to being sensitive to changes in protein levels or modifications, the
humoral response generation could be driven by other factors like the presence of
anti-idiotypic antibodies that constitute the causal mechanism behind the observa-
tion of humoral response against the autoantigen [34]. Such is proven to be the
case for Wegener granulomatosis autoantigen or PRTN3, autoantibodies to which
are found in inflammatory vascular disease [34]. These studies indicate that, dur-
ing vascular inflammation, there occur complementary, or antisense, peptides that
can bind to PRNT3, termed cPR-3, which are the initial targets for generation of
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autoantibodies [34]. These cPR-3-specific idiotypic antibodies then elicit the anti-
idiotypic response, antibodies originating from which can bind to the parent antigen
PRNT3 [34]. In our case, a similar concept may govern the presence of autoan-
tibodies to GLUD1/GLUD2, for which HSP70-like protein has been shown to be
the antisense gene pair in moulds [35]. Further, HSP70 has been shown to elicit
autoantibodies to itself [36, 37]. Accordingly, one might predict that reactivity of
prostate cancer serum to GLUD1/2 may potentially follow a mechanism similar to
the one reported for PRNT3 [34]. Alternately it is worth noting that both GLUD1
and GLUD2 are key regulators of nitrogen metabolism and downstream urea cycle
activity. This gains importance in the context of our earlier gene expression-based
analyses that revealed increased protein biosynthesis in localized prostate cancer [19].
The breakdown of the resulting proteins could lead to increased accumulation of el-
emental nitrogen that will have to be eliminated through nitrogen breakdown and
urea cycle pathways. Our humoral response data coupled with independent assess-
ments showing increased levels of glutamate, aspartate, and constituent urea cycle
metabolites in localized prostate cancer corroborate our gene expression-based hy-
pothesis. Of course the metabolic flux of both GLUD1 and GLUD2 as well their
potential anti-idiotypic antibody response in prostate carcinoma requires further in-
vestigation.
In addition to drawing direct correlates between humoral targets and known pathway
alterations in tumors, it was intriguing to observe proteins in the STAT pathway,
which by themselves did not enrich for any known tumor-associated processes. Speci-
ficity of these STAT pathway-associated proteins to prostate cancer is validated by
their absence in a random humorally-nonreactive signature (see Methods). More-
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over, it has been observed that STATs are regulated by FGF, the activity of which,
according to our data and previous reports, is elevated in prostate cancer [33]. Also,
elevation of STAT signalling has been reported in prostate cancer [38]. Moreover, it
is known that proteins differ in their ability to generate an antibody response [39].
Accordingly, it was tempting to speculate that the existence of a group of proteins in
a given pathway in our prostate cancer-specific humoral signature may signify global
reprogramming of that pathway, in this case, the global perturbation of the STAT
pathway. We further interrogated the dataset for enrichment of the STAT-regulated
proteome with MCM, which revealed multiple immuno-modulatory proteins as de-
fined by an earlier gene expression study [20]. This STAT-induced deregulation
of immuno-modulatory components was validated by meta-analyses of independent
prostate cancer data sets. The meta-analysis reveals existence of high levels of basal
immuno-activity in BPH, which is further inflated during tumor development. This
is not only consistent with reports of neoplastic development occurring on a back-
ground of focal inflammation [40], but also explains the challenge associated with
discerning the two classes, namely BPH and localized cancer based on their response
profiles as reported in this study. Thus, we highlight the ability of autoantibody
repertoires to uncover alterations in biological processes that might otherwise not be
revealed by standard protein profiling platforms owing to the vast dynamic range of
the proteome.
4.5 Conclusion
The ability to correlate the humoral signature with actual cellular processes empha-
sizes the importance of employing a screening platform containing proteins extracted
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from tumor, itself reflecting a physiologically realistic swath of the prostate cancer
proteome. Such correlations to tumor function would be difficult to establish using
proteins fractionated from cell lines [41, 42] or using phage array platforms [14, 43].
In addition, the multi-dimensional protein fractionation-coupled microarray retains
post-translational modifications that are most indicative of the cellular phenotype,
and in most cases better reflects the reality of humoral response to cancer antigens.
This is best illustrated by the observation of phosphorylated PSA as a target antigen
in our dataset (data not shown).
In summary, this study for the first time uses autoantibodies generated against the
tumor proteome to classify a clinically challenging cohort of patients comprised of
BPH and localized PCa and, in the process, reveals multiple alterations in tumor-
associated functional pathways that would otherwise not be discernable by conven-
tional profiling strategies.
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Table 4.1: Clinical and pathology information for the 34 benign prostatic hyperplasia and clinically
localized prostate cancer patient serum samples used in the training/validation set.
∗(1) Plus-minus value are mean ± SD. PSA denotes prostate-specific antigen. (2) Data
were available for 34 patients.
Characteristic∗ Value (Cancer Patients) Value (BPH Patients)
No. of patients 18 16
Age (yr) 63.2 ± 12.77 (35-81) 64.8 ± 10.47 (43-80)
PSA level
Mean (ng/ml) 7.18 ± 5.34 (2.9-20.4) 6.79 ± 3.76 (2.1-14.1)
0-4 ng/ml (%) 38.9 25.0
4.1-10 ng/ml (%) 38.9 50.0












White (non-Hispanic origin) (%) 89 87.5
Black (non-Hispanic origin) (%) 11 6.25
Asian or Pacific Islander (%) - 6.25
Table 4.2: Associations between the 20-fraction humoral response signature and various clinical and
pathological parameters.
Variable Analysis PSA Total Gleason Major Gleason Minor Gleason
20-fraction Pearson correla-
tion
-0.204 -0.214 -0.334 -0.041
signature P-value 0.248 0.394 0.175 0.871
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Table 4.3: Summary of class predictions for the sample set. A prediction model was built using
the 20 fractions selected from a leave-one-out cross validation strategy implementing a
Support Vector Machine. The column ‘Call’ is the prediction of a sample by the model
along with its numeric decision value, which is the signed distance from the hyperplane
constructed by the trained model. Error indicates misclassified samples.
Sample Name Pathology Decision Value Call Error
Serum-1 Cancer -1.793 Cancer
Serum-2 BPH -1.56278 BPH
Serum-3 BPH 0.030892 Cancer *
Serum-4 BPH -2.1205 BPH
Serum-5 BPH -0.149 BPH
Serum-6 BPH -0.57144 BPH
Serum-7 Cancer 0.717425 Cancer
Serum-8 Cancer 0.418136 Cancer
Serum-9 Cancer 0.357485 Cancer
Serum-10 BPH -2.55515 BPH
Serum-11 Cancer 1.644764 Cancer
Serum-12 Cancer 3.678237 Cancer
Serum-13 Cancer -1.33488 BPH *
Serum-14 BPH -0.55419 BPH
Serum-15 Cancer 1.151819 Cancer
Serum-16 BPH 0.115368 Cancer *
Serum-17 BPH 0.829295 Cancer *
Serum-18 Cancer 5.249221 Cancer
Serum-19 BPH -0.28224 BPH
Serum-20 Cancer -0.91374 BPH *
Serum-21 BPH -2.92816 BPH
Serum-22 Cancer 1.803605 Cancer
Serum-23 Cancer 0.997157 Cancer
Serum-24 BPH -0.36761 BPH
Serum-25 Cancer 1.320617 Cancer
Serum-26 BPH -0.18682 BPH
Serum-27 BPH -0.80733 BPH
Serum-28 BPH 1.176218 Cancer *
Serum-29 BPH -0.67047 BPH
Serum-30 Cancer 4.546478 Cancer
Serum-31 Cancer 3.274788 Cancer
Serum-32 Cancer -1.3201 BPH *
Serum-33 Cancer 0.770342 Cancer
Serum-34 Cancer -1.68823 BPH *
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Table 4.4: Comprehensive list of fractions used during the 20-fraction best classification in sensitiv-
ity and specificity. Recurrence is the count of samples that contributed that clone to the
top 20 fractions during leave-one out cross validation (LOOCV). High-stability fractions
are defined as those persistent in high rank regardless of sample left out. The F-statistic
for each fraction is a representative value from a single of the 34 iterations of LOOCV
calculated on that iteration’s 33 training samples.
Fraction Recurrence F-Statistic Fraction Recurrence F-Statistic
3A8PCA3 34 7.793006 22D3Met8 4 6.185279
1B5PCA1 34 11.46584 6F9PCA5 3 5.071975
2F2PCA2 34 8.370373 7A6PCA6 2 6.293373
4H4PCA4 34 9.212151 21E9Met7 2 5.246445
14A8Met2 34 8.2016 21F11Met7 2 5.521059
13B3Met1 34 11.15364 4E11PCA4 1 4.17968
23C5Met9 34 12.90059 6E7PCA5 1 5.659875
19C12Met6 34 7.847889 6E4PCA5 1 4.979168
13D4Met1 34 11.60105 6E12PCA5 1 2.646888
19D12Met6 34 13.66645 3B12PCA3 1 5.743078
23H3Met9 30 6.637657 7B8PCA6 1 4.475109
3H11PCA3 28 7.684081 2C5PCA2 1 5.811833
13H10Met1 28 6.685937 3C8PCA3 1 4.902343
6D9PCA5 27 5.819973 9D7PCA8 1 4.49316
18F3Met5 27 7.442341 4D6PCA4 1 3.782356
2B3PCA2 26 10.26944 3H6PCA3 1 6.13266
22C5Met8 25 5.653969 13A1Met1 1 6.00282
7A12PCA6 22 6.690722 21E7Met7 1 6.222062
3F5PCA3 21 7.154193 24A4Met10 1 6.356494
19C11Met6 15 6.423083 22E12Met8 1 2.533672
3B6PCA3 10 4.878724 24F7Met10 1 4.572809
18G8Met5 10 5.856973 19B10Met6 1 4.746501
7G7PCA6 7 7.162571 23C11Met9 1 2.417708
4E6PCA4 6 7.380854 19C6Met6 1 5.724045
26H3Met11 5 5.859942 13D9Met1 1 4.375554
21D12Met7 5 5.303875 17D7Met4 1 3.899244
2A10PCA2 4 4.955912 17H3Met4 1 3.603949
4B5PCA4 4 4.643863 26H5Met11 1 2.970845
4D11PCA4 4 5.882793
Table 4.5: List of fractions taken for mass spectrometry. The fractions listed in the first two columns
are those clones presented in the heatmap from Figure 4.2 and are most stable in LOOCV
iterations during classification. Fractions are grouped by their reactivity pattern mem-
bership.
Fractions taken for mass spectrometry
BPH PCa Negative Control
2B3PCA2 18F3Met5 1B5PCA1 1A9PCA1 1C5PCA1 14F2MET2 16B5MET3
4H4PCA4 19C11Met6 2F2PCA2 1C3PCA1 1C10PCA1 16B3MET3 17B5MET4
6D9PCA5 19C12Met6 3A8PCA3 1C8PCA1 3G11PCA3 17B3MET4 17G4MET4
13B3Met1 19D12Met6 3F5PCA3 3G9PCA3 7E5PCA6 17G2MET4 22A11MET8
13D4Met1 22C5Met8 3H11PCA3 7E3PCA6 7E11PCA6 22A9MET8 22B12MET8
13H10Met1 23C5Met9 7A12PCA6 7E9PCA6 11A7PCA9 26C12MET11 26D12MET11
14A8Met2 1A11PCA1 23H3MET9 11A5PCA9 14F4MET2
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Table 4.6: Non-overlapping adjacent fraction protein content removed from the final protein com-













gi6382060 27 ABL2 19D12MET6(1, 1) gi51460532 54454 KIAA1240 19D12MET6(1, 1)
gi4557231 34 ACADM 19C11MET6(1, 11),
19C12MET6(0.99, 1)
gi14149742 57658 KIAA1536 19D12MET6(0.9, 1)
gi47078295 100 ADA 19C11MET6(0.99, 1),
19C12MET6(0.98, 1)
gi4504981 3956 LGALS1 19C11MET6(1, 2)
gi32484973 132 ADK 19C11MET6(0.94, 1) gi33636766 64077 LHPP 19C11MET6(0.99, 1)
gi4502013 204 AK2 19C11MET6(0.99, 1) gi51471054 121006 LOC121006 19D12MET6(1, 1)
gi24497577 10327 AKR1A1 19C11MET6(1, 8),
19C12MET6(0.99, 1)
gi51466547 154761 LOC154761 19D12MET6(1, 1)
gi41327764 8574 AKR7A2 19C11MET6(1, 4),
19C12MET6(0.99, 1)
gi23943872 64744 LOC64744 19D12MET6(1, 1)
gi4757756 302 ANXA2 19C12MET6(1, 2),
19D12MET6(1, 5)
gi14211889 84661 LOC84661 19C11MET6(1, 3)
gi4502109 309 ANXA6 19C11MET6(1, 2) gi45827809 9064 MAP3K6 19D12MET6(1, 1)
gi40068462 57492 ARID1B 19D12MET6(1, 1) gi21264363 10747 MASP2 19D12MET6(1, 1)
gi32526896 25852 ARMC8 19D12MET6(1, 1) gi11034825 27430 MAT2B 19C11MET6(1, 5),
19C12MET6(0.99, 1)
gi13435129 23400 ATP13A2 19D12MET6(0.97, 1) gi5174533 4160 MC4R 19D12MET6(1, 1)
gi21361181 476 ATP1A1 19D12MET6(1, 1) gi7661788 29079 MED4 19C12MET6(0.98, 1)
gi4757834 9532 BAG2 19C12MET6(1, 3) gi13129068 79050 MGC3162 19D12MET6(1, 1)
gi46430495 54796 BNC2 19D12MET6(1, 1) gi22749137 153733 MGC39633 19D12MET6(1, 1)
gi36031016 55088 C10orf118 19D12MET6(1, 1) gi33457311 145553 MGC5987 19C11MET6(1, 4)
gi51468578 338616 C10orf52 19D12MET6(0.95, 1) gi8922701 55750 MULK 19C12MET6(0.99, 1)
gi27734837 255352 C10orf93 19D12MET6(0.98, 1) gi32307128 23054 NCOA6 19D12MET6(1, 1)
gi51474886 23211 C19orf7 19D12MET6(0.99, 1),
22C5MET8(1, 1)
gi4505357 4697 NDUFA4 19D12MET6(1, 1)
gi11037061 56683 C21orf59 19C11MET6(1, 5) gi37693993 4832 NME3 19C11MET6(0.93, 1)
gi4502501 721 C4B 19C12MET6(0.99, 1) gi51475065 343578 None 19D12MET6(1, 1)
gi4502517 759 CA1 19C11MET6(1, 2),
19C12MET6(1, 5),
4H4PCA4(0.99, 1)
gi51471384 387946 None 19D12MET6(1, 1)
gi10716563 821 CANX 19D12MET6(0.97, 1) gi51475265 388819 None 19D12MET6(0.99, 1)
gi16507962 64072 CDH23 19D12MET6(1, 1) gi51460480 388922 None 19D12MET6(1, 1)
gi38158011 1149 CIDEA 19D12MET6(1, 1) gi51474106 401887 None 19D12MET6(1, 1)
gi10334859 1159 CKMT1 19C12MET6(0.99, 1) gi42656911 402152 None 19D12MET6(0.98, 1)
gi6912310 22802 CLCA4 19D12MET6(1, 1) gi51467792 439997 None 19D12MET6(1, 1)
gi33457344 57511 COG6 19D12MET6(0.97, 1) gi51464685 441098 None 19D12MET6(1, 1)
gi7656985 1282 COL4A1 19D12MET6(1, 1) gi51466769 442400 None 19D12MET6(1, 2)
gi18105030 8292 COLQ 19D12MET6(1, 1) gi34932414 4841 NONO 19C11MET6(0.96, 1),
19C12MET6(0.99, 1)
gi4502989 1347 COX7A2 19C11MET6(1, 5) gi20127624 79400 NOX5 19D12MET6(0.99, 1)
gi25121972 144402 CPNE8 19D12MET6(1, 1) gi4505431 4863 NPAT 19D12MET6(1, 1)
gi41327708 23418 CRB1 19D12MET6(1, 1) gi38570156 221294 NT5C2L1 19D12MET6(1, 1)
gi4758056 1387 CREBBP 19D12MET6(0.98, 2) gi13259372 4969 OGN 19C11MET6(1, 5)
gi47080099 1393 CRHBP 19D12MET6(0.94, 1) gi4501955 142 PARP1 19C12MET6(1, 5),
19D12MET6(1, 3)
gi29570791 1457 CSNK2A1 19C12MET6(1, 3) gi4505615 5080 PAX6 19D12MET6(1, 1)
gi14702162 7461 CYLN2 19D12MET6(1, 1) gi11761615 5091 PC 19D12MET6(0.95, 1)
gi31542331 3491 CYR61 19D12MET6(1, 1) gi16933555 65217 PCDH15 19D12MET6(0.98, 1)
gi4758128 9201 DCAMKL1 19D12MET6(1, 1) gi19923440 50940 PDE11A 19D12MET6(1, 1)
gi38201710 10521 DDX17 13D4MET1(1, 2),
19C11MET6(0.99, 1)
gi6912582 23578 PEF 19D12MET6(1, 1)
gi24308179 55917 DKFZp547A023 19C11MET6(0.97, 1) gi11863130 5277 PIGA 19D12MET6(1, 1)
gi4557525 1738 DLD 19D12MET6(0.98, 1) gi23397648 84720 PIGO 19D12MET6(1, 1)
gi4503381 1810 DR1 19C12MET6(0.99, 1) gi25777665 5314 PKHD1 19D12MET6(0.9, 1)
gi46195707 1954 EGFL4 19D12MET6(1, 1) gi4826914 8681 PLA2G4B 19D12MET6(1, 1)
gi13324677 5167 ENPP1 19D12MET6(1, 1) gi5032223 10154 PLXNC1 19D12MET6(1, 2)
gi11034849 59084 ENPP5 19D12MET6(1, 1) gi4506193 5689 PSMB1 19D12MET6(1, 1)
gi13654274 81889 FAHD1 19C12MET6(1, 7),
19D12MET6(1, 1)
gi33457332 125950 RAVER1 19C12MET6(0.99, 1)
gi42661041 85302 FBF1 19D12MET6(1, 1) gi41281444 9699 RIMS2 19D12MET6(1, 1)
gi13435350 2232 FDXR 19C12MET6(1, 10) gi8923844 55811 SAC 19D12MET6(1, 1)
gi40255039 55236 FLJ10808 19D12MET6(1, 1) gi4502261 462 SERPINC1 19C12MET6(0.97, 1)
gi41150761 55036 FLJ20753 19D12MET6(1, 1) gi19923315 6472 SHMT2 19C11MET6(1, 18),
19C12MET6(1, 10)
gi27734761 286053 FLJ32440 19D12MET6(0.98, 1) gi27436873 257218 SHPRH 19D12MET6(0.99, 1)
gi20149680 79672 FN3KRP 19D12MET6(1, 4) gi18699722 57619 ShrmL 19D12MET6(0.98, 1)
gi24497501 3169 FOXA1 19C11MET6(0.99, 1),
19C12MET6(0.93, 1)
gi51474764 400709 SIGLECP16 19C12MET6(0.91, 1)
gi4826730 2475 FRAP1 19D12MET6(1, 1) gi42661622 23094 SIPA1L3 19C12MET6(0.9, 1)
gi4503905 8811 GALR2 19D12MET6(1, 1) gi30520363 133482 SLCO6A1 19D12MET6(1, 1)
gi6996010 2617 GARS 19D12MET6(1, 1) gi21071052 6596 SMARCA3 19D12MET6(1, 1)
gi9558729 26088 GGA1 19D12MET6(1, 1) gi30315658 6711 SPTBN1 19D12MET6(1, 1)
gi13518231 2736 GLI2 19D12MET6(1, 1) gi38679884 6717 SRI 19C11MET6(1, 2)
gi7657128 29998 GLTSCR1 19D12MET6(1, 1) gi5454086 8406 SRPX 19D12MET6(1, 1)
gi10567816 2775 GNAO1 19D12MET6(1, 1) gi10835067 6741 SSB 19C11MET6(1, 11),
19C12MET6(1, 3)
gi4504053 2784 GNB3 19D12MET6(1, 1) gi28557788 6744 SSFA2 19D12MET6(1, 1)
gi29826294 26003 GORASP2 19C11MET6(0.95, 1) gi44921606 8867 SYNJ1 19D12MET6(1, 1)
gi29789277 84435 GPR123 19D12MET6(1, 1) gi4507337 6861 SYT5 19D12MET6(1, 1)
gi41406084 2876 GPX1 18F3MET5(1, 8),
18F3MET5(0.99, 3),
19C11MET6(0.99, 1)
gi19913369 10607 TBL3 19D12MET6(1, 1)
gi24308295 80273 GRPEL1 19C11MET6(1, 2) gi21536371 7011 TEP1 19D12MET6(1, 1)
gi4504351 3045 HBD 19C11MET6(0.99, 1) gi23238188 26136 TES 19D12MET6(1, 1)
gi6715607 3048 HBG2 19C12MET6(0.99, 1) gi13569901 81628 THG-1 19C12MET6(0.98, 1)
gi23097260 92521 HCMOGT-1 19D12MET6(1, 1) gi13236587 79188 TMEM43 19D12MET6(0.91, 1)
gi20336761 50865 HEBP1 19C11MET6(0.92, 1) gi22547116 8795 TNFRSF10B 19D12MET6(1, 1)




gi11321607 9319 TRIP13 19D12MET6(1, 1)
Continued on next page
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gi34419635 3310 HSPA6 19C11MET6(0.99, 1),
19C12MET6(0.99, 1),
23C5MET9(1, 1)
gi20143914 7273 TTN 19D12MET6(1, 1)
gi4504517 3315 HSPB1 18F3MET5(1, 4),
19C11MET6(0.92, 1),
4H4PCA4(1, 3)
gi13376539 80086 TUBA4 19C12MET6(0.99, 1)
gi31542947 3329 HSPD1 19C11MET6(1, 4),
23C5MET9(1, 6)
gi14389309 84790 TUBA6 19D12MET6(0.96, 1),
22C5MET8(1, 2)
gi28178825 3417 IDH1 19C12MET6(1, 2),
19D12MET6(1, 8)
gi13562114 81027 TUBB1 19C11MET6(0.98, 1)
gi10800142 3444 IFNA7 19C12MET6(0.99, 1) gi9507221 53347 UBASH3A 19D12MET6(0.91, 1)
gi4557882 3561 IL2RG 19D12MET6(1, 1) gi33188427 7404 UTY 19D12MET6(1, 1)
gi31317249 3570 IL6R 19D12MET6(1, 1) gi21614499 7430 VIL2 19C11MET6(1, 2),
22C5MET8(1, 1)
gi5803115 10989 IMMT 19C11MET6(0.99, 1) gi40068485 64856 WARP 19C12MET6(1, 7)
gi51460530 114818 KBTBD9 19D12MET6(1, 1) gi4507909 7454 WAS 19D12MET6(1, 1)
gi4504825 8514 KCNAB2 19D12MET6(1, 1) gi31543021 22911 WDR47 19D12MET6(1, 1)
gi26051271 3757 KCNH2 19D12MET6(1, 1) gi4507931 7479 WNT8B 19D12MET6(1, 1)
gi51463940 26032 KIAA0527 19D12MET6(1, 1) gi13386506 7490 WT1 19D12MET6(1, 1)
gi41281469 9786 KIAA0586 19D12MET6(1, 1) gi10863945 7520 XRCC5 19C12MET6(1, 2)
gi39930349 23231 KIAA0746 19D12MET6(1, 1) gi28274709 7789 ZXDA 19D12MET6(1, 1)
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gi4502027 213 ALB 13B3MET1(0.99,1), 22C5MET8(1,2),
23C5MET9(1,1), 4H4PCA4(1,3),
7A12PCA6(1,5)
gi34577110 226 ALDOA 13D4MET1(1,6), 13H10MET1(1,9),
18F3MET5(0.95,1),
3A8PCA3(0.99,1)
gi4502101 301 ANXA1 19C11MET6(0.98,1),
19C12MET6(1,2), 7A12PCA6(1,3)
gi32189394 506 ATP5B 23C5MET9(1,4), 23H3MET9(0.99,1)




gi4501885 60 ACTB 22C5MET8(1,4), 23C5MET9(1,2),
23H3MET9(0.92,1)
gi24308169 55567 DNAH3 14A8MET2(0.99,1), 1B5PCA1(1,1),
23H3MET9(0.99,1), 2F2PCA2(1,1),
6D9PCA5(1,1)





















gi11761631 2244 FGB 13H10MET1(1,2),
18F3MET5(1,11), 19C11MET6(1,3),
19C12MET6(0.99,1), 4H4PCA4(1,7)
gi7661968 9685 ENTH 23C5MET9(1,1), 23H3MET9(1,1) gi41327741 23474 ETHE1 18F3MET5(0.9,1), 3F5PCA3(0.99,1),
4H4PCA4(0.99,1)





gi7669492 2597 GAPD 13D4MET1(1,1), 18F3MET5(1,4),
3A8PCA3(1,8), 3F5PCA3(1,8),
4H4PCA4(1,4)
gi4504183 2950 GSTP1 19C11MET6(1,6), 4H4PCA4(0.99,1),
7A12PCA6(1,2)






































gi4885431 3304 HSPA1B 19C11MET6(1,5), 19C12MET6(1,3),
23C5MET9(1,3), 23H3MET9(0.98,1),
3A8PCA3(0.96,1)
gi28178832 3418 IDH2 13D4MET1(0.96,1), 3A8PCA3(1,10),
3F5PCA3(1,9)




gi8922712 55752 NA 18F3MET5(1,4), 3F5PCA3(1,3),
4H4PCA4(1,6)
gi12056473 54187 NANS 19C11MET6(1,3), 19C12MET6(1,15),
19D12MET6(1,4), 3F5PCA3(0.99,1),
7A12PCA6(1,4)
gi37655183 10397 NDRG1 23C5MET9(1,7), 23H3MET9(1,3)
gi51465474 346085 None 18F3MET5(0.95,1), 3A8PCA3(1,2),
3F5PCA3(0.94,1), 4H4PCA4(0.99,1)
gi51464772 389268 None 14A8MET2(0.96,1),
1B5PCA1(0.98,1), 2F2PCA2(0.99,1),
6D9PCA5(0.97,1)
gi10835121 5313 PKLR 19C11MET6(0.95,1),
3A8PCA3(0.98,1)
gi33286418 5315 PKM2 13D4MET1(1,3), 18F3MET5(1,7),
19C11MET6(1,7), 3A8PCA3(1,20),
3F5PCA3(1,28), 4H4PCA4(1,5)
gi5453549 10549 PRDX4 19C11MET6(1,6), 19C12MET6(1,3),
7A12PCA6(1,2)
gi4758638 9588 PRDX6 18F3MET5(1,3), 19C11MET6(1,6),
3F5PCA3(1,6)
gi4506605 9349 RPL23 13B3MET1(0.92,1),
2B3PCA2(0.99,1), 3F5PCA3(0.99,1)
gi4506753 8607 RUVBL1 19C11MET6(1,7), 7A12PCA6(1,8)
gi4506773 6280 S100A9 19C11MET6(1,9), 19C12MET6(1,7),
4H4PCA4(0.93,1), 7A12PCA6(1,2)
gi4507813 7358 UGDH 19C11MET6(1,3),
19C12MET6(0.99,1), 3F5PCA3(1,2)
gi46593007 7384 UQCRC1 19C11MET6(1,11), 19C12MET6(1,7),
19D12MET6(1,3), 7A12PCA6(1,5)




Table 4.8: The final post-subtraction compendium of proteins suspected of eliciting the humoral
response profiles of the 20-fraction predictor. Proteins with increased humoral response















gi7656849 27034 ACAD8 3F5PCA3(0.97,1) gi47132622 4507 MTAP 18F3MET5(0.97,1)
gi6382064 55 ACPP 7A12PCA6(1,8) gi21956645 136319 MTPN 22C5MET8(1,2)
gi4502157 341 APOC1 3A8PCA3(1,6)
3F5PCA3(1,5)
gi33620747 50804 MYEF2 18F3MET5(0.99,2)
gi33946285 330 BIRC3 2F2PCA2(0.9,1) gi21361478 23157 NA 4H4PCA4(1,6)
gi4557395 760 CA2 3A8PCA3(1,6)
3F5PCA3(1,6)
gi21945064 151011 NA 4H4PCA4(0.99,1)
gi26787970 1041 CDSN 3H11PCA3(0.97,1) gi27262628 4678 NASP 22C5MET8(1,1)
gi13994236 27439 CECR6 1B5PCA1(0.91,1) gi4505365 4712 NDUFB6 13H10MET1(1,4)
gi38045913 4830 NME1 3F5PCA3(0.99,1)
7A12PCA6(1,2)
gi10835025 4729 NDUFV2 18F3MET5(0.95,2)
gi7705676 51050 PI15 3A8PCA3(1,2)
3F5PCA3(0.97,1)
gi4885063 230 ALDOC 13H10MET1(1,2)
18F3MET5(1,9)
4H4PCA4(1,7)
gi4506031 5538 PPT1 7A12PCA6(0.96,1) gi8923444 55651 NOLA2 13B3MET1(0.99,1)
gi4557363 639 PRDM1 1B5PCA1(0.98,1)
2F2PCA2(0.98,1)
gi41150140 388076 None 13B3MET1(0.96,1)
gi5453629 10540 DCTN2 23H3MET9(1,5) gi30090003 52 ACP1 22C5MET8(0.99,2)





gi4503643 2153 F5 1B5PCA1(0.93,1) gi4826972 9939 RBM8A 22C5MET8(0.99,1)
gi4502961 1294 COL7A1 3F5PCA3(0.99,1) gi6005848 11201 POLI 22C5MET8(0.98,1)
gi21361120 1264 CNN1 3A8PCA3(1,2)
3F5PCA3(0.99,1)
gi5453974 5586 PKN2 22C5MET8(1,2)
gi51464135 401124 FLJ16686 1B5PCA1(0.91,1) gi15431290 6135 RPL11 13B3MET1(1,4)
gi21314644 10818 FRS2 1B5PCA1(0.91,1) gi16753227 6128 RPL6 13B3MET1(1,2)
gi7382458 5657 PRTN3 2F2PCA2(0.93,1) gi4503379 1809 DPYSL3 2B3PCA2(0.98,1)
gi7657116 26330 GAPDS 3A8PCA3(0.94,1)
3F5PCA3(0.9,1)
gi4506675 6184 RPN1 18F3MET5(1,2
gi4885281 2746 GLUD1 3F5PCA3(1,2) gi4506685 6207 RPS13 13B3MET1(1,6)
gi31377775 2747 GLUD2 3F5PCA3(0.99,1) gi5032051 6208 RPS14 13B3MET1(1,6)
2B3PCA2(1,2)
gi5031755 10236 HNRPR 3A8PCA3(1,2) gi5902102 6632 SNRPD1 13B3MET1(0.99,1)
gi40254873 29062 HSPC049 1B5PCA1(0.93,1)
2F2PCA2(0.9,1)
gi4507155 6652 SORD 13D4MET1(0.97,1)
gi38202209 55777 MBD5 2F2PCA2(0.9,1) gi29788785 203068 TUBB 22C5MET8(1,1)
gi9910244 56945 MRPS22 3F5PCA3(1,9) gi20127460 7508 XPC 13B3MET1(1,3)
gi27734781 286514 MGC33889 2F2PCA2(0.9,1) gi12711674 65109 UPF3B 13B3MET1(1,3)
gi5453832 10525 HYOU1 23H3MET9(1,2) gi21361495 28970 PTD012 4H4PCA4(1,5)
gi42822880 153364 LOC153364 3F5PCA3(0.99,1) gi7524354 23564 DDAH2 19C11MET6(1,7)
19C12MET6(1,11)
19D12MET6(1,6)





gi31543657 10948 STARD3 1B5PCA1(0.92,1) gi4503423 1854 DUT 13B3MET1(1,2)
gi4506181 5683 PSMA2 7A12PCA6(0.98,1) gi25777602 5708 PSMD2 22C5MET8(1,2)
gi14165464 5725 PTBP1 3F5PCA3(0.99,1) gi30240932 10938 EHD1 22C5MET8(1,7)
gi5360210 5819 PVRL2 2F2PCA2(0.99,1) gi15150811 92259 MRPS36 13B3MET1(1,2)
gi7657486 27089 QP-C 3A8PCA3(1,3)
3F5PCA3(1,3)
gi13994257 54460 MRPS21 13B3MET1(0.99,1)
gi16753233 7094 TLN1 3A8PCA3(1,3)
3F5PCA3(1,3)
gi27436901 6182 MRPL12 23C5MET9(1,2)
gi23397427 10492 SYNCRIP 3F5PCA3(0.93,1) gi13489091 4357 MPST 4H4PCA4(0.99,1)
gi22035665 83660 TLN2 1B5PCA1(0.93,1)
2F2PCA2(0.9,1)
gi11125772 4082 MARCKS 13B3MET1(0.99,1)
22C5MET8(1,1)
gi25777692 23087 TRIM35 1B5PCA1(0.9,1) gi24308009 23173 METAP1 4H4PCA4(1,3)
gi11024714 7314 UBB 3A8PCA3(1,2)
3F5PCA3(0.98,2)
gi21361809 494115 LOC494115 13B3MET1(1,8)
22C5MET8(1,2)
gi51458553 23358 USP24 1B5PCA1(0.92,1) gi4557657 3396 ICT1 13B3MET1(1,2)
gi6005942 7415 VCP 23H3MET9(1,8) gi33413400 2098 ESD 4H4PCA4(0.99,1)
gi18959210 147179 WIRE 2F2PCA2(0.9,1) gi4757702 9470 EIF4E2 4H4PCA4(0.99,1)
gi41151132 90649 ZNF486 1B5PCA1(1,1) gi4758862 9521 EEF1E1 13D4MET1(1,1)
gi7661646 25996 DKFZP566E144 7A12PCA6(0.93,1) gi23110942 5686 PSMA5 23C5MET9(1,2)
gi20070255 26286 ARFGAP3 22C5MET8(0.99,1) gi51475270 388823 None 3H11PCA3(0.96,1)
gi4885079 509 ATP5C1 23C5MET9(0.99,1) gi41151603 389842 None 22C5MET8(0.99,1)
gi4502297 513 ATP5D 23C5MET9(1,10) gi51493118 390407 None 2B3PCA2(0.95,1)
gi6005717 521 ATP5I 22C5MET8(1,4) gi51472614 390531 None 4H4PCA4(1,2)
gi18644883 522 ATP5J 13B3MET1(1,7)
22C5MET8(1,2)
gi41150478 390712 None 4H4PCA4(0.99,1)
gi4502303 539 ATP5O 13D4MET1(1,4) gi42657272 401206 None 13B3MET1(0.91,1)
gi32171238 55971 BAIAP2L1 22C5MET8(1,1) gi51475407 440786 None 13B3MET1(0.99,1)
gi37574726 637 BID 23C5MET9(0.98,1) gi7706254 51602 NOP5/NOP58 2B3PCA2(0.98,1)
gi23200008 83451 ABHD11 13D4MET1(1,2) gi4505449 4852 NPY 13B3MET1(1,6)
22C5MET8(1,7)
gi4502419 645 BLVRB 18F3MET5(0.98,3) gi34098946 4904 NSEP1 13B3MET1(1,4)
gi5802976 10974 C10orf116 13D4MET1(1,1) gi7657033 30833 NT5C 4H4PCA4(0.99,1)
gi5803013 10961 C12orf8 22C5MET8(0.97,1) gi21264365 4928 NUP98 22C5MET8(1,1)
gi4502503 722 C4BPA 22C5MET8(0.99,1) gi8923427 54940 OCIAD1 18F3MET5(1,8)
4H4PCA4(1,5)
gi11641247 152007 C9orf19 13B3MET1(1,2) gi45238849 5042 PABPC3 18F3MET5(1,4)
gi4502009 9049 AIP 4H4PCA4(0.95,1) gi4504715 8761 PABPC4 18F3MET5(1,3)
gi13124881 865 CBFB 22C5MET8(1,1) gi4557042 5064 PALM 22C5MET8(1,2)
gi19923356 10602 CDC42EP3 22C5MET8(0.91,1) gi31543380 11315 PARK7 13D4MET1(1,1)
18F3MET5(0.99,1)
gi11095441 4329 ALDH6A1 13D4MET1(1,1) gi4505621 5037 PBP 13B3MET1(1,2)
Continued on next page
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gi40354205 229 ALDOB 18F3MET5(1,4) gi14141166 5094 PCBP2 13B3MET1(0.98,1)
gi5031635 1072 CFL1 13B3MET1(1,4)
22C5MET8(1,4)
gi4885539 5110 PCMT1 18F3MET5(1,4)
gi14719392 1073 CFL2 13B3MET1(1,2)
22C5MET8(0.99,1)
gi4505651 5833 PCYT2 4H4PCA4(1,6)
gi25092725 27341 CGI-96 22C5MET8(0.97,1) gi42476169 54623 PD2 22C5MET8(0.99,1)
gi4502801 1104 CHC1 4H4PCA4(0.99,1) gi7656883 27295 PDLIM3 13B3MET1(0.99,1)
gi4502805 1113 CHGA 22C5MET8(1,1) gi12408675 5202 PFDN2 18F3MET5(0.99,2)
gi19920317 10970 CKAP4 23C5MET9(1,2) gi4826898 5216 PFN1 13B3MET1(0.99,1)
gi21536286 1152 CKB 13D4MET1(1,1)
22C5MET8(1,2)
gi4505753 5223 PGAM1 13D4MET1(1,4)
gi8923900 55907 CMAS 4H4PCA4(0.94,1) gi22165431 311 ANXA11 13D4MET1(1,3)
gi17402875 1292 COL6A2 18F3MET5(0.99,2)
4H4PCA4(0.95,1)
gi21359873 5347 PLK1 14A8MET2(0.92,1)
gi5902134 11151 CORO1A 4H4PCA4(1,6) gi5453930 5438 POLR2I 22C5MET8(1,1)
gi5174675 10321 CRISP3 13B3MET1(0.99,1)
22C5MET8(0.94,1)
gi13699256 5511 PPP1R8 22C5MET8(1,5)
22C5MET8(1,5)
gi20070160 8531 CSDA 13B3MET1(1,3) gi31083236 5527 PPP2R5C 22C5MET8(0.98,1)
gi4503143 1509 CTSD 19C11MET6(1,10)
19C12MET6(1,13)
19D12MET6(1,16)
gi4502133 325 APCS 18F3MET5(0.99,2)
gi41281768 1528 CYB5 22C5MET8(1,7) gi18375501 328 APEX1 22C5MET8(1,1)
gi11128019 54205 CYCS 13B3MET1(0.97,1) gi32189392 7001 PRDX2 19C11MET6(1,4)
19C12MET6(1,12)
19D12MET6(1,4)
gi21361670 28988 DBNL 22C5MET8(1,3) gi41349454 5549 PRELP 18F3MET5(0.99,4)
4H4PCA4(1,16)
gi7657056 30845 EHD3 22C5MET8(1,2) gi40068475 5756 PTK9 4H4PCA4(1,2)
gi4503607 2108 ETFA 13D4MET1(1,1) gi4506413 5906 RAP1A 4H4PCA4(0.97,1)
gi4557581 2171 FABP5 13B3MET1(0.97,1) gi40354214 5948 RBP2 22C5MET8(0.99,1)
gi7661714 10447 FAM3C 13D4MET1(1,1) gi6005854 11331 REA 13D4MET1(1,1)
gi4758356 2237 FEN1 13D4MET1(0.93,1) gi24307923 6120 RPE 18F3MET5(1,11)
4H4PCA4(1,5)
gi4503745 2316 FLNA 4H4PCA4(1,4) gi4506621 6154 RPL26 2B3PCA2(0.94,1)
gi5031699 10211 FLOT1 13D4MET1(1,10) gi4506649 6122 RPL3 2B3PCA2(0.99,1)
gi34577057 23769 FLRT1 14A8MET2(0.94,1) gi16579885 6124 RPL4 13B3MET1(0.99,1)
gi16933542 2335 FN1 22C5MET8(1,4) gi14591909 6125 RPL5 13B3MET1(1,2)
gi17402900 8880 FUBP1 13B3MET1(1,3) gi4506661 6130 RPL7A 13B3MET1(1,2)
gi4826734 2521 FUS 13B3MET1(1,3) gi15431306 6132 RPL8 2B3PCA2(0.99,1)
gi38202257 23193 GANAB 13B3MET1(1,2) gi15431303 6133 RPL9 22C5MET8(1,6)
gi21361657 2923 GRP58 22C5MET8(1,3) gi4506687 6209 RPS15 13B3MET1(1,4)
gi7705704 373156 GSTK1 13D4MET1(1,2) gi4506693 6218 RPS17 22C5MET8(1,6)
gi20357599 94239 H2AFV 4H4PCA4(0.99,1) gi11968182 6222 RPS18 13B3MET1(1,3)
gi4504327 3032 HADHB 18F3MET5(0.93,2)
4H4PCA4(1,3)
gi4506695 6223 RPS19 13B3MET1(1,2)
gi4885403 3054 HCFC1 13B3MET1(1,2) gi15055539 6187 RPS2 13H10MET1(1,2)
gi4885413 3094 HINT1 13B3MET1(0.99,1) gi4506697 6224 RPS20 13B3MET1(1,2)
gi4885375 3006 HIST 1H1C 13B3MET1(1,6)
2B3PCA2(1,2)
gi4506725 6191 RPS4X 13B3MET1(1,3)
13D4MET1(0.99,1)
gi20544168 3010 HIST 1H1T 13B3MET1(1,4) gi4506741 6201 RPS7 22C5MET8(1,1)
gi10800140 3018 HIST 1H2BB 13H10MET1(1,2)
2B3PCA2(0.96,1)
gi4759068 6341 SCO1 22C5MET8(1,1)
gi20270186 9324 HMGN3 13D4MET1(0.95,1) gi14141195 6388 SDF2 13B3MET1(1,3)
gi5803036 10949 HNRPA0 13B3MET1(0.99,1) gi4759080 6389 SDHA 4H4PCA4(0.99,1)
gi14043070 3178 HNRPA1 13B3MET1(1,4) gi32454741 871 SERPINH1 18F3MET5(0.98,3)
22C5MET8(1,4)
gi14043072 3181 HNRPA2B1 13B3MET1(1,35)
22C5MET8(1,7)
gi4506891 6418 SET 22C5MET8(0.99,1)
gi34740329 220988 HNRPA3 13B3MET1(0.96,1) gi4506901 6428 SFRS3 13B3MET1(0.98,1)
22C5MET8(0.99,1)
gi14110428 3183 HNRPC 13B3MET1(1,7)
13B3MET1(0.99,1)
22C5MET8(1,1)
gi4506903 8683 SFRS9 22C5MET8(0.98,1)
gi14110414 3184 HNRPD 13B3MET1(1,2)
22C5MET8(1,7)
gi13775198 83442 SH3BGRL3 23C5MET9(0.97,1)
gi14110407 9987 HNRPDL 22C5MET8(0.98,1) gi23397666 25942 SIN3A 22C5MET8(0.99,1)
gi4826760 3185 HNRPF 22C5MET8(1,3) gi7657431 27044 SND1 22C5MET8(1,2)
gi14141157 3189 HNRPH3 18F3MET5(1,4) gi4759156 6626 SNRPA 13D4MET1(1,16)
14A8MET2(0.97,1)
gi14165435 3190 HNRPK 13B3MET1(0.99,1)
22C5MET8(1,3)
gi38149981 6629 SNRPB2 13D4MET1(0.97,1)
gi14141161 3192 HNRPU 13B3MET1(0.99,1) gi4759160 6634 SNRPD3 13B3MET1(1,2)
gi40018640 79577 HRPT2 18F3MET5(1,6) gi14741936 414153 SNRPEL1 13D4MET1(0.99,1)
gi4504505 3295 HSD17B4 18F3MET5(1,2) gi13027644 6638 SNRPN 13B3MET1(1,3)




gi4507149 6647 SOD1 22C5MET8(1,2)
6D9PCA5(1,1)
gi24234686 3312 HSPA8 19C11MET6(1,9)
19C12MET6(1,4)
19D12MET6(1,2)
gi10835187 6648 SOD2 13D4MET1(1,2)
gi7657015 51493 HSPC117 4H4PCA4(1,21) gi31543653 6727 SRP14 13B3MET1(0.96,1)
gi4557663 3476 IGBP1 23C5MET9(0.98,1) gi4507357 8407 TAGLN2 13D4MET1(1,1)
gi31542984 3700 ITIH4 4H4PCA4(1,2) gi4557871 7018 TF 4H4PCA4(1,13)
gi4504865 8570 KHSRP 13B3MET1(1,3) gi4758152 1678 TIMM8A 22C5MET8(1,2)




gi42518065 9414 TJP2 22C5MET8(0.99,1)
gi5031887 4026 LPP 22C5MET8(0.99,1)
6D9PCA5(1,1)
gi39725636 54732 TMED9 19C11MET6(1,3)
19C12MET6(1,2)
19D12MET6(0.98,1)
gi4505047 4060 LUM 4H4PCA4(1,2) gi19913406 7153 TOP2A 18F3MET5(0.9,1)
gi14195618 4133 MAP2 22C5MET8(1,1) gi5032179 10155 TRIM28 18F3MET5(1,8)
22C5MET8(1,2)
gi47519639 4134 MAP4 2B3PCA2(1,5) gi17402907 23650 TRIM29 4H4PCA4(1,10)
gi21735621 4191 MDH2 13D4MET1(0.97,1) gi21361322 10382 TUBB4 22C5MET8(1,10)
gi4826830 4204 MECP2 2B3PCA2(1,2) gi14249348 84817 TXNL5 22C5MET8(1,2)
gi21362050 84317 MGC12981 13D4MET1(0.99,1) gi21361091 7345 UCHL1 4H4PCA4(0.93,1)
gi29788768 347733 MGC8685 22C5MET8(1,3) gi4827050 9097 USP14 22C5MET8(1,1)
gi15809016 103910 MRLC2 2B3PCA2(1,2) gi4507855 8078 USP5 22C5MET8(0.94,1)
gi22547129 51264 MRPL27 13B3MET1(0.99,1) gi17865802 9525 VPS4B 22C5MET8(1,3)
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Figure 4.1: Overview of the experimental approach.
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Figure 4.2: The 20-fraction predictor (a) chosen as the minimum fraction count producing maxi-
mum accuracy in classification without over-fitting the predictor and a heatmap of the
reactivity profile (b) generated by the 20-fraction predictor revealing a distinct bipartite
pattern.
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Figure 4.3: Reactivity profile of individual protein markers towards BPH and PCa (a), and (b)
shows the receiver-operating characteristic (ROC) curves for the 20-fraction predictor
and measured PSA levels in the sample cohort.
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Figure 4.4: Molecular concept analysis (MCM) on the group of five proteins, c-Etc-1(68), STAT1,
STAT3, STATx and STAT5B, which were identified to have cancer-specific autoanti-
body repertoire.
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Figure 4.5: Figure showing the nitrogen metabolism concept where increased protein biosynthe-
sis is observed during prostate cancer development. The up-regulation of glutamate
as a metabolite coupled to the enhanced enzymatic mediation via humorally reactive
GLUD1 shifts chemical equilibrium toward increased ammonia output. Independent
metabolomic data shows significantly increased levels of glutamate and aspartate in
prostate cancer specimens.
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Figure 4.6: Figure showing concepts enriched by the PCa-specific humoral targets including four
promoter binding sites implicating the enrichment of a STAT-regulating transcrip-
tome. The five enrichment networks obtained from the earlier analysis were sequentially
merged into a single common network shown here.
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Figure 4.7: Figure showing (a) STAT-regulated immune signature for six prostate cancer gene
expression profiling and (b) different humoral response comparisons between normal
prostate, BPH or prostate cancer.
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Figure 4.8: Summary of unique protein content across the 20-fraction predictor as sequenced by
mass spectrometry. Fractions are stratified and colored by their membership in either
of the two dominant humoral response reactivity patterns. The first is increased reac-
tivity in BPH samples relative to PCa (blue), and the second are those with increased
reactivity in PCa relative to BPH (red). The colored fraction of each bar represents
the percent of total proteins per fraction sequenced with two or more peptides and the
integer above each reflects the count of proteins identified with a probability of correct
assignment of one.
Figure 4.9: Workflow for non-specific protein content removal undertaken in the formulation of the
final protein compendium produced from initial mass spectrometry sequencing.
129
Figure 4.10: MS/MS spectra for identified peptides (A) FQELESETLK (Prostatic acid phos-
phatase, ACPP; Swissprot ID P15309) from fraction 7A12PCA6 and (B) IIAEGANG-
PTTPEADK (Glutamate dehydrogenase 1, mitochondrial precursor, GLUD1; Swis-
sprot ID P00367) from fraction 3F5PCA3.
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CHAPTER V
Toward high sequence coverage of proteins in human breast
cancer cells using on-line monolith-based HPLC-ESI-TOF
MS compared to CE MS
5.1 Introduction
An important problem in current proteomics is searching for biomarkers of vari-
ous diseases [1]. This involves searching for proteins that undergo highly dynamic
changes during the course of a disease such as cancer progression. These changes
may involve sequence modifications including truncations, deletions, splice variants,
and sequence substitutions, as well as posttranslational modifications (PTMs), such
as phosphorylation, glycosylation, acetylation, and methylation, and a host of other
modifications that may affect the function of the proteins [2-4] and play a significant
role in the pathways leading to carcinogenesis [5]. In addition to this complexity,
many important proteins involved in regulation are often present in low abundance,
presenting further challenges in proteomic studies. Traditionally, 2D-GE [6] has been
used to profile protein expression and to search for changes in such expression levels
of disease states, including tumor cells.
Despite the tremendous contribution 2D-GE method has made to the study of var-
ious proteomes, it has a number of fundamental limitations. These include the
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labor-intensive and time-consuming nature of the technique, poor reproducibility,
and under-representation of certain classes of proteins, so that truly comprehensive
analysis is impossible. Furthermore, it cannot provide accurate Mr information and it
still remains difficult to interface 2D-GE directly to MS analysis [7,8]. More recently,
a method utilizing 2-D liquid-phase separations based on pI and hydrophobicity of
proteins has been developed for mapping of proteins and applied to large-scale study
of several different types of human cancer cells [9-11]. This method allows for direct
interfacing of chromatographic separation for ESI-TOF MS analysis to obtain an
accurate Mr value. Alternatively, the proteins contained in selected pH ranges can
be collected, enzymatically digested, and analyzed by MALDI-TOF MS to obtain a
peptide map or sequencing information by tandem mass spectrometric analysis. The
protein identification can then be readily obtained by database searching.
The use of peptide mapping by MALDI-TOF MS provides very limited sequence
coverage, typically, 40-50% at the most, due to the ionization efficiency often de-
pending on the choice of matrix [12], peptide composition [13,14], ion suppression,
and suppression or loss of PTMs. Thus, the issue becomes obtaining sufficiently
high sequence coverage to prevent false identification of unknown proteins and then
to identify the presence of important PTMs or other variations that are often par-
ticular to different stages of cancer and other diseases.
In recent work, a method combining CE/ESI-TOF and MALDI-TOF MS was used
to improve the sequence coverage of peptide maps [15]. A sequence coverage of over
90% could be obtained in most cases from tryptic digests by combining the peptides
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detected from both techniques. The sequence could be used with the Mr value de-
termined by ESI-TOF MS and the known Mr value from the database to determine
the sequence coverage and where modifications or isoforms were present. Using this
method, various isoforms of proteins found in breast cancer cells could be identified
and sequence variations could be detected.
An alternate form of capillary separation involves the use of monolithic columns,
which are formed of a single, rigid, and porous polymer. The use of these monolithic
columns has been described in many studies involving biological molecules, includ-
ing nucleic acids, ribonucleic acids, proteins, and peptides [16-22]. It has recently
become a stationary phase of choice in LC with several advantages over conventional
packed columns. Due to the lack of interstitial space, these monoliths can provide
a very fast separation with high resolution. Also, as analyte does not dwell at the
resin, it is capable of producing high recovery, hence increased sensitivity, and can
separate very hydrophobic analytes that might otherwise be difficult to elute with
conventional packed columns. Compared to CE-MS, the method is very rugged where
large numbers of separations can be run and the enhanced loadability allows much
improved sensitivity.
In the present work, proteins isolated from 2-D liquid separations of breast cancer
cell lysates were analyzed by combining several methods to obtain high sequence
coverage and to search for isoforms and modified proteins. The method involved the
use of capillary monolith LC separation of tryptic digests of proteins isolated from
the liquid separations with on-line detection by ESI-TOF MS and linear IT MS. The
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sequence coverage obtained by this method was combined with that from MALDI-
TOF MS to yield >85% coverage in most cases relative to the known sequence for the
protein. Also, a comparison of sequence coverage to previous CE-MS work is shown
for several proteins. The combined MALDI and ESI-MS procedure was performed
for ten proteins from a malignant breast cancer cell line in the pH 7.5 fraction. Also,
tandem mass spectrometric analysis confirmed the presence of a unique peptide in
different isoforms of lamin.
5.2 Materials and Methods
The experimental overview of the work presented here is shown in Figure 5.1. Pro-
teins from lysed cells are subjected to 2-D liquid-phase separations according to their
pI and hydrophobicity. The isolated proteins are then enzymatically digested and
analyzed by MALDI-TOF MS and monolith-based LC-MS for protein identification
by PMF. The sequence coverage results from CE-MS analysis from previous work are
also compared for several proteins. The intact Mr of the proteins is obtained using
nonporous (NPS)-RP-HPLC separations interfaced on-line with ESI-TOF MS. The
results from PMF analysis using the two different MS methods are combined to yield
high sequence coverage and a comparison between the experimental and theoretical
intact Mr is used to provide highly reliable protein identification and to identify the
presence of isoforms. The sequencing information of the selected tryptic peptides




The cells used in this work are CA1a.cl1 and CA1d.cl1, cloned and fully malignant
lines derived from the MCF10A human breast cancer cell line, which are maintained
and prepared by the Barbara Ann Karmanos Cancer Institute (Wayne State Univer-
sity, Detroit, MI) as previously described [23].
5.2.2 Preparative Liquid-Phase IEF
The first-dimensional separation based on pI was performed using the Mini-Rotofor
(BioRad, Hercules, CA) to separate the cell extracts as previously described [9,15].
Briefly, cell extracts were mixed with IEF running buffer containing 8 M urea, 2 M
thiourea, and 2% Biolyte ampholyte at pH 310 (BioRad). The Rotofor chamber was
loaded with 18 mL of the buffer, and the separation was controlled at 12 W for 3.5
hr. The separated pI fractions were harvested into 20 tubes for pH measurements
using an Orion pH meter (model 250A, Allometrics, Baton Rouge, LA) and Accumet
combination electrodes (Fischer, Pittsburgh, PA). Each fraction was subjected to a
colorimetric based Lowry assay (RC Protein Assay, BioRad) for relative quantitation
and stored at -80◦C until use.
5.2.3 NPS-RP-HPLC Separation
The second-dimensional separation was performed using NPS-silica columns. The
NPS-RP-HPLC column (33×4.6 mm) packed with 1.5 µm C18 NPS ODSIIIE silica
beads (Eprogen, Darien, IL) was used at a flow rate of 0.5 mL/min. Approximately
250 µg of protein obtained from each Rotofor fraction was loaded for separation with
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the HPLC System Gold equipped with UV detector (Beckman Coulter, Fullerton,
CA). The solvent system comprised of solvent A: helium-degassed deionized (DI)
water (Millipore, Billerica, MA) with 0.1% TFA (TFA, 99.5%; Sigma, St. Louis,
MO) and solvent B: ACN (ACN, 99.93% HPLC grade; Sigma) with 0.1% TFA. The
column was maintained at 65◦C (model 7971 column heater, Jones Chromatography,
Resolution Systems, Holland, MI) to improve resolution and increase the separation
speed by using a gradient elution profile as follows: 5-15% B in 1 min; 15-25% B in
2 min; 25-31% B in 3 min; 31-41% B in 10 min; 41-47% B in 3 min; 47-67% B in 4
min; 67-100% B in 1 min; 100% B for 2 min; and 100-5% B in 1 min. The proteins
separated by NPS-RP HPLC were monitored at 214 nm and collected into 1.5 mL
Eppendorf tubes using a Beckman SC-100 fraction collector controlled by semiauto-
mated acquisition program. Protein collection was performed off-line according to
the peaks detected from the HPLC separation where 40-50 fractions, each containing
a volume in the range of 100-500 µL, were obtained.
5.2.4 NPS-RP-HPLC/ESI-TOF MS
Intact Mr analysis was performed by analyzing eluent from NPS-RP HPLC for on-
line ESI-TOF MS (LCT, Waters-Micromass, Manchester, UK). The separation was
performed under the same experimental conditions as in the previous section except
that TFA was substituted with 0.3% formic acid (Sigma) in both mobile phases to
improve ESI efficiency. A splitter system was used so that 40% of eluent from the
HPLC was delivered to the LCT. The capillary voltage for electrospray was set at
3200 V, sample cone at 40 V, extraction cone at 3 V, and reflection lens at 750
V. Desolvation was enhanced by controlling the desolvation temperature at 300◦C
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and source temperature at 120◦C. The nitrogen gas flow was maintained at approxi-
mately 650 L/h. One mass spectrum was acquired per second. The intact Mr value
was obtained by deconvoluting the combined ESI spectra of the protein utilizing the
MaxEnt1 feature of MassLynx software version 4.0 (Waters-Micromass).
5.2.5 Protein Digestion
The proteins collected off-line by NPS-RP-HPLC separation were completely dried
down using a SpeedVac (Labconco, Kansas City, MO). 50 µL of 50 mM NH4HCO3
at pH 7.8, filtered through 0.22 µm and 0.5 µg of TPCK-modified sequencing-grade
trypsin (Promega, Madison, WI), was added for digestion at 37◦C for 18 hr and
stopped thereafter by adding 1 µL of 10% v/v TFA. The digestion mixture was di-
vided into 10 µL for MALDI-TOF MS analysis and the rest dried completely with a
SpeedVac. Prior to monolith-based LC-MS and LC-MS/MS analysis, peptides were
reconstituted in 5 µL of deionized water.
5.2.6 MALDI-TOF MS
Each digested protein was analyzed by MALDI-TOF MS. Prior to spotting, each of
the digested samples were desalted and concentrated by using C18 ZipTip (Millipore,
Bedford, MA) and eluted into 0.5% v/v TFA/60% v/v ACN. The MALDI-matrix
solution was prepared by diluting saturated CHCA (Sigma) with 0.5% v/v TFA/60%
v/v ACN at 1:4 ratio v/v. The internal standards included angiotensin I, adreno-
corticotropic hormone (ACTH) fragments 1-17 and 18-39 (all from Sigma). Internal
standard peptides were added so that a final concentration of 50 fmol each was
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reached in each spot of the MALDI plate.
Peptide masses were measured by the TofSpec2E (Waters-Micromass) with delayed
extraction in reflectron mode with positive polarity using a nitrogen laser (337 nm).
The operating voltage was 20 kV and reflectron voltage was 24.5 kV. The pulse
voltage used for delayed extraction was set at 2300 V at a 520 ns delay time. The
sampling rate was 2 GHz. Peptide mass spectra were internally calibrated resulting
in a mass accuracy of 50 ppm or less. The calibrated spectra were processed using
MassLynx version 4.0 to obtain monoisotopic experimental masses for submission to
MS-Fit available from http://prospector.ucsf.edu to search the Swiss-Prot and
NCBI databases for protein identification under the species of Homo sapiens with no
restrictions on Mr and pI range. A maximum of two missed cleavages was allowed,
and cysteine was unmodified. The possible modifications including oxidation of me-
thionine, N-terminal acetylation, and phosphorylation at S, T, and, Y were allowed.
5.2.7 Monolith-based HPLC Separation and On-line Interfacing with ESI-TOF MS
The Ultra-Plus II MD Capillary Pump module (Micro-Tech Scientific, Vista, CA)
with a home-built column heater utilizing a variable autotransformer (Staco En-
ergy Product, Dayton, OH) was used for all chromatographic experiments with the
monolithic-capillary column. Monolithic capillary columns of dimension of 360 µm
od × 200 µm id × 60 mm L were prepared by co-polymerizing styrene and divinyl-
benzene according to the protocol described elsewhere [19]. The capillary column was
directly mounted to a microinjector (model C4-1004-.5, Valco Instruments, Houston,
TX) with a 500 nL internal sample loop and a microtight union with 5 nL swept
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volume (Upchurch Scientific, Oak Harbor, WA) was used to connect a capillary tub-
ing to the LCT. The flow rate of the solvent delivery pump was set at 0.5 mL/min,
which was split precolumn to produce a flow rate of 2.5 µL/min at 60◦C through
the monolithic-capillary column. A mobile-phase system of two solvents was used,
where solvents A and B are composed of 0.05% formic acid (Sigma) in DI water and
ACN, respectively. A linear gradient of 0-100% B in 18 min was applied, immediately
followed by column equilibration.
Each digested protein was analyzed using monolith-based HPLC interfaced on-line
with the LCT. The desolvation temperature was maintained at 120◦C and source
temperature at 80◦C. The nitrogen gas flow was controlled at 90 L/h. One mass
spectrum was acquired per second. The monoisotopic peptide Mr values were ob-
tained by utilizing MaxEnt3 feature of MassLynx version 4.0 software by allowing
maximum charge state of up to +3 in the mass range of 500-4000 Da. All processed
mass spectra were subjected to PMF analysis by database searching in the manner
described in Section 5.2.6.
5.2.8 Monolith-Based HPLC-MS/MS
In order to sequence the tryptic peptide sequence of interest, HPLC-MS/MS exper-
iments were performed using linear IT MS (LTQ, Thermo Finnigan, San Jose, CA).
An identical platform for HPLC separation, described in the previous section, was
utilized. The capillary transfer tube was set at 175◦C, and electrospray needle was
held at +3.5 kV. A sheath gas flow of 15 arbitrary units was used. The ion activation
was achieved by utilizing helium at a normalized collision energy of 35%. All MS/MS
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data obtained were analyzed by using the TurboSequest feature of Bioworks 3.1 SR1
(Thermo Finnigan). By allowing the maximum missed cleavage of two, peptide ions
are automatically assigned with the Xcorr values to consider >3.5 for +3 ions, >2.5
for +2 ions, and >1.5 for +1 ions.
5.3 Results and Discussion
The monolithic column was used in this work to analyze proteins separated from
breast cancer cell lines. All proteins from the human breast cancer cells in this ex-
periment were analyzed with the same monolithic-capillary column. The column
exhibits excellent ruggedness, where the stability of this type of column has been
described elsewhere [24]. The salts and other species that might otherwise clog the
column in CE-MS were cleaned up by running a 100% aqueous solvent prior to RP
separation to wash off the impurities. In addition, only a few femtomoles of injection
was possible with CE-MS in previous work [15], making it difficult to analyze pro-
teins of low abundance, whereas monolith-based LC offers much higher loadability
to improve detection.
5.3.1 High Protein Sequence Coverage with Monolithic LC-MS
A CA1a cell lysate was separated by 2-D liquid separations where NPS-RP-HPLC
separation of proteins prefractionated at the pH of 7.55 is shown in Figure 5.2. A to-
tal of ten proteins contained in this fraction were analyzed for identification through
PMF analysis. The protein digests were analyzed by capillary monolithic LC-MS
where a typical high-resolution separation profile, completed in less than 10 min,
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is shown in Figure 5.3 for one of the proteins (peak no. 6 in Figure 5.2). Typical
full peak widths at half height are in the range of 3-5 s. The speed of separation
is important since in analysis of complex cell lysates, there may be large numbers
of proteins that need to be analyzed. Considering that recovery of proteins sepa-
rated by NPS silica column is approximately 80% [25], it is estimated by performing
peak quantitation with manual baseline by Origin software (version 6.0, Microcal
Software, Northampton, MA, USA) that approximately 40 ng of protein digest was
injected into the monolithic-capillary column. The mass analysis and database search
identify this protein as fructose bisphosphate aldolase A, a 40 kDa protein so that
approximately 1 pmol was consumed for analysis.
Table 5.1 summarizes the comparison between theoretical versus experimental intact
Mr, pI, and the sequence coverage by monolith-based LC/MS and MALDI-TOF MS
for each protein denoted in Figure 5.2. Also shown is the overall sequence coverage
obtained by combining peptide masses from each method into database searching. In
many cases, high sequence coverage was readily obtained solely by the monolithic-
LC-MS method. Figure 5.4 A illustrates the protein coverage map by each MS
method for annexin II, which is found to behighly expressed in the malignant cell of
human breast cancer and suggested as a potential biomarker based on the previous
differential expression study [9]. The sequence coverage of 90% for this protein of ca.
40 kDa was analyzed by monolithic LC-MS alone. As shown in the coverage map,
monolithic LC-MS missed only three peptides, including 1-10, 79-88, and 207-212,
excluding three tryptic peptides composed of one or two amino acids that cannot be
detected in the mass range set for 500-4000 Da for both of the mass spectrometric
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methods. This implies that the protein coverage by monolithic LC-MS was almost
complete. A similar observation can be made with superoxide dismutase, for which
the coverage map is shown in Figure 5.4 B. For this protein, a single tryptic peptide
sequence composed of 38 amino acids (157-194; 4236.16 Da) without any cleavage
site and a single amino acid residue (222) were not detected, of which detection is
limited by the mass range examined in this experiment.
Although significantly higher protein sequence coverage was consistently obtained
with monolith-based LC/MS as compared to MALDI-TOF MS, it is observed that
the addition of peptide mass data from MALDI-TOF MS contributed to an increase
of >10% of the overall protein sequence coverage for many of the proteins analyzed.
It shows that this unique approach of combining different MS methods typically cov-
ers from 80% to over 90% of the overall sequence of the proteins ranging in size from
a few thousands to over 70 kDa. Table 5.2 shows that proteins contained in other
pH fractions of CA1a and a different cell line, CA1d, were also successfully analyzed.
Occasionally, the tryptic peptide sequences that were detected by neither monolith-
based LC-MS or MALDI-TOF MS were detected and successfully sequenced by lin-
ear IT MS. Two of the tryptic peptides of heterogeneous nuclear ribonucleoproteins
A2/B1, LFVGGIK, shown in Fig. 5.5 with the MS/MS spectrum, and EESGKP-
GAHVTVK (110-112) were not detected by either method for PMF analysis, yielding
the overall coverage of only 74%. However, the tandem mass spectrometric analysis
identified these peptides, therefore increasing the overall sequence coverage to 80%.
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5.3.2 Enhanced Peptide Detection by Monolithic LC-MS
In previous work, lamin, which helps maintain and establish the shape and strength
of the interphase nucleus [26,27], was analyzed with CE-MS with sequence coverage
ranging from ca. 68-76% for a few isoforms (Table 5.1)[15]. The same protein was
analyzed by monolithic LC-MS to reveal sequence coverage of higher than 80-90%,
which increased up to 96% with the addition of the results from MALDI-TOF MS.
Figure 5.6 A shows the monolithic LC-MS spectrum scanned over the actual separa-
tion time of a digest of lamin identifying five peptide sequences, mostly within mass
accuracy of less than 100 ppm, that were not detected by the CE-MS method. Given
that both methods utilized the same ionization method, it is strongly believed that
the separation characteristics of monolithic LC, including high recovery and loadabil-
ity, may have contributed to revealing peptides that went undetected by CE. This
is an important observation because peptides bearing certain PTMs are difficult to
detect due to their presence in relatively low concentrations and the monolithic LC
may be a suitable means to overcome this problem. Two additional tryptic peptide
sequences in lamin, key to identifying sequence variations involving isoforms, were
detected by monolithic LC-MS analysis and are discussed in the following section.
Figure 5.6 B shows the direct comparison of sequence coverage for lamin isoforms
obtained by monolithic LC-MS and CE-MS, where it is clearly visualized that en-
hanced sequence coverage was observed by monolithic LC-MS.
5.3.3 Analysis of Isoforms and PTMs Using Monolithic LC-MS and NPS-RP-LC-MS
In addition to very high protein sequence coverage by PMF analysis, an excellent
match between experimental Mr obtained by NPS-RP-HPLC/ESI-TOF MS and the
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theoretical Mr of many of the proteins analyzed in this experiment serves to further
suggest that the protein identification procedures are highly reliable, as several pro-
teins in Tables 5.1 and 5.2 exhibited a very close agreement. Ubiquitin, for example,
contains no suggested modifications in its sequence, and therefore experimental and
theoretical molecular weights are identical.
In our previous study [15], the usefulness of intact Mr in determining sequence varia-
tions of proteins was demonstrated where unique peptides were detected by MALDI-
TOF MS. The use of Mr measurements allowed the identification of the presence
of isoforms of lamin. A single gene of lamin A/C encodes four isoforms, the most
widely studied being lamins A and C, as well as ADelta10, resulting from alterna-
tive splicing [26,28]. The lamin C is identical to that of lamin A for the sequence
(1-566), while a slight difference is observed in (567-572) where GSHCSS in lamin A
is replaced by VSGSRR in lamin C. The rest of the sequence in lamin A (573-664) is
absent in lamin C. In lamin ADelta10, a sequence (537-566) is missing from lamin A,
the rest being identical [27]. In the present study, we successfully identified unique
peptides with no missed cleavages contained in two isoforms, lamins A and C, with
both monolith LC-MS and MALDI-TOF MS, as summarized in Table 5.3. Figures
5.7 A and B show the detection of the peptide sequences unique to lamins A and
C, respectively, by monolithic LC-MS. Figure 5.8 shows that one of these unique
peptides, TALINSTGEEVAMR (528-541), was successfully sequenced, further con-
firming its detection by utilizing monolith-based LC separation. The unique peptide
of lamin ADelta10 was not detected by the present study. It is interesting to note
that none of these unique peptides were observed by CE-MS analysis in our previous
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study, while their presence was observed using monolithic LC-MS, further suggesting
its usefulness in PMF analysis.
Another interesting observation of isoforms was made with cytoplasmic actin. There
are three main groups of actin isoforms in vertebrates, including α, β, and γ forms
[29,30]. β-Actin and γ-actin are known to coexist in most cell types as components
of the cytoskeleton and as mediators of internal cell motility. This protein has been
studied earlier based on intact Mr from NPS-RP-HPLC [31], although unique pep-
tides were not found by MALDI-TOF MS analysis due to their very high degree of
homology where 98.9% (371/375) of the sequence is identical. In this work, both
β-actin and γ-actin were identified with overall coverage of 83 and 88%, respectively,
with closely matching intact Mr values, when peptide maps from different MS meth-
ods were combined (Table 5.2). The unique peptides of these two isoforms are found
in four of the first ten amino acids in their sequences, MEEEIAALVI for γ-actin
and MDDDIAALVV for β-actin, while the remainder of the 371 amino acids in the
sequence of these proteins are identical, making it a difficult task to distinguish them.
In their mature forms, the first amino acid residue of the sequence, methionine, of
both forms of actins is missing and the second amino acid in each of the sequence,
glutamic acid for γ-actin and aspartic acid for β-actin, are acetylated at the N-
terminus [32-34]. Many studies report that the histidine residue at position 73 is
methylated in actins [35,36]. Considering these modifications and alterations in se-
quence, theoretically, γ-actin should have MW of 41,718 Da, which closely matches
our experimentally determined intact MW of 41,714 Da, or less than 100 ppm of mass
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accuracy. The same consideration can be made with β-actin which should have MW
of 41,662 Da, in comparison to the MW of 41,670 Da determined experimentally. In
Figure 5.9, the observation of the presence of the unique peptide sequence of γ-actin
with Mr including acetylation at a glutamic acid residue in its mature form by both
monolithic LC-MS and MALDI-TOF MS is illustrated. Neither MS method revealed
the unique peptide sequence contained in β-actin.
A closer examination of the mass spectrum obtained for actin allowed for the de-
tection of the presence of another PTM. Shown in Figure 5.10 is a doubly and
triply charged peptide sequence containing methylated histidine, YPIEHGIVTNWD-
DMEK (69-84, 1960.911 Da), by monolithic LC-MS. This modified sequence was also
found by MALDI-TOF MS analysis. The modification at this particular residue of
this peptide sequence, common to both β- and γ-actins, was suggested by a recent
study where it appears to play a role in polymerization of actin and ATP hydrolysis
[37]. Although detailed structural study by MS/MS is necessary for characterization,
the results presented here strongly indicate that monolith-based LC-MS followed by
PMF analysis is capable of identifying the presence of PTMs.
5.4 Conclusions
A method for obtaining consistently high sequence coverage of proteins separated
from lysates of human breast cancer cell lines has been successfully demonstrated by
utilizing a polymer-based monolithic-capillary column for LC-MS to obtain a rapid
and high-resolution separation. Very high sequence coverage of proteins readily ob-
tained by combining PMF results from monolithic LC/MS and MALDI-TOF MS
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enhances the reliability of the protein identification procedures. Although CE-MS
could also be used to analyze these samples, an important advantage of the monolith
HPLC-ESI-TOF MS is the ruggedness of the technique. In CE-MS using a sheath-
less interface the electrical connection has been found to be the limiting factor where
the connection needs to be redone after a couple of runs. Although CE can provide
much improved resolution [38] compared to the monolithic columns in the 10 min
separation interval, with the use of MS analysis sufficient resolution is obtained for
distinguishing each peak. In addition, the monolithic columns provide much im-
proved loadability compared to CE and much shorter separation times compared to
packed capillary chromatography.
The monolithic column separations coupled to MS was also used to elucidate the pres-
ence of sequence variations, such as isoforms, and PTMs of proteins, aided by intact
Mr information and MS/MS using linear IT MS. It is important to emphasize the
uniqueness of this study due to the nature of samples analyzed, which originate from
highly complex biological mixtures, suggesting the versatility of this approach for
many other applications. In addition, this method requires no sample preparation or
purification upon completion of enzymatic digestion of proteins prior to MS analysis.
Several proteins analyzed in this work, including annexin II, fructose bisphosphate
aldolase A, phosphoglycerate kinase 1, and peptidyl-prolyl cis-trans isomerase A,
have been reported to be highly expressed in tumor cells and described as potential
biomarkers based on differential expression studies [9,39]. Although further work will
be necessary to fully characterize these proteins, it is clearly demonstrated in this
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study that the method of monolith-based LC on-line hyphenated with MS has great
potential to become a high-throughput methodology. It may be used to characterize
large numbers of potential biomarkers in various types of tumor and other diseased
cells and to study the presence of a wide variety of modifications and structural
changes in protein expression.
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Table 5.1: Comparison between theoretical and experimental intact Mr and pI and sequence cov-
erage between different MS methods for proteins in pH fraction of 7.55 of CA1a cell line
(see Figure 5.2 for peak number.)
Table 5.2: Comparison between theoretical and experimental intact Mr and pI and sequence cover-
age between different MS methods for proteins in other pH fractions of CA1a and CA1d
cell lines
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Table 5.3: Unique tryptic peptides detected by different MS methods to distinguish isoforms
153
Figure 5.1: Experimental scheme of the 2-D liquid-phase separation techniques followed by PMF
analysis and sequencing from different MS methods for identification of proteins in
human breast cancer cell lines with high overall sequence coverage.
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Figure 5.2: NPS-RP-HPLC chromatogram of proteins in pH fraction of 7.55 from CA1a cell line
with peaks annotated for protein identification results shown in Table 5.1.
Figure 5.3: Monolith-based RP-HPLC-MS chromatogram of tryptic digest of fructose bisphosphate
aldolase A.
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Figure 5.4: Illustration of protein sequence coverage maps (red bar by monolith-based HPLC/ESI-
TOF MS; blue bar by MALDI-TOF MS) of (A) annexin II and (B) superoxide dismu-
tase.
Figure 5.5: Monolith-based LC-MS/MS spectrum of the tryptic peptide, LFVGGIK (114-120), of
heterogeneous nuclear ribonucleoprotein A2/B1.
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Figure 5.6: (A) Illustration of several tryptic peptides (sequence information in table inset) from
lamin detected by monolithbased HPLC/ESI-TOF MS that were not detected by CE-
ESI-TOF MS in previous study. (B) Comparison of protein sequence coverage for
lamin A/C (red bar monolith-based LC-MS; yellow bar CE-MS, adapted from [15]
with permission). All tryptic peptides only detected by monolithic LC-MS are in bold.
Note: Sequence in green (537-566) is missing in lamin Adelta10. Sequence in pink (573-
664) is missing in lamin C. Sequence in brown (567-572) is replaced with VSGSRR in
lamin C.
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Figure 5.7: Identification of unique peptides (multiply charged; see Table 5.3 for peptide sequence
information) in the isoforms of lamin, (A) lamins A and C and (B) lamin C, detected
by monolith-based HPLC/ESI-TOF MS with zoomed-in view.
Figure 5.8: Monolith-based LC-MS/MS spectrum of the tryptic peptide, TALINSTGEEVAMR
(528-541), of lamins A and C.
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Figure 5.9: Identification of unique peptide (see Table 3 for peptide sequence information) in g-actin
by (A) monolith-based HPLC/ESI-TOF MS with zoomed-in view and (B) MALDI-TOF
MS.
Figure 5.10: Identification of multiply charged tryptic peptide containing methylated histidine
residue in actin by monolithbased HPLC/ESI-TOF MS.
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CHAPTER VI
Automated integration of monolith-based protein separation
with on-plate digestion for mass spectrometric analysis of
esophageal adenocarcinoma human epithelial samples
6.1 Introduction
The immense complexity of the human proteome [1] presents a great challenge that
requires the analysis of large numbers of proteins [2]. Therefore, it is important that
proteomic methodologies should be simple, automated, and versatile for rapid and
reproducible analysis [3]. 2D-GE [4] is still the most widely utilized method for large
scale proteomics applications, where in-gel digestion of each protein spot is analyzed
by subsequent ESI- or MALDI-based MS analysis. Despite development of robotic
systems for gel-spot picking and excision [5-7], 2D-GE coupled with MS remains
difficult and time-consuming due to extensive sample cleanup and digestion of a few
hundred to several thousands of spots that may be present in a sample representing
the human proteome.
Recently, the integration of HPLC with offline fraction collection for MALDI-MS
analysis has received attention [8,9] and has been applied to several systems [10-13].
LC/MALDI has also proven useful for unique applications and has been demon-
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strated to be useful in quantitative studies [14] and in the characterization of post-
translational modifications [15] of proteins. In experiments utilizing LC/MALDI and
applied to complex biological mixtures, proteins have been exclusively analyzed by
enzymatic digestion of whole cell lysates [16-20] using sequential coupling of ion ex-
change and RP-HPLC separations. Although this shotgun proteomics approach is
useful for a comprehensive analysis on a global scale [21], the results can be mis-
leading, where the complexity of samples may result in false positive identifications
when only a small number of peptides are matched [22]. It was previously shown
that proteome analysis performed at the level of intact proteins [23] through 2-D
liquid phase separations can help avoid such problems, where each of the protein
fractions was further examined in detail and compared with intact molecular weight
(MW) analysis [24-27]. This concept was used to develop a novel method that inte-
grates monolithic HPLC separation of intact proteins with on-MALDI plate tryptic
digestion [28] for rapid identification of proteins. It has been recently applied to a
human breast cancer cell line [29], where lengthy experimental procedures required
by in-solution digestion were greatly minimized. Also, unique characteristics of the
monolith [30-32] as a separation medium, including high recovery and rapid sepa-
ration speed [33,34], were found to be ideally suited for the purpose of LC/MALDI
analysis.
Automation of the sample-handling process is an important issue to be considered in
proteomics in order to develop a truly high-throughput methodology facilitating the
analysis of large numbers of proteins [35]. An automated integration of HPLC with
offline fraction collection for MALDI-MS analysis has been attempted previously in
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several studies for the analysis of protein digests [10,36]. In the present studies, we
focus on the advancement of this method by automation of all liquid-handling pro-
cedures. The proteins from human esophageal adenocarcinoma [37,38] a cancer type
that is demonstrating an alarming increase in incidence, were analyzed to demon-
strate the versatility and applicability of this method using whole tissue proteins.
A selected set of pH-fractionated Barrett’s cancer tissue samples was analyzed for
protein identification. HPLC/ESI-TOF MS was performed to compare intact protein
MW for further confirmation.
6.2 Materials and Methods
Proteins from esophageal tissue samples were separated by chromatofocusing (CF)
for pH fractionation. One of the fractions was selected for further separation by
monolithic capillary RP-HPLC connected to the modified nano-plotter (GeSim),
equipped with xyz-robotic unit for automatic offline peak collection. The fractions at
30 s intervals were collected directly on the MALDI plate precoated with trypsin for
on-plate digestion and subsequent MS analysis. A simplified LC/MALDI configura-
tion is described in Figure 6.1, where all liquid-handling procedures were automated
in this experiment. The same pH fraction was also analyzed by online nonporous
(NPS) RP-HPLC/ESI-TOF MS to obtain accurate intact protein MW values for
comparison with theoretical MW values.
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6.2.1 Sample Preparation
Patient consent was received according to guidelines set forth by the institutional
review board (IRB) of the University of Michigan. Tissues were collected and ana-
lyzed from patients undergoing esophagectomy at the University of Michigan Health
System between 1991 and 2001. Patients received no preoperative radiation or
chemotherapy. Each esophageal adenocarcinoma tumor specimen was immediately
frozen in liquid nitrogen and stored at -80◦C. Cryostat sectioning of all tumors were
performed and only portions of tumors containing >80% tumor cellularity were uti-
lized for subsequent protein isolation.
6.2.2 Cell Lysis and Buffer Exchange
200 µg of tissue sample was lysed with 2 mL of lysis buffer which consisted of 7.5
M urea, 2.5 M thiourea, 4% OG, 10 mM TCEP, 10% glycerol, 50 mM Tris (all from
Sigma, St. Louis, MO), and 40 µL protease inhibitor solution (one tablet in 1 mL
PBS buffer, Roche, Indianapolis, IN). Samples were then homogenized, vortexed fre-
quently for 1 hr at room temperature, and centrifuged at 30,000 rpm for 70 min at
4◦C. The collected supernatant was subjected to buffer exchange against CF start
buffer using a PD-10 G-25 column (Amersham Biosciences, Piscataway, NJ). Brad-
ford protein assay kit (BioRad, Hercules, CA) was used to quantify the amount of




CF separation was performed on an HPCF-1D column (250×2.1 mm, Beckman Coul-
ter, Fullerton, CA) using a Beckman System Gold HPLC. Prior to sample loading,
the column was equilibrated with a start buffer containing 25 mM BisTris propane
(Sigma), 6 M urea, and 1% OG, where its pH was adjusted to pH 7.4 with saturated
IDA (Sigma). 4.5 mg protein was loaded to the elution buffer at pH 4.0 contain-
ing 10% Polybuffer 74 (Amersham Pharmacia), 6 M urea, and 1% OG at a flow
rate of 0.2 mL/min. A linear pH gradient was generated so that proteins eluted off
according to their pI for detection at 280 nm. Accurate pH was measured online
by a postdetector pH electrode (Lazar Research Laboratories, Los Angeles, CA) for
fraction collection at every 0.2 pH unit in the range of pH 7.0-4.0.
6.2.4 Online NPS-RP-HPLC/ESI-TOFMS for intact protein molecular weight deter-
mination
Fractions obtained from CF were subjected to NPS-RP HPLC separation using an
ODSIII-E column (33×4.6 mm, Eprogen, Darien, IL) packed with 1.5 µm NPS sil-
ica. The column was maintained at 60◦C by a column heater (model 7971, Jones
Chromatography, Resolution Systems, Holland, MI) to perform separation at a flow
rate of 0.5 mL/min, where 40% was split into an ESI-TOF MS (LCT Premier, Wa-
ters/Micromass, Milford, MA). Formic acid (0.5%, Sigma) was added post splitter
using a syringe pump (Harvard Apparatus, Holliston, MA). The remainder of the
flow was monitored at 214 nm (detector model 166, Beckman Coulter) for offline peak
collection using a fraction collector (model SC100, Beckman Coulter) controlled by
an in-house acquisition program. A mobile phase system of A and B was comprised
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of 0.1% TFA (J. T. Baker, Phillipsburg, NJ) in purified DI water (Millipore RG
system, Bedford, MA) and ACN (Sigma), respectively. The gradient profile was as
follows: 5-15% B in 1 min, 15-25% B in 2 min, 25-31% B in 3 min, 31-41% B in 10
min, 41-47% B in 3 min, 47-67% B in 4 min, and 67-100% B in 1 min. The capillary
voltage for electrospray was set at 3200 V, sample cone at 35 V, extraction cone at
3 V, and reflectron at 750 V. Desolvation temperature was maintained at 330◦C and
source at 130◦C with desolvation gas flow of 650-800 L/h. Intact protein MW was
obtained by automatic deconvolution using Protein Trawler software.
6.2.5 Monolithic Capillary HPLC for Protein Separation
The preparation of copolymerized styrene and divinylbenzene monolithic capillary
columns (0.2×66 mm) was performed according to procedures described elsewhere
[33]. A capillary pump (Ultra-Plus II MD, Micro-Tech Scientific, Vista, CA) was
used for separation. The capillary column was directly mounted on a microinjector
with a 500 nL internal sample loop (Valco Instruments, Houston, TX). The capillary
HPLC separation was controlled at 60◦C with an in-house column heater. The flow
from the solvent delivery pump was split precolumn to generate a flow rate of ca. 2.5
µL/min through the monolithic columns. A mobile phase system of two solvents was
used, wherein solvents A and B were composed of 0.05% formic acid in HPLC-grade
water (Fisher Scientific, Hanover Park, IL) and ACN, respectively. A linear gradient
of 0-100% B in 18 min was applied and held at 100% B for 3 min.
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6.2.6 Integration of Protein Separation to Automated on-MALDI Plate Enzymatic
Digestion
A syringe pump was interfaced with an xyz-module of Nano-Plotter 2.0 piezoelec-
tric pipetting system (GeSiM, Germany) by a capillary tubing in order to precoat
the MALDI plate with 0.5 µL of TPCK-modified trypsin solution of 0.15 µg/mL
(Promega, Madison, WI) into each spot. Prefractionated esophageal tumor proteins
at pH 5.6-5.8 were loaded onto a monolithic capillary column for separation, where
the connecting capillary tubing off the column was interfaced directly to the print
head of the nano-plotter. An instrument controller program written in nano-plotter
language (NPL) was used to control the print head for precise movements along the
x, y, and z axes for automatic control over the designated fraction deposition time
of 30 s intervals onto the MALDI plate. Fraction collection was performed in a
real-time mode with proper calibration. Following the protein collection onto each
trypsinized spot, 0.5 µL of 50 mM NH4HCO3 (Sigma) was automatically added to
the top layer of each spot using a syringe pump and the plate was maintained at
room temperature for digestion for around 10 min. Then, 0.5 µL of 0.1% TFA was
added to each spot to halt digestion, followed by addition of 0.5 µL of CHCA matrix
solution prepared by diluting saturated CHCA with 60% ACN/0.1% TFA at a 1:4
ratio. The internal standards of angiotensin I, adrenocorticotropic hormone (ACTH)
fragment 1-17, and 18-39 (all from Sigma) were included to have a final concentration
of 50 fmol for every spot.
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6.2.7 MALDI-TOF MS Analysis and Database Searching
The MALDI-TOF MS analysis was performed on a Tof-Spec2E (Waters/Micromass)
equipped with delayed extraction in reflectron mode using a 337 nm Nd:YAG laser as
the ionization source. The delay time was set at 520 ns, the extraction voltage at 1:1
to the source voltage at 20 kV, and the pulse voltage at 2300 V. Each spectrum was
internally calibrated and monoisotopic peptide masses were obtained using MassLynx
software version 4.0 (Waters-Micromass) for submission to the MS-Fit search engine
using Swiss-Prot database for protein identification. The search was carried out un-
der the species of Homo sapiens at <100 ppm of mass tolerance with no limitation
set for MW and pI. One missed cleavage was allowed and the possible modifications
included N-terminal Gln to pyroGlu, oxidation of Met, N-terminal acetylation, and
phosphorylation at S, T, and Y. Protein identification was accepted as a match by
filtering according to the following parameters: MOWSE score of >103 and sequence
coverage of >20% and comparison with intact MW values.
6.2.8 MALDI-TOF/TOF MS Analysis and Database Searching
The MALDI-TOF/TOF MS analysis was performed using a 4800 MALDI TOF/TOF
analyzer (Applied Biosystems, Foster City, CA) with a 384-well plate. A CID voltage
of 2 kV was used throughout the runs. S/N threshold of 50 and 30 were used for
selecting the precursor and fragment peaks, respectively. The MASCOT available
online at www.matrixscience.com was used for database searching under Swiss-Prot
for Homo sapiens. Mass tolerances of 50 ppm and 0.3 Da were used for precursor
and fragment ions, respectively, by allowing one missed cleavage. The same variable
modifications were allowed as in PMF analysis.
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6.3 Results and Discussion
6.3.1 Design of Automated Platform for Integration of Monolithic LC-based Protein
Separation and on-plate Trypsin Digestion
A number of different approaches have been developed to interface HPLC and MALDI-
MS. It has recently been shown that the use of sheath gas flow around the emerging
droplet of LC effluent assisted solvent evaporation, but prevented the oxidation of
analytes [18]. In another study, a pull-down deposition method, applying an electric
field to the analyte-collection device, has been demonstrated to effectively deposit
a droplet from the HPLC [36]. This method can be particularly useful where very
small droplets are generated through nanoscale LC to reduce droplet adhesion to the
connecting tubing. However, it may complicate the experimental platform with the
use of high voltage applied across the entire analyte-collection device, where elec-
trochemical reactions may adversely affect MS spectra. Others reported a pressure
pulse-driven dispenser device [39] and a heated droplet interface [40].
Figure 6.1 describes the schematic of the automated configuration to integrate a
monolithic capillary HPLC with onplate digestion of intact proteins for subsequent
MALDI-TOF MS analysis. This experimental configuration involves a continuous
liquid deposition through contact to the MALDI plate for simplicity, which also
proved to provide sufficiently high precision for the purpose of this study. Given
the flow rate used for HPLC separation in our experiment, around 1.2 µL from the
HPLC is deposited on each spot. Unlike nano-LC applications, this effluent volume
is considered to be sufficiently large so that droplet adhesion to the connecting cap-
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illary is less of a concern, eliminating the need for a sophisticated platform for liquid
collection.
Figure 6.2 shows a very close proximity between the interface of LC effluent and the
MALDI plate, which measures around 0.1 mm. Compared to the protein collection
and liquid deposition performed manually in our previous study [29], this automated
device can ensure highly precise positioning of liquid deposition into a very small
area of the spot surface. This provides a method enhancing protein concentration
for highly efficient digestion, therefore, detection for improved sensitivity for MS
analysis. This added advantage can be particularly useful for analyzing proteins
present in low abundance or limited amounts of sample.
The optimal time interval for analyte collection will be dependent on the complexity
of the samples [17]. Although a 30 s interval was used for protein collection time in
this study, our automation device can be programed for shorter analyte deposition
time down to several seconds or less that may be necessary for the analysis of very
complex proteomes. The flexibility of the automated system allows multiple num-
bers of the MALDI plates of varying sizes to be accommodated, which can further
enhance throughput of this method.
6.3.2 Identification of Human Esophageal Cancer Tissue Protein
In our previous study, human breast cancer cell line proteins prefractionated by a
Rotofor device of preparative scale were chosen as a model to show the applicability
of LC/MALDI to biological mixtures [29]. However, the use of the Rotofor device
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is less appropriate when the samples to be analyzed are limited in quantity, as it is
often the case for human tissue samples. Recently, the usefulness of CF [41] as a
fractionation method has been successfully demonstrated for the analysis of various
human cancer proteomes [24,25]. In addition to reducing the complexity of samples,
it is important to note that experimental pI values of proteins can be monitored
online by CF so that the presence of possible PTM can be assessed by comparing
to theoretical pI values [42]. In this experiment, we extended the application of
the LC/MALDI scheme to human cancer tissue samples, where prefractionation was
performed by CF.
Proteins fractionated in the pH range of 5.6-5.8 from an esophageal adenocarcinoma
tissue sample was subjected to monolithic HPLC separation interfaced with onplate
digestion for subsequent MALDI-TOF MS and MALDI-TOF/TOF MS analyses by
automating all liquid handling procedures. In these experiments, a limited amount
of CF-fractionated sample was required due to the low loading capacity of the mono-
lithic capillary column [43]. Table 6.1 shows a list of proteins identified through both
PMF and intact protein MW analyses in each of the collection times, where the LC
system used a delay time of around 6.5 min. A monolith-based protein separation
was performed for the collection time of 20 min. As discussed in a recent work [29],
a monolithic capillary column of the small id used in the experiment may not be the
most suitable means to separate many proteins present in complex mixtures with
high resolution and high efficiency. However, a somewhat lower resolution of protein
peaks obtained from HPLC separation does not pose a serious problem for reliable
protein identification, since subsequent MS analysis can resolve the proteins.
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Figure 6.3 illustrates a MALDI-TOF MS spectrum obtained for the splicing factor,
proline- and glutamine-rich, a large protein of >70 kDa, that was identified with 43%
of sequence coverage, where its identified tryptic peptide sequences are summarized
in Table 6.2. As shown in Table 6.1, relatively high sequence coverage was obtained
for most of the proteins and this is considered to be primarily due to minimal sample
transfers associated with direct LC/MALDI interface to prevent sample loss. Also,
compared to traditional in-solution digestion, it appears that protein enrichment ef-
fects obtained through a small spot size due to precise control of liquid-handling
combined with a large surface area for enzymatic reactions provided by precoated
trypsin perhaps resulted in more efficient digestion. Also, reduced trypsin autolysis
relative to in-solution digestion may be expected due to trypsin immobilization [44]
on the plate to generate less complicated mass spectra for unambiguous interpreta-
tion. In order to further confirm the protein identification procedures, LC/MALDI
based sequencing analysis was performed using MALDI-TOF/TOF MS. Figure 6.4
shows an example for one of the proteins in Table 6.1, calgranulin B, where one of
its tryptic peptides, NIETIINTFHQYSVK (11-25) has been successfully sequenced.
This protein was identified with >50% of sequence coverage through sequencing
analysis.
Also, since proteins are sufficiently separated from each other for direct deposition
onto the MALDI target plate to be confined into a very small spot size with minimal
sample loss expected, several less abundant proteins were identified in this work, such
as cyclin H [45] in Table 6.1. Another protein, MAPK-interacting serine/threonine
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kinase 1 [46], activated by phosphorylation, is also known to be expressed at low
levels. It would be difficult to detect these proteins using a traditional proteomics
approach, where sample loss due to sample-handling procedures is inevitable.
In addition to helping to confirm protein identifications determined by PMF and
sequencing analyses, intact protein MW values were obtained separately by NPS-RP
HPLC/ESI-TOF MS for comparison to theoretical MW values with excellent agree-
ment, as shown in Table 6.1. Although the LC/MALDI method alone can provide
highly confident protein identification due to relatively high sequence coverage, the
usefulness of intact MW values can be observed from a close examination of several
proteins. For instance, the splicing factor, proline- and glutamine-rich, is annotated
with two distinct isoforms A and F (Acc. nos. P23246-1 and P23246-2, respectively)
that slightly differ in amino acid compositions in the region of 663-707 to result in
the isoform A being larger than the isoform F by around 4000 Da (www.expasy.org).
Protein identification by PMF or tandem MS-based sequencing analysis is solely
based on partial sequence coverage of proteins, where sequence variations, such as
truncation and isoforms, are often undetected. In our experiment, however, a com-
parison between theoretical and experimental intact protein MW allows us to con-
clude that it is likely that the isoform A of splicing factor, proline and glutamine-rich,
is present in the esophageal tumor sample. Also, significant deviation observed be-
tween the experimental and theoretical protein MW values can suggest the presence
of possible modifications in certain proteins. An example can be found from ATP
synthase beta chain that becomes truncated by the loss of transit peptide sequence
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upon entry into mitochondria, where this can also be explained by an excellent agree-
ment between its theoretical intact MW value and experimental MW value, as shown
in Table 6.1. A close match between theoretical and experimental MW values of all
proteins in Table 6.1 further confirms the protein identification obtained by PMF
analysis, where slight deviations can suggest the presence of potential PTMs [24].
6.4 Conclusiuons
We have developed a novel method that automates the integration of monolithic
capillary HPLC separation of intact proteins and on-plate enzymatic digestion for
MALDI-based MS analysis. The method is shown to be highly versatile and robust
and is suitable for the analysis of complex proteomes, as successfully demonstrated
for the analysis of esophageal tissue proteins. It is important to emphasize that
the current study analyzed the proteome at the protein level, unlike the majority
of previous LC/MALDI work performed by shotgun proteomics that may result in
ambiguous identifications due to the complexity of mixtures upon digestion of a
large number of proteins. Based on the measured intact protein MW values and
substantially higher protein sequence coverage from the protein-based LC/MALDI,
compared to shotgun-derived LC/MALDI, it is likely that the developed method can
help analyze PTM or other sequence variations. Although the analysis of complex
proteomes is often performed by ESI-based MS, integration of protein separation
directly to MALDI is an effective means to solve compatibility issues with various
LC solvent compositions and contaminants to which the ESI process is substantially
less tolerant.
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Automated coupling of LC-based protein separation for direct on-plate enzymatic
digestion is an attractive means to realize high-throughput proteomics, where the
process can be fully automated and enhance reproducibility. Another distinct ad-
vantage includes accurate control of the spot surface area upon deposition that allows
for the analysis of low-abundance proteins by enrichment of analytes [47]. This is
essential in proteomics studies, where a wide dynamic range of protein concentration
presents a great challenge. Considering that the droplet size is dependent on the
surface tension and viscosity of the solution [48], further development is ongoing to
diminish the spot diameter. The method has potential to become even more powerful
when protein identification through automated software analysis can be combined.
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Table 6.1: List of proteins identified by automated interfacing of monolithic HPLC with MALDI-
TOF MS through on-plate digestion for Barrett’s esophageal adenocarcinoma samples
prefractionated by CF at pH 5.6-5.8
Table 6.2: A list of sequenced tryptic peptides identified from splicing factor, proline- and
glutamine-rich, where peptides with * are shown in Figure 6.3
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Figure 6.1: A simplified diagram of automated LC/MALDI configuration constructed by modifying
nano-plotter (not to scale) for all liquid-handling procedures.
Figure 6.2: Automated LC/MALDI interface where proteins separated by capillary monolithic
HPLC are deposited directly onto the MALDI target plate precoated with trypsin.
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Figure 6.3: MALDI-TOF MS spectrum (unprocessed) obtained for the splicing factor, proline- and
glutamine-rich, from an esophageal tissue sample. * Indicates peptides identified by
monolithic LC/MALDI scheme through on-plate digestion. Refer to Table 6.2 for in-
formation regarding each peptide.
Figure 6.4: MALDI-TOF/TOF MS spectrum for a tryptic peptide NIETIINTFHQYSVK (11-25)
of calgranulin B.
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Studies in proteomics present us with a direct approach for investigating disease at
the individual patient level. Since most therapeutic targets are proteins, proteomics
is vital for developing methods for cure. The human proteome is so more com-
plex than previously assumed, that it is almost impossible to depend on one single
method for its reliable in-depth characterization. The ultimate goal of application
of proteomics in personalized clinical diagnostics requires methods with higher sen-
sitivity, dynamic range, throughput and multiplexing capability than the traditional
methods in use today. The multitude of methods presented here utilizing the power
of mass spectrometry, multidimensional separations and microarray based discovery,
detection, identification and characterization techniques attempts to develop a holis-
tic approach to realize that goal.
Over the years, mass spectrometry has demonstrated its critical role in biomolecule
analysis and is used almost exclusively in proteomics today. But mass spectrometry
has very little to no capability in analyzing complex mixtures such as the proteome,
unless they have been fractionated and purified of salts and other interfering agents.
In this respect, many factors including ease in interfacing makes multidimensional liq-
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uid phase separations the method of choice for mass spectrometry based proteomics.
The work presented in this thesis applies multidimensional separations for generating
reverse phase protein microarrays and applies mass spectrometry to identify proteins
of interest.
The majority of studies in biomarker discovery has been limited to individual pro-
teins, but it is gradually becoming clear that information on entire networks may
be necessary for robust diagnostics. The use of microarrays provides an excellent
platform for such large scale parallel analysis. New types of protein arrays com-
bined with advanced bioinformatics for data processing have been presented here to
identify molecular signatures of individual tumors based on protein pathways and
signaling cascades. Global protein phosphorylation detection and discovery meth-
ods have been realized using a small molecule phospho-sensor dye. This provides
an improved alternative than antibody based approaches but despite the speed and
sensitivity of dye-array techniques must be enhanced significantly for detection of
the biologically relevant proteins. Using nitrocellulose slides with high adsorption
capacity, autoantibody response methods have been used to obtain biomarker pools
for improved sample discrimination. Correlations between classification based on
biomarker pools and prostate cancer gleason grades presented in Chapter IV demon-
strate the power of such techniques. Multiplexed analysis from microarrays where
complementary molecular concept modeling approaches have helped discover signal-
ing and metabolic pathways have been verified through experimental means to be
a practical approach for diagnosis. The use of piezo-electric pins for non-contact
printing have significantly reduced spot variability as is evident from comparisons
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between array images presented in Chapter II and IV where quill-type pins had been
used for contact printing in the earlier work. However, subtle differences in protein
expression levels may still be difficult to detect owing to factors mostly related to
solution phase chemistry where uneven background staining from local variations in
concentration or solvent hydrodynamics can degrade the quality of microarray data.
Great care had been taken for the experiments described here and all comparative
experiments were conducted the same day whenever possible to eliminate any day-
to-day variations. Subtle non-critical procedural improvements were readily applied
whenever possible and have often provided huge improvements in the quality of data
obtained.
More than half of the serum and a significant portion of the cellular or tissue proteome
contain proteins which have no role in signaling or are not useful in diagnostics. Mul-
tidimensional liquid separation techniques have been able to fractionate such samples
so that the low abundant proteins are available for analysis. The work presented in
this thesis describes a monolithic capillary LC based technique for analysis of low
concentrations of proteins and may be useful in the study of the low abundant pro-
teins in the proteome. The above method was applied for on-line interfacing with
both ESI- and MALDI-MS based techniques. Both techniques provide highly effi-
cient separations of protein digests within several minutes and peak widths of only a
few seconds thereby providing high peak capacities suitable for fast high-throughput
analysis. LC separations using the polymer based monolithic capillary was described
as an alternative to CE in obtaining nearly the same peptide coverages. More rugged
than CE-MS, monolithic-LC MS provided peak capacities of nearly 100 within a 10
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min window. With extremely high sequence coverage obtained from this method, sev-
eral sequence variations could be observed among proteins. Monolithic-LC/MALDI
method on the other hand demonstrates the ability of such columns for intact protein
separations and robot assisted MALDI spotting was used to increase the through-
put. This method also provides higher sensitivity because there is very little sample
loss between the separation and mass spectrometry based identification steps. This
method also allows for scaling down proteomic analysis so that 2-D virtual maps can
be obtained from as little as 100 µg of sample.
The multiplexed high-throughput proteomics platforms and micro-scale liquid sepa-
ration methods implemented in this research may help in the detection of low abun-
dant proteins and their associated characterization using mass spectrometry. The
ability to analyze lower amounts of sample will be helpful in analyzing alternative vi-
able sources of biomarkers, eg. buccal cells so that strategies to amplify and harvest
biomarkers will greatly enhance the capabilities of current proteomics modalities.
Additional methods of validation of proteins identified through mass spectrometry
will increase the reliability of such techniques.
